<SEC-DOCUMENT>0001193125-19-315266.txt : 20191216
<SEC-HEADER>0001193125-19-315266.hdr.sgml : 20191216
<ACCEPTANCE-DATETIME>20191216165110
ACCESSION NUMBER:		0001193125-19-315266
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20191216
DATE AS OF CHANGE:		20191216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEI Pharma, Inc.
		CENTRAL INDEX KEY:			0001262104
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				510407811
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-217645
		FILM NUMBER:		191287757

	BUSINESS ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-792-6300

	MAIL ADDRESS:	
		STREET 1:		3611 VALLEY CENTER DRIVE
		STREET 2:		SUITE 500
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARSHALL EDWARDS INC
		DATE OF NAME CHANGE:	20030902
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d841008d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration Statement No. 333-217645 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman"><FONT COLOR="#de1a1e">The information in this preliminary prospectus supplement is not
complete and may be changed. Neither this preliminary prospectus supplement nor the accompanying base prospectus is an offer to sell the securities described herein and neither is soliciting any offer to buy these securities in any jurisdiction
where the solicitation, offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
 COLOR="#de1a1e"><B>SUBJECT TO COMPLETION </B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#de1a1e"><B>DATED DECEMBER 16, 2019 </B></FONT></P>
<P STYLE="margin-top:15pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">(TO PROSPECTUS DATED MAY&nbsp;15,
2017) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841008g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">We are offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock, par value $0.00000002 per share. Our common stock is listed on
the Nasdaq Capital Market under the symbol &#147;MEIP.&#148; The last reported sale price of our common stock on the Nasdaq Capital Market on December 13, 2019 was $2.02&nbsp;per share. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>An investment in our common stock involves significant risks. You should carefully consider the Risk Factors beginning on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519232454/d783135d10k.htm#tx783135_2">page&nbsp;13
</A> of our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the Securities and Exchange Commission on August&nbsp;28, 2019, and on <A HREF="#supptoc841008_4">page <FONT STYLE="white-space:nowrap">S-10</FONT></A> of this
prospectus supplement before investing in our common stock. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><I>Neither the Securities and Exchange Commission nor any state securities commission
has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying base prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">Underwriting discounts<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:11pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman; " ALIGN="left">See the section entitled &#147;Underwriting&#148; for additional information regarding underwriter
compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">We have granted the underwriters an option exercisable for up to 30 days from the date of this prospectus supplement to
purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock at the public offering price less underwriting discounts. If this option were exercised in full, we would receive
approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of additional proceeds, before expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">Certain of our officers and directors have
expressed indications of interest to purchase shares of common stock with an aggregate public offering price of approximately $185,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">The underwriters
expect to deliver the shares of common stock to the purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center"><I>Joint Book-Running Managers </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:20pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:20pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:20pt; font-family:Times New Roman"><B>Stifel</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Wells Fargo Securities</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">The date of this prospectus supplement
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2019. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus Supplement </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_1">About This Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_2">Cautionary Statement About Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_3">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_5">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_6">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_7">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_8">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_9">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptoc841008_10">Incorporation Of Certain Information By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_2">Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_4">Cautionary Statement about Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_5">Securities Offered by this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_6">Use Of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_7">Ratios of Earnings to Combined Fixed Charges and Preferred Stock Dividends
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_8">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_9">Description of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_10">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_11">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_12">Incorporation Of Certain Information By Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_13">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference into this prospectus supplement and the accompanying base
prospectus and any free writing prospectuses prepared by us or on our behalf. We have not authorized any person to provide any information or make any statement that differs from what is contained in this prospectus supplement, the accompanying base
prospectus and any free writing prospectuses prepared by us or on our behalf. If any person does make a statement that differs from what is in this prospectus supplement, the accompanying base prospectus or any free writing prospectuses, you should
not rely on it. This prospectus supplement is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any jurisdiction in which the offer or sale is not permitted. You should assume that the information contained in
this prospectus supplement, the accompanying base prospectus, any free writing prospectus and the documents incorporated by reference is accurate only as of its respective date, regardless of the time of delivery of this prospectus supplement, the
accompanying base prospectus, any free writing prospectus or of any sale of shares of our common stock in this offering. Our business, financial condition, results of operations and prospects may have subsequently changed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying base prospectus are part of a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission, or SEC, using a &#147;shelf&#146; registration statement. Under the shelf registration statement, we may offer and sell any combination of
securities described in the accompanying base prospectus in one or more offerings. The accompanying base prospectus provides you with a general description of the securities we may offer. Each time we use the accompanying base prospectus to offer
securities, we will provide a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add, update or change information contained in the accompanying base prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying base prospectus and the documents incorporated by reference herein include important information
about us, our common stock and other information you should know before investing. This prospectus supplement describes the specific details regarding this offering, including the price, the amount of common stock being offered and the risks of
investing in our common stock. The accompanying base prospectus provides general information about us, some of which may not apply to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">To the extent that any statement that we make in this prospectus supplement is inconsistent with statements made in the accompanying base
prospectus, the statements made in this prospectus supplement will be deemed to modify or supersede those made in the accompanying base prospectus. You should read both this prospectus supplement and the accompanying base prospectus together with
additional information described under the heading, &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_2"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the documents incorporated by reference herein include forward-looking statements within the meaning
of Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than statements of historical
facts contained in this prospectus supplement and in the documents incorporated by reference herein, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are
forward-looking statements. The words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and
similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe
may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in
&#147;Risk Factors&#148; in this prospectus supplement and in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019, including, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">parties with which we have entered into collaboration, license, development and/or commercialization agreements
may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our payment obligations under license agreements for certain of our drug candidates, which may reduce our cash
available for other development efforts, and other obligations and risks related to the license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">clinical studies by their nature typically have a high level of risk and may not produce successful results;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and completed clinical trials are not
necessarily predictive of future results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in the clinical development programs and/or receipt of U.S. Food and Drug Administration (the
&#147;FDA&#148;) or other required foreign and domestic governmental approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from preclinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pricing regulations, third-party reimbursement practices and healthcare reform initiatives;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials and manufacture our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from our defense against third party intellectual property infringement claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our exposure to potential product liability claims and other claims may exceed our insurance limits;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to attract and retain key employees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">cybersecurity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">one-time</FONT> events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this prospectus supplement and the documents incorporated by reference herein include
additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict
all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iv </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_3"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere or incorporated by reference in this prospectus supplement and
accompanying base prospectus and may not contain all of the information that is important to you. This prospectus supplement and the accompanying base prospectus include or incorporate by reference information about the shares we are offering as
well as information regarding our business, risks and detailed financial data. You should read this prospectus supplement and the accompanying base prospectus in their entirety, including the information incorporated by reference. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are a
late-stage pharmaceutical company focused on leveraging our extensive development and oncology expertise to identify and advance new therapies intended to meaningfully improve the treatment of cancer. Our portfolio of drug candidates contains four
clinical-stage candidates, including one candidate in an ongoing Phase&nbsp;3 global registration trial and another candidate in an ongoing Phase 2 clinical trial intended to support an accelerated approval of a marketing application with the FDA
under 21 CFR Part 314.500. Our common stock is listed on the NASDAQ Capital Market under the symbol &#147;MEIP&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our approach to
building our pipeline is to license promising cancer agents and build value in programs through development and commercialization, or strategic partnerships as appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">As of September 30, 2019, we had $65.9&nbsp;million in cash, cash equivalents and short term investments. In order to continue the development
of our lead drug candidates, at some point in the future we may pursue one or more additional capital raising transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Clinical Development Programs </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Cancer is often a highly adaptable disease capable of evading the body&#146;s defenses and resisting treatment, allowing it to grow and
spread. Despite new treatments that strive to leverage actionable insights into cancer biology, even the most cutting-edge therapies can struggle to balance potency with safety. As a result, the oncology community strives to improve on existing
therapies and search for new and better options to optimize benefits for patients. This approach includes medicines that not only act alone, but also work well in combination with other therapies to deliver the best possible outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We currently have four clinical-stage development programs with diverse approaches to inhibiting cancer, including epigenetics, cell signaling
and cancer metabolism: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-401,</FONT> an oral phosphatidylinositol
<FONT STYLE="white-space:nowrap">3-kinase</FONT> (&#147;PI3K&#148;) delta inhibitor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Voruciclib, an oral cyclin-dependent kinase (&#147;CDK&#148;) inhibitor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">ME-344,</FONT> a mitochondrial inhibitor targeting the oxidative phosphorylation
(&#147;OXPHOS&#148;) complex; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Pracinostat, an oral histone deacetylase (&#147;HDAC&#148;) inhibitor. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g841008g97g16.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Phase 2 study intended to support an accelerated approval marketing application with FDA.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Study arm initiated under clinical collaboration with BeiGene, Ltd. </I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Initiation of clinical studies is subject to opening of a new Investigational New Drug application with FDA.
</I></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Investigator-initiated trial. </I></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ME-401:</FONT> PI3K Delta Inhibitor in Phase 2 Trial to Support Accelerated Approval in Relapsed or Refractory Follicular
Lymphoma </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-401 is an oral, once-daily, selective PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitor in clinical
development for the treatment of B-cell malignancies. We maintain worldwide rights to ME-401 in all geographies except Japan, which we licensed to Kyowa Kirin Company (&#147;KKC&#148;) in October 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are conducting two ongoing studies evaluating ME-401. The first is a Phase 2 clinical trial evaluating ME-401 as a monotherapy for the
treatment of adults with relapsed or refractory follicular lymphoma (&#147;FL&#148;) after failure of at least two prior systemic therapies including chemotherapy and an anti-CD20 antibody. Subject to the results, upon completion of the Phase 2
clinical trial, we are planning a submission with the FDA to support an accelerated approval of a marketing application under 21 CFR Part 314.500, Subpart H. The second is a multi-arm, open-label, Phase 1b dose escalation and expansion trial
evaluating ME-401 as a monotherapy and in combination with other therapies or investigational agents in patients with relapsed or refractory B-cell malignancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">While PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors as a group are a clinically validated class for the treatment of B-cell
malignancies, the FDA approved orally administered products, idelalisib (marketed as Zydelig<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) and duvelisib (marketed as COPIKTRA<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>),
and the intravenously administered PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT>/<FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT> inhibitor copanlisib (marketed as Aliqopa<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), are challenged
by dose-limiting toxicities. We believe this provides an opportunity for the development of a next-generation candidate with pharmaceutical properties that may better maximize the biological potential of
PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibition by limiting toxicities, which hinder clinical utility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The molecular
structure and pharmacodynamic characteristics of ME-401 are distinct from the FDA approved PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> inhibitors. ME-401 is characterized by prolonged target binding, preferential cellular accumulation, high
volume of distribution throughout the body tissues, and an approximately 28-hour half-life suitable for once daily oral administration. These properties of ME-401 allow exploration of flexible dosing regimens such as an intermittent dosing schedule,
which has the potential to maintain clinical benefit while minimizing immune-related toxicities common to other PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> agents, either as a monotherapy or in combination with other therapies or
investigational agents. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ME-401 Scientific Overview: at the Crossroads of B-cell Signaling Pathways </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The PI3K/AKT/mTOR pathway is an important signaling pathway for many cellular functions such as cell survival, cell cycle progression and
cellular growth. PI3Ks are a family of enzymes within this pathway that have been shown to play a critical role in the proliferation and survival of certain cancer cells. Specifically, the PI3K<FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> isoform
is at the crossroads of B-cell receptor signaling pathways that are major drivers of survival and proliferation of many B-cell malignancies. Because the <FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT> isoform is largely restricted to leukocytes, it
is an attractive target for selectively inhibiting the PI3K pathway in B-cell malignancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PI3K</I><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT><I></I><I> Inhibitors and B-Cell Malignancies </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are conducting two
ongoing studies: a Phase 2 trial evaluating patients with relapsed or refractory FL intended to support an accelerated approval of a marketing application with the FDA under 21 CFR Part 314.500, Subpart H, and a multi-arm, open-label, Phase 1b dose
escalation and expansion trial as a monotherapy and in combination with other therapies or investigational agents in patients with FL and other B-cell malignancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 1b Multi-arm Trial </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In October
2019, we reported updated interim data from the ongoing Phase 1b clinical trial evaluating ME-401 as a monotherapy and in combination with rituximab in patients with relapsed or refractory B-cell malignancies. Over 95 patients were enrolled at the
time of the update, of which data on 73 patients were reported on for response: 55 patients with relapsed or refractory FL and 18 with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (&#147;CLL/SLL&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-401 is administered once daily at 60 mg for two 28-day cycles and then on an intermittent schedule (i.e.&nbsp;IS) of once daily dosing for
the first seven days of each subsequent 28-day cycle. A previous cohort of monotherapy patients in the trial was treated with ME-401 at 60 to 180 mg administered continuously once daily (i.e. CS) or were switched to the IS in later cycles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The overall response rate, a secondary objective, was 81% among the 73 evaluable r/r FL and r/r CLL/SLL patients. The overall response rate
was 78% and 89% in the 55 and 18 patients with FL or CLL/SLL, respectively. Responses appeared durable with a median observation time between 7.4 and 24.5&nbsp;months, depending on the dosing schedule, the subject&#146;s disease state, and whether
ME-401 was used as a monotherapy or combination therapy. Overall response rates and durability of response appeared consistent across various groups, including dosing schedule, dosing regiment and number of prior systemic therapies received. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLL/SLL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B><br><B>Evaluable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Overall</B><br><B>Response</B><br><B>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number</B><br><B>Evaluable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Overall</B><br><B>Response</B><br><B>Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All patients</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43&nbsp;(78%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16&nbsp;(89%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By regimen:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ME-401 alone</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31&nbsp;(79%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ME-401 + rituximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12&nbsp;(75%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5&nbsp;(71%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By schedule:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23&nbsp;(79%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6&nbsp;(75%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CS</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20&nbsp;(70%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10&nbsp;(100%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-401 was generally well-tolerated and no grade 4 or grade 5 adverse events of special
interest have been observed in the Phase 1b trial. Among drug related grade 3 adverse events of special interest, the most common was diarrhea/colitis at 5.0% (3/57) on IS dosing and 23% (9/39) on CS dosing. Grade 3 elevations in ALT and AST were
transient and in each case were associated with grade 3 diarrhea or rash. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Grade 3 Drug Related Adverse Events of Special Interest</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CS&nbsp;Group</B><br><B>(N&nbsp;=&nbsp;39)</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>IS&nbsp;Group</B><br><B>(N&nbsp;=&nbsp;57)</B><br><B>n&nbsp;(%)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diarrhea/Colitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9&nbsp;(23%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(5%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rash, all types</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ALT/AST increased</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3&nbsp;(8%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mucositis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(3%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pneumonia/Pneumonitis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4&nbsp;(10%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1&nbsp;(2%)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The Phase 1b trial is additionally evaluating ME-401 (60 mg) in combination with zanubrutinib, an
investigational inhibitor of Bruton&#146;s tyrosine kinase (&#147;BTK&#148;) being developed by BeiGene, Ltd. (&#147;BeiGene&#148;). Pursuant to a collaboration initiated with BeiGene in October 2018, we began evaluating the safety and efficacy of
ME-401 in combination with zanubrutinib for the treatment of patients with various relapsed or refractory <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies. The cost of the combination trial is being equally shared. Each company is
supplying its own investigational agent. We retain all commercial rights to ME-401 and BeiGene retains all commercial rights to zanubrutinib. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Phase 2
Trial Intended to Support an Accelerated Approval Marketing Application </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are recruiting patients in a global Phase&nbsp;2 trial
evaluating the efficacy, safety, and tolerability of <FONT STYLE="white-space:nowrap">ME-401</FONT> in patients with FL after failure of at least two prior systemic therapies including chemotherapy and anti-CD20 antibody. This study is intended to
support an FDA accelerated approval New Drug Application. The study was initially designed to evaluate both the CS and IS dosing regimens; in one arm, <FONT STYLE="white-space:nowrap">ME-401</FONT> was administered once daily continuously and in the
other arm, <FONT STYLE="white-space:nowrap">ME-401</FONT> was administered once daily for two cycles (i.e., eight weeks) followed by an intermittent schedule whereby <FONT STYLE="white-space:nowrap">ME-401</FONT> was administered once daily for the
first seven days of a 28-day cycle followed by 21&nbsp;days of placebo. Based on maturing data from the Phase&nbsp;1b trial, which demonstrates that the IS regimen is as active as the CS regimen, with durable response, and is at the same time
associated with improved tolerability, we amended the protocol to continue enrollment in the IS regimen only. Approximately 120&nbsp;patients will be enrolled in the IS arm and the primary efficacy endpoint will be the rate of objective responses to
therapy and tolerability of <FONT STYLE="white-space:nowrap">ME-401.</FONT> We currently estimate completion of enrollment in summer 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voruciclib:
CDK Inhibitor with CDK9 Inhibition in Phase 1 Studies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Voruciclib is an orally administered CDK inhibitor differentiated by its potent
in vitro inhibition of CDK9 in addition to CDK6, 4 and 1. Voruciclib is currently being evaluated in a Phase 1b dose ranging trial in patients with B-cell malignancies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voruciclib Scientific Overview: Cell Cycle Signaling </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The CDK family of proteins are important cell cycle regulators. CDK9 is a transcriptional regulator of the myeloid leukemia cell
differentiation protein (&#147;MCL1&#148;), a member of the family of anti-apoptotic proteins which, when elevated, may prevent the cell from undergoing cell death. Inhibition of CDK9 blocks the production of MCL1, which is an established resistance
mechanism to the B-cell lymphoma (&#147;BCL2&#148;) inhibitor venetoclax (marketed as Venclexta<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In pre-clinical studies voruciclib shows dose-dependent suppression of MCL1; in December
2017 a study of voruciclib published in the journal Nature Scientific Reports reported that the combination of voruciclib plus the BCL-2 inhibitor venetoclax was capable of inhibiting two master regulators of cell survival, MCL-1 and BCL-2, and
achieved synergistic antitumor effect in an aggressive subset of DLBCL pre-clinical models. (Scientific Reports. (2017) 7:18007. DOI:10.1038/s41598-017-18368-w). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Additionally, at the 2018 American Society of Hematology (&#147;ASH&#148;) annual meeting we presented results from pre-clinical studies
demonstrating that voruciclib synergizes with venetoclax to induce apoptosis in both venetoclax sensitive and resistant acute myeloid leukemia (&#147;AML&#148;) cells. The pre-clinical data further demonstrated that voruciclib transiently
downregulates MCL1 and that MCL1 downregulation is likely responsible for the bulk of the synergy between voruciclib and venetoclax. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">CDK9
is also a transcriptional regulator of MYC, a transcription factor regulating cell proliferation and growth which contributes to many human cancers and is frequently associated with poor prognosis and unfavorable patient survival. Targeting MYC
directly has historically been difficult, but CDK9 is a transcriptional regulator of MYC and is a promising approach to target this oncogene. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical
Program </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are evaluating patients with hematological malignancies in a dose ranging Phase 1b clinical trial of voruciclib. The trial
is initially intended to evaluate voruciclib as a monotherapy in patients with relapsed and/or refractory B-cell malignancies or AML after failure of prior standard therapies to determine the safety, preliminary efficacy and maximum tolerated dose.
In parallel, subject to FDA agreement, we also plan to evaluate voruciclib in combination with a BCL2 inhibitor such as venetoclax to assess synergies and the opportunity for combination treatments across multiple indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Voruciclib was previously evaluated in more than 70 patients in multiple Phase 1 studies with a tolerability profile consistent with other
drugs in its class. In pre-clinical studies, voruciclib shows dose-dependent suppression of MCL1 at concentrations achievable with doses that appear to be generally well tolerated in earlier Phase 1 studies. Pre-clinical studies additionally show
inhibition of MYC protein expression. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ME-344:</FONT> Mitochondrial Inhibitor with Combinatorial Potential </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-344 is our novel and tumor selective, isoflavone-derived mitochondrial inhibitor drug candidate. It directly targets the OXPHOS complex 1,
a pathway involved in ATP production in the mitochondria. ME-344 was recently studied in an investigator-initiated, multi-center, randomized clinical trial in combination with the vascular endothelial growth factor (&#147;VEGF&#148;) inhibitor
bevacizumab (marketed as Avastin <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in a total of 42 patients with HER2 negative breast cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>ME-344 Scientific Overview: Cancer Metabolism </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Tumor cells often display a high metabolic rate to support cell division and growth. This heightened metabolism requires a continual supply of
energy in the form of adenosine triphosphate (&#147;ATP&#148;). The two major sources of ATP are the specialized cellular organelles termed mitochondria and through the metabolism of carbohydrates, proteins and lipids. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-344 was identified through a screen of more than 400 new chemical structures originally created based on the central design of naturally
occurring plant isoflavones. We believe that some of these synthetic compounds, including our drug candidate ME-344, interact with specific mitochondrial enzyme targets, resulting in the inhibition of ATP generation. When these compounds interact
with their target, a rapid reduction in ATP occurs, which leads to a cascade of biochemical events within the cell and ultimately to cell death. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-344 demonstrated evidence of single agent activity against refractory solid tumors in a Phase 1 trial, and in pre-clinical studies tumor
cells treated with ME-344 resulted in a rapid loss of ATP and cancer cell death. In addition to single agent activity, ME-344 may also have significant potential in combination with anti-angiogenic therapeutics. In pre-clinical studies, it was shown
that one outcome of anti-angiogenics was to reduce the rate of glycolysis in tumors as a mechanism to slow tumor growth. However, tumor metabolism was able to shift to mitochondrial metabolism for energy production to support continued tumor
proliferation. In such cases of tumor plasticity in the presence of treatment with anti-angiogenics, targeting the alternative metabolic source with ME-344 may open an important therapeutic opportunity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Support for this combinatorial use of ME-344 was first published in the June 2016 edition of Cell Reports; pre-clinical data from a
collaboration with the Spanish National Cancer Research Centre in Madrid demonstrated mitochondria-specific effects of ME-344 in cancer cells, including substantially enhanced anti-tumor activity when combined with agents that inhibit the activity
of VEGF. These data demonstrating the potential anti-cancer effects of combining ME-344 with a VEGF inhibitor due to an inhibition of both mitochondrial and glycolytic metabolism provided a basis for commencement of an investigator-initiated trial
of ME-344 in combination with bevacizumab in HER2 negative breast cancer patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In June 2019, at the American Society of Clinical
Oncology annual meeting, further support for the combinatorial use of ME-344 with anti-angiogenic therapeutics was presented from a multicenter, investigator-initiated, randomized, open-label, clinical trial that evaluated the combination of ME-344
and bevacizumab in 42 patients with early HER2-negative breast cancer. Patients were randomized one-to-one to either ME-344 in combination with bevacizumab or saline in combination with bevacizumab. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The primary objective of the trial was to show proof of ME-344 biologic activity as measured by Ki67 reductions (a measure of cell
proliferation that is highly correlated with tumor response) from day 0 to 28 compared to the control group who received bevacizumab alone. Secondary objectives included determining whether ME-344 biologic activity correlates with vascular
normalization. The data demonstrate significant biologic activity in the ME-344 treatment group: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In ME-344 treated patients, mean absolute Ki67 decreases were 13.3 compared to an increase of 1.1 in the
bevacizumab monotherapy group (P=0.01). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In ME-344 treated patients, mean relative Ki67 decreases were 23% compared to an increase of 186% in the
bevacizumab monotherapy group (P &lt; 0.01). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The mean relative Ki67 reduction in patients experiencing vascular normalization in the ME-344 treated patients
was 33%, compared to an increase of 11.8% in normalized patients from the bevacizumab monotherapy group (P=0.09). Approximately one-third of patients in each arm had vascular normalization. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Treatment was generally well tolerated; three Grade 3 adverse events of high blood pressure were reported, two in the ME-344 arm and one in
the bevacizumab monotherapy arm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Results from our earlier, first-in-human, single-agent Phase 1 clinical trial of ME-344 in patients with
refractory solid tumors were published in the April 1, 2015 issue of Cancer. The results indicated that eight of 21 evaluable patients (38%) treated with ME-344 achieved stable disease or better, including five who experienced progression-free
survival that was at least twice the duration of their last prior treatment before entry into the trial. In addition, one of these patients, a heavily pre-treated patient with small cell lung cancer, achieved a confirmed partial response and
remained on study for two years. ME-344 was generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Treatment-related adverse events included nausea, dizziness and fatigue.
Dose-limiting toxicities were observed at both the 15 mg/kg and 20 mg/kg dose levels, consisting primarily of grade three peripheral neuropathy. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pracinostat: HDAC Inhibitor Candidate in a Phase 3 Global Registration Clinical Trial </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Pracinostat is an oral HDAC inhibitor being evaluated in a pivotal Phase 3 global registration clinical trial for the treatment of adults with
newly diagnosed AML who are unfit to receive intensive chemotherapy. Pracinostat is also being evaluated in a Phase 2 trial in patients with high or very high-risk myelodysplastic syndrome (&#147;MDS&#148;). In August 2016, we entered into an
exclusive worldwide license, development, manufacturing and commercialization agreement with Helsinn Healthcare SA, a Swiss pharmaceutical corporation (&#147;Helsinn&#148;) for pracinostat in AML, MDS and other potential indications (the
&#147;Helsinn License Agreement&#148;). Under the agreement, Helsinn is primarily responsible for funding global development and commercialization costs for pracinostat. We are responsible for conducting the Phase 2 MDS trial, the cost of which is
being shared equally with Helsinn. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Breakthrough Therapy Designation for pracinostat was granted by the FDA in 2016, and in January 2018
the European Medicines Agency granted Orphan Drug Designation to pracinostat for the treatment of AML. The designations in the US and European Union (&#147;EU&#148;) are supported by data from a Phase 2 trial of pracinostat plus azacitidine
(marketed as Vidaza<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in elderly patients with newly diagnosed AML who are not candidates for induction chemotherapy. The trial showed a median overall survival of 19.1 months and a complete
remission (&#147;CR&#148;) rate of 42% (21 of 50 patients). These data compare favorably to an international Phase 3 trial of azacitidine (AZA-001; Dombret et al. Blood. 2015 May 18), which showed a median overall survival of 10.4 months with
azacitidine alone and a CR rate of 19.5% in a similar patient population. The combination of pracinostat and azacitidine was generally well tolerated, with no unexpected toxicities. The most common grade 3/4 treatment-emergent adverse events
included febrile neutropenia, thrombocytopenia, anemia and fatigue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Pracinostat Scientific Overview; Epigenetics </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">HDACs play a key role in epigenetic regulation of gene expression by regulating chromatin structure. Acetylation of positively charged lysine
residues present in histone proteins by the histone acetyltransferase (&#147;HATs&#148;) reduces the affinity between histones and negatively charged DNA, resulting in the opening of the chromatin structure. This makes it easier for the
transcriptional machinery to access the DNA, enhancing RNA transcription. Conversely, deacetylation by the HDACs closes the chromatin structure leading to a repression of gene transcription. In normal cells, HDACs and HATs together control histone
acetylation levels to maintain a balance. In diseases such as cancer, this regulation can be disturbed. HDAC inhibitors cause accumulation of acetylated histones, enhance transcription and result in changes to a variety of cellular responses
including differentiation, proliferation, migration, survival and response to metabolic and hypoxic stress. In general, tumor cells are more susceptible than normal cells to the anti-proliferative and pro-apoptotic effects of HDAC inhibitors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">There are currently three HDAC inhibitors, one oral and two injectable, approved by the FDA for the treatment of T-cell lymphoma and a fourth
orally administered HDAC inhibitor approved for multiple myeloma. Other HDAC inhibitors are being evaluated in clinical trials as monotherapies and in combination for the treatment of various hematologic diseases and solid tumors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Pracinostat is an orally available, potent HDAC inhibitor with potentially improved physicochemical, pharmaceutical and pharmacokinetic
properties when compared to other compounds of this class, including increased bioavailability and increased half-life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Clinical Program </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The ongoing pivotal Phase 3 registration trial, which is being run by Helsinn and was initiated in June 2017, is a randomized, double-blind,
placebo-controlled study that will enroll worldwide approximately 500 adults with newly diagnosed AML who are unfit to receive intensive chemotherapy. Patients are randomized 1:1 to receive </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pracinostat or placebo with azacitidine as background therapy. The primary endpoint of the trial is overall survival. Secondary endpoints include morphologic CR rate, event-free survival and
duration of CR. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Additionally, pracinostat is being investigated in a Phase 2 dose optimization trial evaluating patients with high and
very high-risk MDS who are previously untreated with hypomethylating agents. This patient group represents the highest unmet need in MDS, with median survival estimates of 1.6 years and 0.8 years, respectively (Greenberg et al, Blood 2012). The
ongoing Phase 2 open-label trial is evaluating a 45 mg dose of pracinostat in combination with the standard dose of azacitidine. The trial is designed to evaluate tolerability of the combination, with the intent of maintaining patient enrollment
longer than in an earlier Phase 2 trial evaluating a 60 mg dose. A prolonged treatment may result in a systemic exposure to pracinostat and azacitidine sufficient to achieve the desired treatment effect; data from the earlier Phase 2 trial suggested
that insufficient exposure to treatment may have limited the treatment effect of the combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">A pre-planned interim analysis of the
ongoing Phase 2 MDS trial demonstrated a 10% discontinuation rate among the first 20 evaluable patients treated, meeting the predefined threshold in the first 3 treatment cycles. The 10% rate is consistent with the discontinuation rate for
azacitidine given as a monotherapy in earlier studies with pracinostat. Having met this threshold, the trial expanded open-label enrollment to a total of 60 patients in the study. An interim analysis presented at the 2018 ASH meeting demonstrated a
discontinuation rate due to adverse events in the first 3 months of 4%, substantially lower than the rate of 26% reported in the Company&#146;s prior Phase 2 trial. The Phase 2 trial has completed enrollment and patients will be followed for one
year to evaluate safety and efficacy. The primary endpoints of the trial are 1) safety and tolerability and 2) overall response rate, defined as CR, partial remission (&#147;PR&#148;) and marrow CR. Secondary endpoints include CR rate, overall
hematologic improvement (&#147;HI&#148;) response rate, clinical benefit rate (defined as rate of CR + PR + HI + Marrow CR), rate of cytogenetic complete response/remission, duration of response, rate of leukemic transformation, event-free survival,
progression-free survival and overall survival. If the Phase 2 open-label trial is successful, Helsinn intends to initiate a global registration trial. All future development and commercialization costs after the completion of the Phase 2 trial are
the responsibility of Helsinn. Pracinostat has been previously investigated in more than 300 patients in multiple Phase 1 and Phase 2 clinical trials and found to be generally well tolerated with manageable side effects often associated with drugs
of this class, including fatigue, myelosuppression and gastrointestinal toxicity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 3611 Valley Centre Drive, Suite 500, San Diego, CA 92130, and our phone number is (858) <FONT
STYLE="white-space:nowrap">369-7100.</FONT> Our website is located at www.meipharma.com. Information on or accessible through our website is not part of, or incorporated by reference into, this prospectus supplement, other than documents filed with
the SEC that we incorporate by reference. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock offered by us pursuant to this prospectus supplement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock outstanding after the offering (assuming no exercise of the underwriters&#146; option
to purchase additional shares)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Option to purchase additional shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We have granted the underwriters an option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock. This option is exercisable,
in whole or in part, for a period of 30 days from the date of this prospectus supplement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Use of proceeds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">We intend to use a portion of the net proceeds from this offering, together with other available funds, to progress our clinical development programs and for other general corporate purposes. See &#147;Use of Proceeds&#148; on
page S-13.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nasdaq Capital Market symbol</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&#147;MEIP&#148;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk factors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">This investment involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page S-10 of this prospectus supplement, the risk factors beginning on page 13 of our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> as filed with the Securities and Exchange Commission on August&nbsp;28, 2019, as well as the other information included in or incorporated by reference in this prospectus supplement and the accompanying
base prospectus for a discussion of risks you should consider carefully before making an investment decision.</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on 73,654,927 shares of common stock outstanding as of November 30, 2019. Excludes (i) 10,966,551 shares
of our common stock subject to outstanding options, with exercise prices ranging from $1.21 to $6.47&nbsp;per share, (ii) 16,061,602&nbsp;shares of our common stock subject to outstanding warrants, with an exercise price of $2.54&nbsp;per share and
(iii) 6,830,587&nbsp;shares of our common stock available for awards under our Amended and Restated 2008 Stock Omnibus Equity Compensation Plan, in each case as of November 30, 2019. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:3%; font-size:10pt; font-family:Times New Roman">Unless otherwise stated, all information contained in this prospectus supplement assumes no exercise of the underwriters&#146; option to
purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Any investment in our common stock involves a high degree of risk. In addition to the other information included or incorporated by
reference in this prospectus supplement and the accompanying base prospectus, you should carefully consider the important factors set forth under the heading &#147;Risk Factors&#148; starting on page 13 of our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended June&nbsp;30, 2019 and incorporated herein by reference before investing in our common stock. For further details, see the sections entitled &#147;Where You Can Find More
Information&#148; and &#147;Incorporation of Certain Documents by Reference&#148; in this prospectus supplement. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><I>Any of the risk
factors set forth below or referred to above could significantly and negatively affect our business, results of operations or financial condition, which may lower the trading price of our common stock. The risks referred to above are not the only
ones that may exist. Additional risks not currently known by us or that we deem immaterial may also impair our business operations. You may lose all or a part of your investment. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Securities Markets and Investment in our Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of the shares of our common stock has been and may continue to be highly volatile and could decline in value and we may incur
significant costs from class action litigation. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The trading price of our common stock could be highly volatile in response to
various factors, many of which are beyond our control, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">failure to successfully develop our drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">design, results and timing of clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">announcements of technological innovations by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">new products introduced or announced by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in financial estimates by securities analysts; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated variations in operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">expiration or termination of licenses, research contracts or other collaboration agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conditions or trends in the regulatory climate and the biotechnology, pharmaceutical and genomics industries;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">instability in the stock market as a result of current or future domestic and global events;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidity of any market for our securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">threatened or actual delisting of our common stock from a national stock exchange. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Equity markets in general, and the market for biotechnology and life sciences companies in particular, have experienced substantial price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies traded in those markets. In addition, changes in economic conditions in the U.S., Europe or globally, particularly in the context of
current global events, could impact upon our ability to grow profitably. Adverse economic changes are outside our control and may result in material adverse impacts on our business or our results of operations. These broad market and industry
factors may materially affect the market price of shares of our common stock, regardless of our development and operating performance. In the past, following periods of volatility in the market price of a company&#146;s securities, securities
class-action litigation has often been instituted against that company. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales of our common stock, including common stock issued upon exercise of outstanding warrants
or options, may depress the market price of our common stock and cause stockholders to experience dilution. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The market price of
our common stock could decline as a result of sales of substantial amounts of our common stock in the public market, including upon exercise of outstanding warrants or stock options, and any subsequent sales of such shares. As of September&nbsp;30,
2019, we had outstanding warrants issued in our May 2018 private placement exercisable to purchase 16,061,602 shares of common stock at an exercise price of $2.54 per share, which expire in May 2023. We also had outstanding options to purchase
8,356,961 shares of common stock. We may seek additional capital through one or more additional equity transactions in the future; however, such transactions will be subject to market conditions and there can be no assurance any such transactions
will be completed. If we sell shares in the future, the prices at which we sell these future shares will vary, and these variations may be significant. Stockholders, including investors in this offering, will experience significant dilution if we
sell these future shares at prices significantly below the price at which such stockholders invested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investors in this offering will experience
immediate and substantial dilution and may experience further dilution in the future. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The public offering price of the common
stock offered pursuant to this prospectus supplement is substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase shares of common stock in this offering, you will incur immediate and substantial
dilution in the net tangible book value per share of common stock from the price per share that you pay for the common stock. Furthermore, we expect that we will seek to raise additional capital from time to time in the future. Such financings may
involve the issuance of equity and/or securities convertible into or exercisable or exchangeable for our equity securities. We also expect to continue to utilize equity-based compensation. To the extent the warrants and options are exercised or we
issue common stock, preferred stock, or securities such as warrants that are convertible into, exercisable or exchangeable for, our common stock or preferred stock in the future, you may experience further dilution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not intend to pay, and have not paid, any cash dividends on our shares of common stock, our stockholders will not be able to receive a
return on their shares unless the value of our common stock appreciates and they sell their shares. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We have never paid or
declared any cash dividends on our common stock, and we intend to retain any future earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our common stock in the foreseeable future.
Therefore, our stockholders will not be able to receive a return on their investment unless the value of our common stock appreciates and they sell their shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will have broad discretion over the use of the net proceeds from this offering and upon any exercise of outstanding warrants and options.
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We will have broad discretion to use the net proceeds to us from this offering and upon any exercise of outstanding warrants and
options, and investors in our stock will be relying on the judgment of our board of directors and management regarding the application of these proceeds. Although we expect to use a substantial portion of the net proceeds from this offering and upon
any exercise of the warrants and options for general corporate purposes and progression of our clinical trial programs, we have not allocated these net proceeds for specific purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are authorized to issue blank check preferred stock, which could adversely affect the holders of our common stock. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation allows us to issue blank check preferred stock with rights potentially senior to those
of our common stock without any further vote or action by the holders of our common stock. The issuance of a class of preferred stock could decrease the amount of earnings and assets </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
available for distribution to the holders of our common stock or could adversely affect the rights and powers, including voting rights, of such holders. In certain circumstances, such issuance
could have the effect of decreasing the market price of our shares, or making a change in control of the Company more difficult. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our executive
officers and directors may sell shares of their stock, and these sales could adversely affect our stock price. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Sales of our stock
by our executive officers and directors, or the perception that such sales may occur, could cause the market price of our common stock to decline or could make it more difficult for us to raise funds through the sale of equity in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we have entered into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for a period of 90 days
following this offering and our directors and officers have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements for a period of 90 days following this offering, in each case, subject to certain exceptions. We and our directors
and officers may be released from the <FONT STYLE="white-space:nowrap">lock-up</FONT> prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period at the sole discretion of Stifel, Nicolaus&nbsp;&amp; Company, Incorporated
and Wells Fargo Securities, LLC, as representatives of the underwriters. See &#147;Underwriting.&#148; Upon expiration or earlier release of the <FONT STYLE="white-space:nowrap">lock-up,</FONT> we and our directors and officers may sell shares into
the market, either as part, or outside of trading plans under SEC Rule <FONT STYLE="white-space:nowrap">10b5-1,</FONT> which could adversely affect the market price of shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from our sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our
common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million (or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters&#146; option to purchase additional shares is
exercised in full), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We intend to
use a portion of the net proceeds from this offering, together with other available funds, to progress our clinical development programs, as well as for working capital and other general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We have not specifically identified the precise amounts we will spend on particular areas or the timing of these expenditures. The amounts
actually expended for each purpose may vary significantly depending upon numerous factors, including the amount and timing of the proceeds from this offering, the progress of our clinical trials and other product development activities. In addition,
expenditures may also depend on the establishment of new collaborative arrangements with other partners, the availability of other financing and other factors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We anticipate that we will be required to raise substantial additional capital to continue to fund the clinical development of our drug
candidates. We expect to seek to raise additional capital through additional public or private financings, principally through equity issuances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_6"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Subject to the terms and conditions set forth in the underwriting agreement, dated December &nbsp;&nbsp;&nbsp;&nbsp;, 2019, between us and
Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Wells Fargo Securities, LLC, as the representatives of the underwriters named below, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not
jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Number<BR>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the obligations of the several underwriters are subject to certain
conditions precedent such as the receipt by the underwriters of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the
shares of common stock if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We
have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of
those liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that, following the completion of this offering, they currently intend to make a
market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion.
Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be
favorable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and
subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Certain of our officers and directors have expressed indications of interest to purchase shares of common stock with an aggregate public
offering price of approximately $185,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the
proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>Option&nbsp;to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With<BR>Option&nbsp;to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Without<BR>Option&nbsp;to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>With<BR>Option&nbsp;to<BR>Purchase<BR>Additional<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and
commissions referred to above, will be approximately $200,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;MEIP.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stamp Taxes </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">If you purchase shares of
common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Option to Purchase Additional Shares </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We
have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the
underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We
and our officers and directors have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Securities Exchange Act of 1934, as amended, or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or
securities exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">publicly announce an intention to do any of the foregoing for a period of 90 days after the date of this
prospectus without the prior written consent of Stifel, Nicolaus&nbsp;&amp; Company, Incorporated and Wells Fargo Securities, LLC. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This restriction terminates after the close of trading of the common stock on and including the 90<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company,
Incorporated and Wells Fargo Securities, LLC may, in their sole discretion and at any time or from time to time before the termination of the <FONT STYLE="white-space:nowrap">90-day</FONT> period release all or any portion of the securities subject
to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our officers and directors who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing
consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stabilization </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The underwriters have advised us that they may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or
the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market.
Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of
our common stock in this offering. The underwriters may close out any covered short </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares to
close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase
additional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our common stock. The
underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our
common stock in the open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">A stabilizing bid is a
bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf
of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising
or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market.
A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a
syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the
underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and,
if commenced, any of the activities may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The underwriters may also engage in passive market making
transactions in our common stock on The NASDAQ Capital Market in accordance with Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the
completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must
then be lowered when specified purchase limits are exceeded. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format may be made available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through
online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares of common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic
format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and
should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The underwriters and certain of their respective affiliates are full service financial institutions engaged in various activities, which may
include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The underwriters and certain of their respective affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory
services for us and our affiliates, for which they received or will receive customary fees and expenses. Stifel, Nicolaus &amp; Company, Incorporated is the sales agent under our &#147;at-the-market&#148; equity offering program, pursuant to which
it receives customary fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriters and certain of their respective
affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers,
and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates.&nbsp;&nbsp;&nbsp;&nbsp;If the underwriters or their respective affiliates have a lending relationship with us, they routinely
hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default
swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely affect future trading prices of the common stock offered
hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or
instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the European Economic Area </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be made to
the public in that Relevant Member State other than: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to any legal entity which is a qualified investor as defined in the Prospectus Directive;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD
Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representative; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided that no such offer of shares shall require the Company or the representative to publish a prospectus pursuant to Article 3 of the
Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Each person in a Relevant Member
State who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing
Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented,
acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to,
persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member State to qualified investors as so defined or in circumstances in which the prior consent of the
representative has been obtained to each such proposed offer or resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The Company, the representative and their affiliates will rely
upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus has been prepared on the
basis that any offer of shares in any Relevant Member State will be made pursuant to an exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an
offer in that Relevant Member State of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares which are the subject of the offering contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a
prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises
for the Company or the underwriters to publish a prospectus for such offer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">For the purpose of the above provisions, the expression
&#147;an offer to the public&#148; in relation to any shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an
investor to decide to purchase or subscribe the shares, as the same may be varied in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148;
means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending
Directive&#148; means Directive 2010/73/EU. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the United Kingdom </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may
only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19 (5) of the Financial Services and
Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the
Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment or investment
activity to which this document relates is only available to, and will be engaged in with, relevant persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Switzerland </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;)
or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the
disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing
material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Neither
this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the
offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes
(&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services
Authority (&#147;DFSA&#148;). This prospectus supplement is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for the prospectus
supplement. The shares to which this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If
you do not understand the contents of this prospectus supplement you should consult an authorized financial advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors
in Australia </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the
Australian Securities and Investments Commission (&#147;ASIC&#148;), in relation to the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus does not constitute a
prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the &#147;Corporations Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or
other disclosure document under the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt
Investors&#148;) who are &#147;sophisticated investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to
one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of
allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is
pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian <FONT STYLE="white-space:nowrap">on-sale</FONT> restrictions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular
needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a
&#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the securities has been
or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except
if permitted to do so under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance and any rules made under that Ordinance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in
effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Singapore </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities may not be circulated or distributed, nor may the
<FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional
investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the
conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Where the <FONT STYLE="white-space:nowrap">Non-CIS</FONT> Securities are subscribed or purchased under Section&nbsp;275 of the SFA by a
relevant person which is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each
beneficiary of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">securities (as defined in Section&nbsp;239(1) of the SFA) of
that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the <FONT STYLE="white-space:nowrap">Non-CIS</FONT>
Securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any
person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus supplement constitutes an &#147;exempt offering document&#148; as defined in and for the purposes of applicable Canadian
securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the common stock. No securities commission or similar regulatory authority in Canada has
reviewed or in any way passed upon this prospectus supplement or on the merits of the common stock and any representation to the contrary is an offence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><B>Canadian investors are advised that this prospectus supplement has been prepared in reliance on section 3A.3 of National Instrument <FONT
STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (&#147;NI <FONT STYLE="white-space:nowrap">33-105&#148;).</FONT> Pursuant to section 3A.3 of NI <FONT STYLE="white-space:nowrap">33-105,</FONT> this prospectus supplement is exempt from
the requirement that the Company and the underwriter(s) provide investors with certain conflicts of interest disclosure pertaining to &#147;connected issuer&#148; and/or &#147;related issuer&#148; relationships that may exist between the Company and
the underwriter(s) as would otherwise be required pursuant to subsection 2.1(1) of NI <FONT STYLE="white-space:nowrap">33-105.</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resale Restrictions </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The offer and sale of the common stock in Canada is being made on a private placement basis only and is exempt from the requirement that the
Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of the common stock acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary
depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus
requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the
common stock outside of Canada. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Representations of Purchasers </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Each Canadian investor who purchases the common stock will be deemed to have represented to the Company and the underwriter(s) that the
investor (i)&nbsp;is purchasing the common stock as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii)&nbsp;is an
&#147;accredited investor&#148; as such term is defined in section 1.1 of National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act
(Ontario); and (iii)&nbsp;is a &#147;permitted client&#148; as such term is defined in section 1.1 of National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation and Eligibility for Investment </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Any discussion of taxation and related matters contained in this prospectus supplement does not purport to be a comprehensive description of
all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the common stock and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax
consequences to a resident, or deemed resident, of Canada of an investment in the common stock or with respect to the eligibility of the common stock for investment by such investor under relevant Canadian federal and provincial legislation and
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rights of Action for Damages or Rescission </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum
(such as this prospectus supplement), including where the distribution involves an &#147;eligible foreign security&#148; as such term is defined in Ontario Securities Commission Rule <FONT STYLE="white-space:nowrap">45-501</FONT> Ontario Prospectus
and Registration Exemptions and in Multilateral Instrument <FONT STYLE="white-space:nowrap">45-107</FONT> Listing Representation and Statutory Rights of Action Disclosure Exemptions, as applicable, with a remedy for damages or rescission, or both,
in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a &#147;misrepresentation&#148; as defined under applicable
Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defenses under,
applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Language of Documents </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Upon receipt of
this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or
any notice) be drawn up in the English language only. <I>Par la reception de ce document, chaque investisseur Canadien confirme par les presentes qu&#146;il a expressement exige que tous les</I> <I>documents faisant foi ou se rapportant de quelque
maniere que ce soit a la vente des valeurs mobilieres decrites aux presentes (incluant, pour plus de certitude, toute confirmation d&#146;achat ou tout avis) soient rediges en anglais seulement</I>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_7"></A><A NAME="supptoc841008_7"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP, New York, New York. Goodwin
Procter LLP, New York, New York, is acting as counsel for the underwriters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_8"></A><A NAME="supptoc841008_8"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The financial statements as of June&nbsp;30, 2019 and 2018, and for each of the three years in the period ended June&nbsp;30, 2019 and
management&#146;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2019, incorporated by reference into this prospectus supplement have been so incorporated in reliance on the reports of BDO USA, LLP,
an independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_9"></A><A NAME="supptoc841008_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptoc841008_10"></A><A NAME="supptoc841008_10"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus supplement the information we have filed with the SEC. The
information we incorporate by reference into this prospectus supplement is an important part of this prospectus supplement. Any statement in a document we incorporate by reference into this prospectus supplement or the accompanying base prospectus
will be considered to be modified or superseded to the extent a statement contained in this prospectus supplement or any other subsequently filed document that is incorporated by reference into this prospectus supplement modifies or supersedes that
statement. The modified or superseded statement will not be considered to be a part of this prospectus supplement or accompanying base prospectus, as applicable, except as modified or superseded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus supplement the information contained in the documents listed below, which is considered to be
a part of this prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519232454/d783135d10k.htm">Annual Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the fiscal year ended June&nbsp;30, 2019, filed with the SEC on August&nbsp;
28, 2019, as amended by <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308275/d805454d10ka.htm">Amendment No. 1 on Form 10-K/A</A> filed with the SEC on December&nbsp;6, 2019; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519287262/d667344d10q.htm">Quarterly Report on
 <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT></A> for the quarterly period ended September&nbsp;30, 2019, filed with the SEC on November&nbsp;7, 2019; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519189160/d769812d8k.htm">July
 3, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519308280/d842836d8k.htm">December&nbsp;6, 2019</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519232454/d783135d10k.htm">Annual
 Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT></A> for the year ended June&nbsp;
30, 2019 from our <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312519271911/d820020ddef14a.htm">definitive proxy statement on Schedule&nbsp;14A</A> (other than information furnished rather than filed), which was filed with the SEC on
October&nbsp;23, 2019; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in the <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000095012303013241/y92081ae8va12g.txt">Registration
 Statement on <FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A> filed on November&nbsp;26, 2003 and any further amendment or report filed thereafter for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents filed pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of
this prospectus supplement and prior to the termination of this offering; provided, however, that we are not incorporating any information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of any current report on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> we may subsequently file. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Statements made in this prospectus supplement or the accompanying base prospectus or in any
document incorporated by reference in this prospectus supplement or the accompanying base prospectus as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in each instance reference is
made to the copy of such contract or other document filed as an exhibit to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">3611 Valley
Centre Drive, Suite 500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Tel: (858) <FONT STYLE="white-space:nowrap">369-7100</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Copies
of these filings are also available, without charge, through the &#147;Investors&#148; section of our website (www.meipharma.com) as soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our
website is not a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>$150,000,000 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841008g84s08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>MEI PHARMA, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:42pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">We may offer up to $150,000,000 aggregate dollar
amount of our common stock, preferred stock and warrants to purchase our common stock or preferred stock from time to time in one or more offerings. This prospectus provides you with a general description of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">We may offer these securities at prices and on terms to be set forth in one or more supplements to this prospectus. These securities may be offered directly,
through agents on our behalf or through underwriters or dealers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">Our common stock is traded on the Nasdaq Capital Market under the symbol
&#147;MEIP.&#148; On May&nbsp;2, 2017, the closing price of our common stock on the Nasdaq Capital Market was $1.61 per share. The aggregate market value of the outstanding shares of our common stock held by non-affiliates was $59,155,000, based on
36,772,428 shares of common stock outstanding, of which 30,254 are held by affiliates, and a closing sale price on the NASDAQ Capital Market of $1.61 on May&nbsp;2, 2017. Pursuant to General Section I.B.6. of Form S-3, in no event will we sell
securities in a public primary offering with a value exceeding more than one-third of our &#147;public float&#148; (the market value of our common stock held by our non-affiliates) in any 12-month period so long as our public float remains below
$75,000,000. We have not sold any shares of our common stock or other securities pursuant to General Instruction I.B.6. of Form S-3 during the twelve calendar months prior to and including the date of this prospectus.</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B>An investment in our securities involves significant risks. See &#147;<A HREF="#toc841008_3">Risk Factors</A>&#148; on page 5 of this prospectus and in any
applicable prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of factors you should carefully consider before deciding to purchase our securities. </B></P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman"><B><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy of this prospectus. Any representation to the contrary is a criminal offense. </I></B></P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman">The date of this prospectus is May 15, 2017. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_2">SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_4">CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_5">SECURITIES OFFERED BY THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_7">RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED STOCK
DIVIDENDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_9">DESCRIPTION OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_10">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_11">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_12">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc841008_13">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Unless we have indicated otherwise, references in this prospectus to &#147;MEI Pharma,&#148; &#147;we,&#148; &#147;us&#148; and
&#147;our&#148; or similar terms are to MEI Pharma, Inc., a Delaware corporation. References in this prospectus to &#147;FDA&#148; refer to the United States Food and Drug Administration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or SEC, utilizing a
&#147;shelf&#148; registration statement. This prospectus provides you with a general description of the securities we may offer. We will describe the specific terms of those securities, as necessary, in supplements that we attach to this prospectus
for each offering. Each supplement will also contain specific information about the terms of the offering it describes. The supplements may also add to, update or change information contained in this prospectus. In addition, as we describe in the
sections entitled &#147;Incorporation of Certain Information by Reference&#148; and &#147;Where You Can Find More Information,&#148; we have filed and plan to continue to file other documents with the SEC that contain information about us. Before
you decide whether to invest in our securities, you should read this prospectus, the supplement that further describes the offering of those securities and the information we otherwise file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The registration statement that contains this prospectus, including the exhibits to the registration statement, contains additional
information about us and the securities being offered under this prospectus. You should read the registration statement and the accompanying exhibits for further information. The registration statement and exhibits can be read and are available to
the public over the Internet at the SEC&#146;s website at http: //www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman"><B>You should rely only on the information contained or
incorporated by reference in this prospectus and in any prospectus supplement. We have not authorized any person to provide any information or make any statement that differs from what is contained in this prospectus. If any person does make a
statement that differs from what is in this prospectus, you should not rely on it. This prospectus is not an offer to sell, nor is it a solicitation of an offer to buy, these securities in any state in which the offer or sale is not permitted. The
information in this prospectus is accurate as of its date, but the information may change after that date. You should not assume that the information in this prospectus is accurate as of any date after its date. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_2"></A>SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are an
oncology company focused on the clinical development of novel therapies for cancer.&nbsp;Our common stock is listed on the Nasdaq Capital Market under the symbol &#147;MEIP&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our business purpose is the development of drugs for the treatment of cancer. Our portfolio of clinical drug candidates includes Pracinostat,
an oral histone deacetylase (&#147;HDAC&#148;) inhibitor being developed in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (&#147;AML&#148;) who are unfit for intensive chemotherapy, and
patients with high or very high-risk myelodysplastic syndrome (&#147;MDS&#148;). In August 2016, we entered into an exclusive worldwide license, development and commercialization agreement with Helsinn Healthcare SA (&#147;Helsinn&#148;) for
Pracinostat in AML, MDS and other potential indications. Our clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase (&#147;PI3K&#148;) delta currently in a Phase Ib study in patients with
relapsed/refractory chronic lymphocytic leukemia (&#147;CLL&#148;) or follicular lymphoma, and ME-344, a mitochondrial inhibitor currently in an investigator-sponsored study in combination with bevacizumab for the treatment of human epidermal growth
factor receptor 2 (&#147;HER2&#148;)-negative breast cancer. We own exclusive worldwide rights to ME-401 and ME-344. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Clinical
Development Programs </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>HDAC Inhibitor Drug Candidate: Pracinostat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In August 2016, we announced that the U.S. Food and Drug Administration (&#147;FDA&#148;) granted Breakthrough Therapy Designation for
Pracinostat in combination with azacitidine for the treatment of patients with newly diagnosed AML who are unfit for intensive chemotherapy. In addition, agreement has been reached with the FDA on the proposed Phase III study design. According to
the FDA, Breakthrough Therapy Designation is intended to expedite the development and review of drugs for serious or life-threatening conditions. The criteria for Breakthrough Therapy Designation require preliminary clinical evidence that
demonstrates the drug may have substantial improvement on at least one clinically significant endpoint over available therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The
Breakthrough Therapy Designation is supported by data from a Phase II study of Pracinostat plus azacitidine in elderly patients with newly diagnosed AML who are not candidates for induction chemotherapy. The study showed a median overall survival of
19.1 months and a complete response (CR) rate of 42% (21 of 50 patients). These data compare favorably to a recent international Phase III study of azacitidine (AZA-001; Dombret et al. <I>Blood</I>. 2015&nbsp;May&nbsp;18), which showed a median
overall survival of 10.4 months with azacitidine alone and a CR rate of 19.5% in a similar patient population. The combination of Pracinostat and azacitidine was generally well tolerated, with no unexpected toxicities. The most common grade 3/4
treatment-emergent adverse events included febrile neutropenia, thrombocytopenia, anemia and fatigue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In August 2016, we entered into an
exclusive license, development and commercialization agreement with Helsinn, a Swiss pharmaceutical corporation, for Pracinostat in AML, MDS and other potential indications (&#147;Helsinn License Agreement&#148;). Under the terms of the agreement,
Helsinn is granted a worldwide exclusive license to develop, manufacture and commercialize Pracinostat, and is primarily responsible for funding its global development and commercialization. As compensation for such grant of rights, we received
payments of $20.0 million, including a $15.0 million upfront payment in August 2016 and a $5.0 million payment in March 2017. In addition, we will be eligible to receive up to $444 million in potential regulatory and sales-based milestones, along
with royalty payments on the net sales of Pracinostat which, in the U.S., are tiered and begin in the mid-teens. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">As part of the Helsinn License Agreement, we will work with Helsinn to determine an optimal
dosing regimen of Pracinostat in combination with azacitidine for the treatment of high and very high-risk MDS. The cost of this study will be shared by Helsinn and us and enrollment is anticipated to commence in the second quarter of calendar year
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PI3-Kinase Delta Drug Candidate: ME-401 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In September 2013, we acquired exclusive worldwide rights to ME-401 from Pathway Therapeutics, Inc. for an undisclosed upfront cash payment
with no future milestone or royalty obligations. Data from pre-clinical studies show ME-401 to be a potent and selective oral inhibitor of PI3K delta, a molecular target that plays a critical role in the proliferation and survival of certain
hematologic cancer cells. PI3K delta is a class of drugs that has shown promise in the treatment of B-cell malignancies, but with particular toxicities. We believe this provides an opportunity for development of a next-generation oral drug that can
produce therapeutic responses at a safe, effective dose. ME-401 has a distinct chemical structure from certain other PI3K delta inhibitors, including idelalisib (marketed as Zydelig<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>). Data
presented at the ASH Annual Meeting in December 2012 demonstrated that ME-401 has superior pre-clinical activity compared to idelalisib. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Results from a first-in-human, single ascending dose clinical study of ME-401 in healthy volunteers were presented at the American Association
for Cancer Research Annual Meeting in April 2016. The data demonstrated on-target activity at very low plasma concentrations. In addition, the results from the study suggest that ME-401 has the potential for a superior pharmacokinetic and
pharmacodynamic profile and an improved therapeutic window compared to idelalisib, with a half-life that supports once-daily dosing. In March 2016, the FDA approved our Investigational New Drug application for ME-401 in B-cell malignancies. A Phase
Ib dose-escalation study of ME-401 in patients with relapsed/refractory CLL or follicular lymphoma opened for enrollment in September 2016. The goal of the study is to demonstrate an improved therapeutic window with repeated dosing in cancer
patients. This study is now actively dosing patients and interim data are expected in June 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mitochondrial Inhibitor Drug Candidate: ME-344
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">ME-344 is our isoflavone-derived mitochondrial inhibitor drug candidate. In preclinical studies, ME-344 has been shown to cause cell
death in multiple human tumor cell lines, including ovarian cancer stem cells, by interfering with mitochondrial energy generation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Results from our first-in-human, single-agent Phase I clinical trial of ME-344 in patients with refractory solid tumors were published in the
April&nbsp;1, 2015 issue of Cancer. The results indicated that eight of 21 evaluable patients (38%)&nbsp;treated with ME-344 achieved stable disease or better, including five who experienced progression-free survival that was at least twice the
duration of their last prior treatment before entry into the study. In addition, one of these patients, a heavily pre-treated patient with small cell lung cancer, achieved a confirmed partial response and remained on study for two years. ME-344 was
generally well tolerated at doses equal to or less than 10 mg/kg delivered on a weekly schedule for extended durations. Treatment-related adverse events included nausea, dizziness and fatigue. Dose limiting toxicities were observed at both the 15
mg/kg and 20 mg/kg dose levels, consisting primarily of Grade 3 peripheral neuropathy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In May 2015, we announced new pre-clinical data
from a collaboration with the Spanish National Cancer Research Centre in Madrid showing mitochondria-specific effects of ME-344 in cancer cells, including substantially enhanced anti-tumor activity when combined with agents that inhibit the activity
of vascular endothelial growth factor (&#147;VEGF&#148;). These new data demonstrate that the anti-cancer effects when combining ME-344 with a VEGF inhibitor are due to an inhibition of both mitochondrial and glycolytic metabolism. An
investigator-sponsored study of ME-344 in combination with the VEGF inhibitor bevacizumab (marketed as </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Avastin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) in HER2-negative breast cancer opened for enrollment in August 2016. This study is now actively dosing patients and interim data
are expected in December 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Corporate Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 11975 El Camino Real, Suite 101, San Diego, California, 92130, and our phone number is
(858)&nbsp;792-6300. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Any investment in our securities involves a high degree of risk. In addition to the other information included or incorporated by reference in
this prospectus and any accompanying prospectus supplement, you should carefully consider the important factors set forth under the heading &#147;Risk Factors&#148; in our Annual Report on Form 10-K for the fiscal year ended June&nbsp;30, 2016, and
in our subsequent annual reports on Form 10-K and in other reports we file with the SEC from time to time, which are incorporated herein by reference, before investing in our securities. Any of the risk factors referred to above could significantly
and negatively affect our business, results of operations or financial condition, which may lower the trading price of our common stock. The risks referred to above are not the only ones that may exist. Additional risks not currently known by us or
that we deem immaterial may also impair our business operations. You may lose all or a part of your investment. For further details, see the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain
Information by Reference.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_4"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein include forward-looking statements within the meaning of Section&nbsp;27A
of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;) and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). All statements other than statements of historical facts contained in
this prospectus and in the documents incorporated by reference herein, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The
words &#147;believe,&#148; &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;continue,&#148; &#147;anticipate,&#148; &#147;intend,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;expect,&#148; and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition,
results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, without limitation, those described in &#147;Risk Factors&#148; and elsewhere
in this prospectus and the documents incorporated by reference herein, including, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to obtain required additional financing or financing available to us on acceptable terms, or at
all, which may cause us to delay, scale-back or eliminate plans related to development of our drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Helsinn or other parties with which we have entered into collaboration, license, development and/or
commercialization agreements may not satisfy their obligations under the agreements which could impact future revenues; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are in an early stage of clinical studies for our product candidates on which our development plans are based;
clinical studies by their nature typically have a high level of risk and may not produce successful results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of pre-clinical studies and completed clinical trials are not necessarily predictive of future
results, and our current drug candidates may not have favorable results in later studies or trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to maintain or enter into, and the risks resulting from our dependence upon, contractual
arrangements necessary for the clinical development, manufacture, commercialization, marketing, sales and distribution of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs and delays in our clinical development programs and/or receipt of FDA or other required governmental or
regulatory approvals, or the failure to obtain such approvals, for our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the FDA&#146;s interpretation and our interpretation of data from pre-clinical and clinical studies may differ
significantly; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our failure to successfully commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure of any products to gain market acceptance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to control the costs of manufacturing our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on acquisitions or licenses from third parties to expand our pipeline of drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">competition and competitive factors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our inability to operate our business without infringing the patents and proprietary rights of others;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">costs stemming from our defense against third party intellectual property infringement claims;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">technological changes; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">government regulation generally; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in industry practice; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">one-time events. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">These risks are not exhaustive. Other sections of this prospectus and the documents incorporated by reference herein include additional
factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk
factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You should not rely upon forward looking statements as predictions of future events. We cannot assure you that the events and circumstances
reflected in the forward looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or
achievements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_5"></A>SECURITIES OFFERED BY THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Using this prospectus, we may offer from time to time, in one or more series, together or separately, at prices and terms to be determined at
the time of offering: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of common stock, $0.00000002 par value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">shares of preferred stock, $0.01 par value; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">warrants to purchase shares of common stock or preferred stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The shares of preferred stock may be convertible into or exchangeable for shares of our common stock or preferred stock issued by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">See &#147;Description of Securities&#148; for a description of the terms of the common stock, preferred stock and warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Although we expect to use a substantial portion of the net proceeds from the sale of securities under this prospectus for general corporate
purposes, including to progress our clinical trial programs, we have not allocated these net proceeds for specific purposes. If, as of the date of any prospectus supplement, we have identified any additional use for the net proceeds, we will
describe them in the prospectus supplement. The amount of securities offered from time to time pursuant to this prospectus and any prospectus supplement, and the precise amount of the net proceeds we will receive from the sale of such securities, as
well as the timing of receipt of those proceeds, will depend upon our funding requirements. If we elect at the time of an issuance of securities to make different or more specific uses of the proceeds than as set forth herein, we will describe those
uses in the applicable prospectus supplement. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_7"></A>RATIOS OF EARNINGS TO COMBINED FIXED CHARGES AND PREFERRED
STOCK DIVIDENDS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We incurred net losses for each of the fiscal years ended June&nbsp;30, 2016, 2015, 2014, 2013 and 2012. We had net
income of approximately $7.0 million for the nine months ended March&nbsp;31, 2017. We did not have any fixed charges for the nine months ended March&nbsp;31, 2017 or the fiscal years ended June&nbsp;30, 2016, 2015, 2014, 2013 and 2012, other than
insignificant charges related to a premises rental agreement. We did not have any shares of preferred stock outstanding during the nine months ended March&nbsp;31, 2017 or the fiscal years ended June&nbsp;30, 2016, 2015, 2014, 2013, and 2012.
Accordingly, we are unable to present a ratio of earnings to combined fixed charges and preference share dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We may sell the securities included in this prospectus (i)&nbsp;through agents, (ii)&nbsp;through underwriters, (iii)&nbsp;through dealers,
(iv)&nbsp;directly to a limited number of purchasers or to a single purchaser, or (v)&nbsp;through a combination of any such methods of sale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The distribution of the securities may be effected from time to time in one or more transactions, including block transactions and
transactions on the Nasdaq Capital Market or any other organized market where the securities may be traded: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or at final prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Offers to purchase securities may be solicited directly by us, or by agents designated by us, from time to time. Any such agent, which may be
deemed to be an underwriter as that term is defined in the Securities Act, as amended, involved in the offer or sale of the securities in respect of which this prospectus is delivered will be named, and any commissions payable by us to such agent
will be set forth, in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">If an underwriter is, or underwriters are, utilized in the offer and sale of
securities in respect of which this prospectus and the applicable prospectus supplement are delivered, we will execute an underwriting agreement with such underwriter(s) for the sale to it or them and the name(s) of the underwriter(s) and the terms
of the transaction, including any underwriting discounts and other items constituting compensation of the underwriters and dealers, if any, will be set forth in such prospectus supplement, which will be used by the underwriter(s) to make resales of
the securities in respect of which this prospectus and such prospectus supplement are delivered to the public. The securities will be acquired by the underwriters for their own accounts and may be resold from time to time in one or more
transactions, including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be
changed from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">If a dealer is utilized in the sale of the securities in respect of which this prospectus is delivered, we
will sell such securities to the dealer, as principal. The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. The name of the dealer and the terms of the transaction will be
identified in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">If an agent is used in an offering of securities being offered by this prospectus,
the agent will be named, and the terms of the agency will be described, in the applicable prospectus supplement relating to the offering. Unless otherwise indicated in the prospectus supplement, an agent will act on a best efforts basis for the
period of its appointment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">If indicated in the applicable prospectus supplement, we will authorize underwriters or their other agents to
solicit offers by certain institutional investors to purchase securities from us pursuant to contracts providing for payment and delivery at a future date. Institutional investors with which these contracts may be made include commercial and savings
banks, insurance companies, pension funds, investment companies, educational and charitable institutions and others. In all cases, these purchasers must be approved by us. The obligations of any purchaser under any of these contracts will not be
subject to any conditions except that (a)&nbsp;the purchase of the securities must not at the time of delivery be prohibited under the laws of any jurisdiction to which that purchaser is subject, and (b)&nbsp;if the securities are also being sold to
underwriters, we must have sold to these underwriters the securities not subject to delayed delivery. Underwriters and other agents will not have any responsibility in respect of the validity or performance of these contracts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Certain of the underwriters, dealers or agents utilized by us in any offering hereby may be
customers of, including borrowers from, engage in transactions with, and perform services for us or one or more of our affiliates in the ordinary course of business. Underwriters, dealers, agents and other persons may be entitled, under agreements
which may be entered into with us, to indemnification against certain civil liabilities, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Until the distribution of the securities is completed, rules of the SEC may limit the ability of the underwriters and certain selling group
members, if any, to bid for and purchase the securities. As an exception to these rules, the representatives of the underwriters, if any, are permitted to engage in certain transactions that stabilize the price of the securities. Such transactions
may consist of bids or purchases for the purpose of pegging, fixing or maintaining the price of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">If underwriters create a
short position in the securities in connection with the offering thereof (in other words, if they sell more securities than are set forth on the cover page of the applicable prospectus supplement), the representatives of such underwriters may reduce
that short position by purchasing securities in the open market. Any such representatives also may elect to reduce any short position by exercising all or part of any over-allotment option described in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Any such representatives also may impose a penalty bid on certain underwriters and selling group members. This means that if the
representatives purchase securities in the open market to reduce the underwriters&#146; short position or to stabilize the price of the securities, they may reclaim the amount of the selling concession from the underwriters and selling group members
who sold those shares as part of the offering thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">In general, purchases of a security for the purpose of stabilization or to reduce
a syndicate short position could cause the price of the security to be higher than it might otherwise be in the absence of such purchases. The imposition of a penalty bid might have an effect on the price of a security to the extent that it was to
discourage resales of the security by purchasers in the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Neither we nor any of the underwriters, if any, makes any
representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of the securities. In addition, neither we nor any of the underwriters, if any, makes any representation that the
representatives of the underwriters, if any, will engage in such transactions or that such transactions, once commenced, will not be discontinued without notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of the securities offered by this prospectus will be described in the applicable prospectus supplement
relating to the offering. The securities offered by this prospectus may or may not be listed on a national securities exchange or a foreign securities exchange. We cannot give any assurances that there will be a market for any of the securities
offered by this prospectus and any prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We will bear costs relating to all of the securities being registered under
this prospectus, other than underwriters&#146; discounts and commissions. In compliance with the guidelines of the Financial Services Regulatory Authority, Inc., or FINRA, the maximum compensation to be received by a FINRA member or independent
broker-dealer may not exceed 8% of the offering proceeds.&nbsp;It is anticipated that the maximum compensation to be received in any particular offering of securities will be less than this amount. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_9"></A>DESCRIPTION OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Securities We May Offer Under this Prospectus </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">For a description of our
common stock, please see our Registration Statement on Form 8-A filed with the SEC on November&nbsp;26, 2003, and any further amendment or report filed thereafter for the purpose of updating such description. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The material terms of
any series of preferred stock that we offer through a prospectus supplement will be described in that prospectus supplement. Our board of directors is authorized to provide for the issuance of blank check preferred stock in one or more series with
designations as may be stated in the resolution or resolutions providing for the issue of such preferred shares. At the time that any series of our preferred stock is authorized, our board of directors will fix the dividend rights, any conversion
rights, any voting rights, redemption provisions, liquidation preferences and any other rights, preferences, privileges and restrictions of that series, as well as the number of shares constituting that series and their designation. Our board of
directors could, without stockholder approval, cause us to issue preferred stock which has voting, conversion and other rights that could adversely affect the holders of our common stock or make it more difficult to effect a change in control. Our
preferred stock could be used to dilute the share ownership of persons seeking to obtain control of us and thereby hinder a possible takeover attempt which, if our stockholders were offered a premium over the market value of their shares, might be
viewed as being beneficial to our stockholders. In addition, our preferred stock could be issued with voting, conversion and other rights and preferences which would adversely affect the voting power and other rights of holders of our common stock.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We may issue warrants to
purchase our common stock or preferred stock. Warrants may be issued independently or together with any other securities and may be attached to, or separate from, such securities. Each series of warrants will be issued under a separate warrant
agreement to be entered into between us and a warrant agent. The terms of any warrants to be issued and a description of the material provisions of the applicable warrant agreement will be set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the following terms of any warrants in respect of which this prospectus is being delivered:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate number of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such warrants will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies, in which the price of such warrants will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the securities purchasable upon exercise of such warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which and the currency or currencies in which the securities or other rights purchasable upon
exercise of such warrants may be purchased; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise such warrants shall commence and the date on which such right shall
expire; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the minimum or maximum amount of such warrants which may be exercised at any one time;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which such warrants are issued and the number of
such warrants issued with each such security; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which such warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">information with respect to book-entry procedures, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, a discussion of any material United States federal income tax considerations; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such warrants, including terms, procedures and limitations relating to the exchange and
exercise of such warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Description of Share Capital </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We are authorized to issue 113,000,000 shares of common stock, par value $0.00000002 per share, and 100,000 shares of preferred stock, par
value $0.01 per share. As of May&nbsp;2, 2017, we had 36,772,428 shares of common stock outstanding and no shares of preferred stock outstanding. Also as of May&nbsp;2, 2017, we had outstanding (i)&nbsp;4,258,792 shares of our common stock subject
to outstanding options, with exercise prices ranging from $1.21 to $10.00 per share, (ii)&nbsp;745,891 restricted stock units, each representing the contingent right to receive one share of our common stock, (iii)&nbsp;3,545,686 shares of our common
stock subject to outstanding warrants, with exercise prices ranging from $3.12 to $7.14 per share, (iv)&nbsp;based on an assumed price per share of $1.61, which was the last reported sale price of our common stock on the Nasdaq Capital Market on
May&nbsp;2, 2017, up to 310,559 shares of common stock that may be issuable upon our achievement of certain clinical and regulatory milestones pursuant to the terms of the August 2012 Asset Purchase Agreement between the Company and S*Bio, and
(v)&nbsp;5,094,844 shares of our common stock available for awards under our Amended and Restated 2008 Stock Omnibus Equity Compensation Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_10"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The validity of the securities described herein will be passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_11"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The financial statements as of June&nbsp;30, 2016 and 2015, and for each of the three years in the period ended June&nbsp;30, 2016, and
management&#146;s assessment of the effectiveness of internal control over financial reporting as of June&nbsp;30, 2016, incorporated by reference in this Prospectus, have been so incorporated in reliance on the reports of BDO USA, LLP, an
independent registered public accounting firm, incorporated herein by reference, given on the authority of said firm as experts in auditing and accounting. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_12"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus and any accompanying prospectus supplement the information we
have filed with the SEC. The information we incorporate by reference into this prospectus is an important part of this prospectus. Any statement in a document we incorporate by reference into this prospectus will be considered to be modified or
superseded to the extent a statement contained in this prospectus, any accompanying prospectus supplement or any other subsequently filed document that is incorporated by reference into this prospectus or any accompanying prospectus supplement
modifies or supersedes that statement. The modified or superseded statement will not be considered to be a part of this prospectus or any accompanying prospectus supplement, as applicable, except as modified or superseded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We incorporate by reference into this prospectus the information contained in the documents listed below, which are considered to be a part of
this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312516701415/d215811d10k.htm">Annual Report on Form
 10-K</A> for the fiscal year ended June&nbsp;30, 2016; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form 10-Q for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312516763751/d447194d10q.htm">September&nbsp;30,
 2016</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312517033915/d336012d10q.htm">December&nbsp;
31, 2016</A>, as amended by the Form 10-Q/A filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312517046707/d321318d10qa.htm">February&nbsp;
16, 2017</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312517157424/d331257d10q.htm">March&nbsp;31, 2017</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312516675918/d208186d8k.htm">August&nbsp;9,
 2016</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312516684112/d244204d8k.htm">August 17, 2016</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312516700420/d226335d8k.htm">September&nbsp;2,
2016</A>,&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312516783125/d308008d8k.htm">December&nbsp;2, 2016</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000119312517107676/d372036d8k.htm">April&nbsp;3,
2017</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in the <A HREF="http://www.sec.gov/Archives/edgar/data/1262104/000095012303013241/y92081ae8va12g.txt">Registration
 Statement on Form&nbsp;8-A</A> filed on November&nbsp;26, 2003 and any further amendment or report filed thereafter for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference all documents filed pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after
(i)&nbsp;the date of the initial registration statement and prior to the effectiveness of the registration statement and (ii)&nbsp;the date of this prospectus and prior to the termination of the offering of the securities under this registration
statement (except in each case for the information contained in such documents that is deemed to be &#147;furnished&#148; and not &#147;filed&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Statements made in this prospectus or any accompanying prospectus supplement or in any document incorporated by reference in this prospectus
or any accompanying prospectus supplement as to the contents of any contract or other document referred to herein or therein are not necessarily complete, and in each instance reference is made to the copy of such contract or other document filed as
an exhibit to the documents incorporated by reference, each such statement being qualified in all material respects by such reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, at no cost, by writing or telephoning us at the
following address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">MEI Pharma, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">11975 El Camino Real, Suite 101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">San Diego, California 92130 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Tel:
(858)&nbsp;792-6300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Attn: Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">Copies of these filings are also available, without charge, through the &#147;Investors&#148; section of our website (www.meipharma.com) as
soon as reasonably practicable after they are filed electronically with the SEC. The information contained on our website is not a part of this prospectus. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc841008_13"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:2%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the
public over the Internet at the SEC&#146;s website at http://www.sec.gov. The SEC&#146;s website contains reports, proxy and information statements and other information regarding issuers, such as us, that file electronically with the SEC. You may
also read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Room&nbsp;1580, Washington, D.C. 20549. You may also obtain copies of these documents at prescribed rates by writing to the SEC.
Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P> <P STYLE="font-size:101pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g841008g63p02.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:13pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:39%">&nbsp;</P></center>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Stifel </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:20pt; font-family:Times New Roman" ALIGN="center"><B>Wells Fargo
Securities </B></P>
<P STYLE="margin-top:100pt; margin-bottom:0pt; font-size:11pt; font-family:Times New Roman" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;, 2019 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g841008g63p02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g841008g63p02.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5V.:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @(&QO9V\Q+F%I)B-X03M5<V5R;F%M93H@(" @
M(" @(" @(" @(')R,3$V,#$T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @
M(" P,RU*=6XM,C Q.2 Q-3HU,CHQ,28C>$$[15-4(%1I;64Z(" @(" @(" @
M(" @(" P,RU*=6XM,C Q.2 Q.#HU,CHQ,28C>$$[4V-R:7!T(%9E<G-I;VXZ
M(" @(" @(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP
M+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X
M03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@
M96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S
M<RXJ*BHF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @
M/'AM<#I-971A9&%T841A=&4^,C Q.2TP-BTP,U0Q-3HU,CHR,2TP-SHP,#PO
M>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P
M,3DM,#8M,#-4,34Z-3(Z,C$M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @
M(" @(" \>&UP.D-R96%T941A=&4^,C Q.2TP-BTP,U0Q-3HU,CHR,"TP-SHP
M,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^
M061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4
M;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR
M9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^
M,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM
M9SIH96EG:'0^,C4V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @
M(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @
M(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"
M06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!
M04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!
M1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!
M;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X
M<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X
M03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G0D%!14%!=T52)B-X03M!04E205%-
M4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+
M0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],
M14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC
M645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9
M,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"
M<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q
M9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X
M03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%9
M14-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(
M4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*
M0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L
M9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/
M16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A
M;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ
M-T9867$W)B-X03M&6%EQ-T953&8V<G!U;G@X-S(U:G0Q-FIM=T)0>5AQ9F]Y
M=DIM:$%826=)2G!I,F]F;6IO<T)+,F--=#1W-DXO9$EF<&%R9CA,;71Y)B-X
M03LY<UDT+U-$3#=0>#AM0GE":C$U*UHK=E1%:3-J:'16-T5+6&(W,E!(+VAC
M,2M4=&I+95%!62M)56]U4$XS;5<T2DUM;WI#=BLK,CE-)B-X03MF.$IX>D1N
M<G,P=6-J.3,S231I9UI,-CEL3EIB:5-1*TQ/>"]78WAP6DI(;5-T<5%/5DMU
M0G=+=4)W2W5"=TI8031&6$$T17)G8T-R)B-X03MG8VEL8T1G5F-$9U-U0G=+
M=4)W2W5"=T5*6$$U1DLX2$%R64]"5C1/4E,Y9'HQ3EA9<3=&6%EQ-T9867$W
M1EA9<6LR=2MB9$4P5E-,)B-X03MU8FQC57%T=$8X56@K62]:+W=";%1-6%5A
M>DAI*V\W.7I'56=(;G5T9FUD<F0V5VIS44Q#03=66#1P4U!D>4YV.6E0<'I3
M-2LQ36MT)B-X03MO*VMF83%(25=*>7IZ5%-.3$Y),&MJ8G,W:W-X*UI/8752
M2DYL9S!$:U98031%<F=C0W)W8T-T9S5&2S1(06QC1&=68T1G5F-$9U-U)B-X
M03M"=TMU0G=*6$$T1EA!-49+-$A!<31(06QC1&=68T1G5F-$9TE3=4)Y2U8T
M3T)7=V-#=EE-.5)3-T9867$W1EA9<3=&5D,K=C=+=W1N)B-X03MU<GE:64E%
M*S%)-6]0:U!%*W=Y13AK64,U1V=G;6YM4&UB.'HW>3=,,C)J5G1B8F]B:R\S
M>F8V=CAG+T@U6F\Y5C)N2U<P3F@S.5=M)B-X03M76'593S!J=7AD,DQ/>'%Z
M13%*2C=K;DY19#)P,D),64]"5G=/0E9W3T)+-$A!;&-$9U9E1&=6<TA)<%A!
M-$5R9V-#<F=C0W)G8T-6)B-X03MW3T)6=T]"2S1(07$T2$EP6$$T1EA!-$5R
M9V-#<F=C0W)G8T)#5G=/4E-V0G=+.6AZ,4),<U9D:7)S5F1I<51E6G9.96UE
M6#=4,6)K)B-X03LK<&-302]6-U94.&)K9CA!158X5&U.<6162$5,4%!U67EM
M03A:.'=E6F15,3(W.64Y:RM"9C=Q,U=O:E%E=SAF9G)N3V%J55-Y;35/)B-X
M03M,2UI+5T$U:DEB0GA68T1G4W5W2F)"=TMU0G=+=4)W2EA!-$5R9V-#<G=C
M0W1G-49+-$A!;&-$9U9C1&=68T1G4W5"=TMU0G=*6$$T)B-X03M&6$$U1DLT
M2$%Q-$A!;&-$9U9C1&=68T1G25-U0GE+6'-M96YP9&ER<U9D:7)(4$]8;DMZ
M.'97;$)38E5::"]O.78T9'5B,#9+4'@O)B-X03M6:6%V5FI%4#940V,K1C1P
M<4]P6'5P6&ML-65Y;5<T;$Y78R]G04]W2%E:>F542DM:<S@S14UR431/5F]8
M031%<F=C0U=W8U98031%)B-X03MR<T-7=V-#<F=C0W)G8T-6=T]"2S1(07$X
M2$%R64]24W5"=TI8031&6$$T1EA!-$5R9V-#<F=C0U9W3T)6=T]24W5"=TMU
M0G=*6$$T)B-X03M&6$$T1EA!-$-%=EIS.4Y:3WA6,DMP2C5T.#!7;FPS5$1D
M4S!K=4I+<F$R.6%&,R]!3V%6-VY-9E4V9UEO,F5F4FA/9D-(:$=O-FYE)B-X
M03LV;&5Y,W0W2UIB:5DQ9&HK04$W061H;DY:36AM8E!.=WI):S)604A+,$YG
M-$5R9V-#<F=C0U9W3T),64]+<F=C0U8R0DQ93T)6=T]")B-X03M6=T]"2S1(
M06QC1&=6941G5G-(27!8031%<F=C0W)G8T-R9V-#5G=/0E9W3T)+-$A!<31(
M27!8031&6$$T17)G8T-R9V-#=F%-.4U:)B-X03MU>%9$-FIQ1G)P,6I.93-B
M*VYB,C9L-4<Y:#)(=51S36I/66E#5'E#0V$S9E S;6)Z2&0V+W$P;#EC9D-N
M,F)E1W122$=/:2]0=50T)B-X03LU>E=O>DA*2WDT334X4G1+=V-X,DLT2$%Q
M-$A!;'-(06QC1&=68T1G4W5"=TIB0GA68T1G4W5W2F)"=TMU0G=+=4)W2EA!
M-$5R9V-#)B-X03MR=V-#=&<U1DLT2$%L8T1G5F-$9U9C1&=3=4)W2W5"=TI8
M031&6$$U1DLT2$%Q-$A!;&-$9U8W5FYP8DXR2W9(+W=!,E!.;C$R+T=I)B-X
M03M7<B\V3%IT5S999G1Z:F)J.&LO6#AS,'9A1V\T:G=$:U!V8U10:W,P."M"
M>E=/3W5"=TI8031%<F=C0W)G8T-7=V-#5G=/0E9W3T)+)B-X03LT2$%L<TA&
M5G=/0DLW06QS2$%Q-$A!<31(06QC1&=3=4)W2W9"=TLR1&M5<F=C0U9W3T)6
M=T]"5G=/0DLT2$%Q-$A!;&-$9U9C1&M5)B-X03MR9V-#<F=C0UAT;65L33!H
M.#=E66PP1'DO4&5+4CEA9CDQ84ME.'(Y1"]S4E9V;WI(,4]B=S1%.5='4V9#
M3&905%-/-W,W:W,W16QM)B-X03M/-4I/-4IZ;D,V-C)W8T-7=V-#<SDX9V9L
M-49R;',R<&%J23AD:T=+47A2,$131F9T17-184M$='1M=S!E:4=18U5U5&M9
M<U8W;$YF)B-X03M.6#554E$R9C%N45!596%+<&QT2D=$1C$X67I19D501'8R
M.3=D5#)A04QH.&UC.%!C.#!)6E=+<T-'0F]19&E#33%$:DYG-49,64]")B-X
M03M+-$A!<31(06Q5:6IK;&M73TI3.&IK2VE+2VMK.4%!35%#5%%32' S;#<X
M<DQ0-FES=71.26)U458Y0TYG<7AJ=TIO870T.7,S;6XW)B-X03M+:G<S4&TS
M>'AD-E%E95!*0S9#27)U>FMA5WAL8F=22E%V1SE+9T5I;%%A1VTR65=U,%!H
M97%0,&QJ3T9-5'I7<T4R.'0K6&(S6&(O)B-X03M!3W$R>$-+9S545$XY;$8V
M9E-4,D=8-F)44WI3;TUO>'1N4R]L3%I!1&QQ17!08VA&02]78S(S.&I2+VY&
M=#A)3B\X04MP<D0O<313)B-X03LO=T1!3"]82"M262]Z:79H:'8X03564%EF
M.'0X=B]!3"]82"M262]Z:79H=&HX<6)(+VQV;"\T0F8V-"]Y3$0K8U8X3G8O
M;%96:B]Y)B-X03LS>2\X078X05A"+TEK4#5X6'<R+RM65C)0+TQF3"]W0R]W
M0F-(.&E1+VY&4$%H.5,O3&5Z<SE/=7)T8C)2;70T6DI1<%910U55=%0X)B-X
M03M-<7ID:GAH0U5U23=!;$)G=TU(3V994%%F3%AK:E)B+T%%83%V8FHQ5$Q-
M<D9W2$%86FE.='$Y=DA/:3!86F5,2FEJ3U8R5W=21%AM)B-X03M(.'9R84-Y
M:W4Y360K8TML,V=K25E-<3=N:6%!,7!K9%HR4$=-1$Q'5'0P57A92T1N3TU&
M=T]"2S1(07$T2$EP6$$T1F4S6C93,E!%)B-X03MF>F(X=V9P1'I#3E!I871T
M<&\T141O6FUO6D0Y1WDO46,P;79Y.%4V-D)W=%)/>EAC=V-(34)O6$$T1EA!
M-$5V979Y>"]W0U5(,#,O)B-X03M!2C<O05!54DIN439(*S5(>"LY>G-0,&AL
M1UIB87=0>CDK6&ME<')*<6UL244Q269&3D%.;&UP,4DX2"]!1C5R9&)O=5 Q
M4BMR-S)N)B-X03M*:79C8S-K5&\X8G1(27!2,4I$27=O45(Q0D)Z4D5/2S1(
M27$R1&=3<E<P13EX3VM%0TY,3DMW5T].4E9I5#!!1T522DY$;6M"-THU)B-X
M03M(.&EW-DI'3'DX0WDV;S0V:F1945)U<2\U6&DS,$0S-DA28459=E9,-G9U
M8W%'3VU86G-'>&E0-6\O.$%+2W0O>&YJ+T%)-7)U,5 W)B-X03MN-&AR>6-N
M:G=/8S T-S!Z.&]!4%$Q43 S-5%G;C9(>F5D:F-P9D0Y3&9I96@U=6TQ,DMU
M>%8R2W5X5C)+<% U=79O3%1Y-V9.2W=()B-X03MR479$1W1D>3AQ;%%".3EC
M=SEF:T5-37(V:79M:5(R94UG-7AB4SEI.&LO.&]T668V<F8X;D=Z<W5Z9C=I
M4#0V='-E4V-84"LX,'8K)B-X03MO,S9S>DHO4U=4=W-(4%!M;&-$9U9C1&=3
M=4)W2W5">4M8<U=U87!&<%=J,VUO>54T,G-44T%(=7=(=W(O<VUO33E&>50T
M66LY>DM5)B-X03MQ1G9M964T;'5*-4HU;4QY>7-Z>4]E<%IJ56XW.#5O;7IB
M<D-B84)W2S)$9U-U0G=+.3<O04-W+S518E1F*V4O+U522FY184@K-DAX)B-X
M03LK.7HX4#!H;$]:8F$W1E=&9690>2]I,7!7,414=W-7<4E0:5AO<S1!,D(X
M1SA$.2]T<CE:;VAK.55F<2LY<7E9<C-(3C0U3$9,0DLX)B-X03M->4Y(3$=X
M5U-.:%)L66)%14A.05%184QI2W1L6C-6-V12,G1R13 Q>$ME36-A:7!*>&I!
M>4Y$;6M#,W10:VYY4&$V1&)R8UA!5V)6)B-X03M:0CAC=E529R]S4B]X4&9/
M:#!E:D=)5V9Q8W9(:C1F97ER335S9&ER169Z4R]W0U568B]J4$@O2$YD,G O
M8R]%3F58:SAC0GIM,T=E)B-X03MM+VLK9CE(,50O6&@O52MB=G-F;$PT3BM*
M-DIM-F)N:W9M9GIH-6MT4$U&+V)7.3@X8T55<%=.07%503A.>&Y.-G97-5DU
M6D%3,D)A)B-X03M*5$E+5VIZ,35R+S9U3"\X0VXO3D]9,SAO6B\U,S-)-'DR
M4%!0;78O04MU3"]W1$%P+WI49R]L1% O3RLU94UR:#4T.#%F.$%6=V8O)B-X
M03M!2490*V%C9C51>B]!33<W:SA:8DAN:GI6+S%C2"\T1E K86-(.&\U+W=#
M9#EY.%I13V]A>'%7<$]R,S%Y.#=,.6M-9&A8=T$R1UDR)B-X03MB4%!)8FMB
M451A1D)Y:%AS;FMJ+T%*4F%W+S%8+W=#5&I:,E!:=CA!8U(O2%9U:GE4:34O
M,VUL+S%'+U9M6E V4WEE16<U-2LP3&=C)B-X03M#5G=/0E9W3T)+-$A!<DU0
M>F\Q53(O;"LS,#5';SDO3E9X-'AW,%EJ+V=Y;61V,FA/;T%D-T15>7%.4$9G
M8S!Z9W)G8T-R9V-5=&<T)B-X03M%=F9F>7<O-5%B5% K92\O049%4UIV.$%1
M+S-1*U S=69H*V=-;'5N6DQA6C%.1U9'25!U0FU63&LR<U0X:&5F64YF9T9P
M9&Q9=%AI)B-X03M8-&PV3$UO+V)4,R]!2FPO:#!W.4IQ>&M&2#9M<D9L-'9E
M>D1-,719:#4U.&A7,G5W;3=S=W-/<DE.;C9,2T%0<W8W*T1F-6I",65J)B-X
M03M'45=0<2LY<7E9*TPS;W)Y6C5*<R],,70V:D54-FQ+;T4Y>#)8+TEJ.$8O
M6&MT3'!":4AF2D]01TES;'I-8D=)*V)V4%5';#-53VPR)B-X03M*5UA56FY2
M6E0Q5T97238O-5)(46938W=.5G)"06E-9G$K-7)N:V\P>3=-.7-9:"MA9CA!
M>6EJ9CA:-'8T-7)U,"\W<C1T95@V6&IG)B-X03M/8S(T>C S.&YV.$%E9E90
M.65(.50U=D]X*U5V9S,T6&]U8FQU961A.2M7=7)A:G).,V926$YU:V1X25A6
M6$PX9T0T,%4U<$Y2,EI/)B-X03MC>DE%8G15<UI*45 O2W!T8B\U8DQB-S50
M*V%C;R]K9DHS:C=59457>"M5*W0O.$%,6&)F9DHO>E1J+TDR5'9(,G(T4F(O
M-594<E@O)B-X03M!0S$R,S-Y9C@P-% U1WED.&9T6'=Y>&)6=$YM,'I56C=#
M6FQE4T%H5UI+.%1503=6<#0U<DTK130U;4HU:&=24T9">6Q6-$]"6'-V)B-X
M03MK9CA!-5)7=R]W0E8O=T1K-#)D9C)B+V-2+TA6=FIY5&DU+S-M;"\Q1R]6
M;5I0:U=4=V-(3T%A1G=/0E9W3T)+-$A!<31(06Q7+T]B)B-X03M51&-E85DW
M44@T3$\S4E-0.'51;'EF.$%G4W5D6C)H2S4Q,T)X=%-F5E1!<W=82&-$9U9C
M1&=68T1I;#<Y*U8O+TM#-EHO>C,O=T-O)B-X03MI5$XO;W8W;V9(-S-965!O
M1$DW,R]E3V8O:D<O+T54;5),:U<P=FUE,G5:-V%E3S1T-4=I;6E93DA)<&]Y
M<T]H0GIL9U-$66191%0R)B-X03LW>48U.6<Q*T%7;#)6:3%E2F9I6&]S>6HY
M=%!F*UIF-&1..7!.5TUG;R]5-3),3'AE.6U'6G)A-T9712MF=E P96IX=' R
M;DU(,5)X)B-X03LX8CE2040S4"M8-$0V5&UU,75T.% P>"MR-VUN2FMR66,S
M:S%J3$I,<71V2DEX95(U,%HS63%*2F-%:VLU;S1'-4%N=F-E2C-F4BMD)B-X
M03MA-7I%4'I5+S524G8K33A8.&,Q+V%F.$%D9D9R>2]3.&%">FTS1F5N+VLU
M+W90<6XK=D0K<#@S9EI(2UAW8VI#.49Z8W1Z<U9D:7)S)B-X03M69&ER>%AZ
M=V8K9'(Q2"]86"]I0S5Y4&%0.2],.&1(2&YZ4TU(34I#-$A!<C)F>4XO=T%O
M<G O*W$O.$%Y8V)/=C=/+W5)+VIQ,W@U)B-X03M*>F,O-WI3+S9J9G%Z3&YY
M3$HT2T1N071#-$A!<31(07$T2$%L8T1G5DHO4%8R8G)Z:'$X<$YE3GDX45!8
M84@Y,E!W5$]J,4UR>5,Y)B-X03LW:#548VEK5U5T8G-68T1G5F-$9U8W+RM6
M,R]+0S9:+WHS+S9I2DTS*VDO=6@X9G9D:F<K9TUK=F8Y-#4O=T1J1R\X07A%
M-6M3-49T)B-X03M,-6A">FQN5G$Q=&-Z,C X9'AB>4Y&3D5W84]25%)L661#
M1&E#46)#46%E>655=GI1,&TO<VQI,6UD3%!527A2,V(T67!!4#)G96EN)B-X
M03MX2#-:=3E0<C1Y1E-.4V,R1UE%8G%8;D@X>CE0=&)2<EA1-3%U8C9154YW
M;W)(15!%13=-,V@R.&9$239R6'A!<4)S;WE:9T]4>4]3)B-X03M74U=2<$I'
M3'E/4WIU>'%35'534V,P6DYU3&%),'<O-VMB6"]!27I2+W=$16AH>"]54&5Y
M:GIF4V5D834W1"]Z5B\U4DYV.$%J4$8O)B-X03M(3F8R;B]D9D9R>2]3.%I"
M>FY(165O9FLU+W90<78X07)W+W%F3C,R4GEL.$A*=SAN;S)B:'5E82M94'I,
M,3-4=&%V3$=#0S%A2S-K)B-X03M+27IP25=)2&I3440X33!M;S=3>5%M66=$
M8C,O04LR;5=19S!G0BMB6&U0+T%*6G)0+V=*9BMQ;55F>79L-V\O8BMT:C1P
M8B]!3U9S)B-X03LK678K5V%Z+T%/06PO=T-Q;40K5CAV9$@W9C%P.%5T+SAR
M63AX9CA!3$Y:+SA"3"]!3E9-9C58>3DP9G0O5W9I;&DK<6%P4'%E;U18)B-X
M03LY=W%R3D]1>G)'0T9&04)S0U=08GAZ6%IS<'E336IZ3$%M,$U$;$MR9V-#
M6'10:U@O;$9.4"\Q6"]W0U1J6C$S6C,Y>$@X9%<K2$I/)B-X03MB<B]E85@O
M56(Y5UIC*U):4$%W8S1*>#%W3T)+-$A!<31(07$T2$%L:6UO>D=F54QM63E:
M6EAC+TYM2GIE>4YK;'=*2&-O9D%H,DMU)B-X03MX5G=/0E@P1"M6=B]!0V=M
M;68X05!F.$$V:4I-,S)I+W5H.&9V9&IG*V=-:W9F.$%E3V8O04EX=B]W05)/
M6D5U4F)3*UAW8S5D,6$T)B-X03M(07$T2$%L<TA!<31(06Q&85EF.7E.<B]!
M35IO+W=$:5%Y55!Q2'9:4C5V<%A/<V1G=S<X,78X06Q%,B\T>GAF>'I8.7!F
M,UAX87,S)B-X03LP=D=!8S4Q>%AQ4#5.2"]2.58O,31F,5!M-C=*-5,K1&M9
M3U)E:C5U1SDT4#4P4"]!1'1E<"\X04=D=C1:>6UT+W9:93EX6B]5:W=/)B-X
M03M9<D)C1&=3=7=*8D)W2W5"=TMU0G=*93%E4F8K550P+R]69B]!2D].;E<Y
M;F8S169X,6-I2$I/<G(O96%8+U5B.5=:8RM26E!!9V,T)B-X03M2>&UW8VEL
M8T1G4W5"=TMU0G=+=S=.,C1$<U9D:7)S5F1I<C9!+TLS+VQ"3DTO-3<O=T15
M4DIM.3!8.3!0:CDW<TU(,$)K=#<O=DA0)B-X03LO=T%9,R\T:6-Y2F-I,T8X
M=D$U>D1Q;7=C0U9W3T)6=T]"3%E/0E58<&@O,TDR=B]!0FUJ+W=#2D1*42MO
M330X=RML<S9T,D1$=GI8)B-X03LO=T-54V(O:E!&+TA-1'1,*S8K3%9M*VPT
M=41N3W5).5(O2FXO96969CEE2#E4-75U>655=F<U3T1K6'!'8F1V53)T<EIM
M3$Y%:DUE)B-X03MP2V=N23A)-VQA*W%7;BLK62\X06=2+U1(9TAC<G9Q;'(O
M=FU0+V=2+U1(9TAC<G9Q;'(O04PU5"]G4B]42&=(8W)V<6QR+W9L4#A!)B-X
M03MG4B]42&=(8W)&=E!8;%A48G)2<FTK9V=31SET54UW:VI53'E60E8Q86Q+
M+T0P>EAD;V%317-::T)5:'5W;DA:-4=$;DUU3SES.&EF)B-X03LX;VYP+W=$
M<78O>6-B3W,W3R]U22]J<35-3U-D6%@K.# S*V\S-G-Y-3AI>690-$]C2S1Y
M.$A!<EE/4E-U0G=*6$$T1EEH;39C0C)+)B-X03MU>%8R2W5X5C9V-4@O36YY
M,6\S;&5Y,#(Y85E834AQ*V]%:C5,.&-Z=4M'=F=W>F%A8E9W:$%24$YZ35=A
M26E!535U9GID.&YY5SAS)B-X03MA=&-C;E)L1EEU-4902$Q:83='4C%:+VU)
M=D518S!J9TQG8U5T9S1%<F=C0W)G8T-697EM4TLX9VQF-T5C:4TQ4$)70D]'
M2F]G<V]N)B-X03MD-U(O>71R>6HO3E O=T%I=C=C,VXX;S1V3GI01VEX-WHU
M-3DP1%<Y06%X<U=L335L4C9/;D555W1D-C5I-GI747E1-%)Z83AM4455)B-X
M03M(;D%/86AX,EAF;#4U=F<P0R]M4SA"*V\S65533V]Q55I+.%=P,4DK26<P
M>D\P3W%'2U)V-E,S67 Q>F5P<#4Q.'%/9UID571W1# U)B-X03M0>% S1VAZ
M8VI6-'8U=V-N:DAE=2]W05DK5F8K<G)B9CAJ0F@O3C1V-7=8:DAE-R]!0F@U
M5R\V=6QT+WE-1U U=D8O3T,X63<S9C1W)B-X03LX<F8Y6%,R+S5'1$@X,VDO
M;D)E360W9BM,+TLO+U8P='8K4F=W9FTX6#@T3'AJ=F0O:2]Y=B\Q9$QF.$$U
M1T1(.#5I+VY"94UD-D(Q)B-X03LO=T$P95A:=$,Q1T=(55E(;&MT6FMJ4EA"
M3$TP8D%!9DTU5'%.5FE/3U%%:&9#9G522U%P-'=$;DQ/3SE0+TQR>EIP<395
M;6Q8:S8R)B-X03LX.757.49P0T96,%II,GI(86]*3S)B+W-Z5U$T3T-2;VAU
M>'DR<&PY>G%E;6TR;$%U-%-3:E5(<4PT9E!.;E!,0VIU1WDS9S1/8U4T)B-X
M03LV-$A!<3A(07)93U)3=4)W2EDQ<55*9S%'-FA05TMA4D0O<U=)-UIU<&EI
M431-=5I1*T)$<U9D:7)S5F1I<G-68T1G5F-$9U8V3#5G)B-X03LO=T1*4#9$
M+T%->&8O6E)M=WDO-'1(,R]!2S-+;B]D:#4V1&UU8V1C1&=68T1G4S)$9U9C
M1&=3=4)W2EA!-$98031%=&<T17)G8T-R)B-X03MG8T-6=T]"3%E/2W)G8T-6
M,D),64]"5G=/0E9W3T)+-$A!;&-$9U9E1&=615=%6FQV8F5)9%AK4E(Y3$%:
M3$9'-4%E8DE*6#4X=$=T)B-X03MF3T]R>$553%A$>2]23BLY2"]%.#-7<&I7
M4UAV8U1-2VM5:'EL<F1I<G-69&ER,%AY<BM8,6AR+T%*2F4W:%AJ<D0S2'!X
M,T1/,T)5)B-X03M74D]:2T$P3DDK5UHK2%-I94]X.59U5&IW:5503G%E1#AP
M9$%M3FQD<&1A,V1X1VLX,%)P1W)G-V=C6DE6*VHT=FYI4F=G84YY2VM9)B-X
M03LT-V,P8D0U3CAH96$W1U=4>79-.6AQ15,X:F%Y<WIF3&UR;#)O96Y*5TE'
M5$=N>%I2-DYI>3A/17@V6&UL,V$S1FYD4S)L>6AJ;F=C)B-X03MX>6]E;UI4
M46I.8DM*0F]U2U)2<#9X8F586#$W.'-D0W1F6%,Q=#1:,G5,=35K<%-/1E!8
M1$YU4E@W47IA1$1X-$EI-C,O5S5G:'A1)B-X03M#5'!F+VLY<#4K<F958G95
M:75Z6&TY1U!I05I)9G=42V5,5%(R;WDO2'996&I(;74Q>GEF-5DQ2'DY3C5G
M.'!Y<T5T45=U<DIY>F-6)B-X03M55F(W5E=6;$<K-4E)-EE-=6YX>6AX-"MN
M4EI9-&U.>&5F3%5K04-P3W=!>EA/3SE.<W9*4&Q4>3EP8T]O96(U:3$Q3TMP
M6DMZ04$P)B-X03MR>$-X,&1M1F9I3F5)>EIX,'502$AI>3@K-7EH:FI%6$IU
M2SDO2B]56D9T5%IY5U)F-%5U1S5O064Q5U8S*SEH5'AX171,3&%Q5&5-)B-X
M03MS63@V*U4U4$QM<')#<VAM<S=H5$IA>D553D%A1E=P='E8,GI$,5=M.$M6
M9$,Q6DEC2E(S-6,K5W1-,2LO=31D441L25EG-F5M,T4Q)B-X03M,57EE:# X
M8VMI2DUS54),;7E#1'EX-44X=5=%4CAZ4VEF53551'9">6-L82]S<6M:1W<O
M;6)R;5-.4&AX4B]E8GEB0D--4G5X6'EZ)B-X03MP;6UA>#5W:G-75FAP,7A*
M3U564U9927%/-D-U+W=$2TUW9%!I:FMZ8U X04-B831!1U1+<C-Y;#5*.'58
M16LK=51V36MR:S)/;F]7)B-X03M,96U$449I=D9I9G!!*V5::SE,:'A'-6XS
M0G1-27@U<71H8F9L:C5I;"]2.7!B>5=.-'=P07@U27AO2R]$.%1O>"\Q<TU)
M-F)-945$)B-X03MH2VIG;'-O2C5'.'8K6#0U8C-Z4&1E<D0V:DIA5SA824=6
M4C!*0R]&52M!3D(S3U9J430X5GEY;F)O=FAG8S%3>6XO2S=73&A.4&IS)B-X
M03M:8DMA52MN0DTQ57%X,D9'1'5+;G1Y1T=",'51.$Y'2B](;6]-1'-X2'I.
M;U5M:#9X3EE-+W%)=$AH:S9&;S(S0E!V,D]A,U994$-M)B-X03M9=&-O,%4S
M.&UE5&]T66EM,4A52G9Q,FQ7>$ED-FA3>%568C1M,E962%4U:V%04D1)1$M2
M<4%:=VAE-51H.5,O2VTS67=*67E4<4M!)B-X03MZ05-%1VYC1C-6=G=Z24]8
M4FIB:'8X93EL8U5.-6@X<#9(4&]R83DU8VQ,5W-F.$%F,C5*4$5$<E1L.%E+
M,3-$9'0X<C%/:GAN2#1M)B-X03M)-V1Y>6E+<TU+0GI53E,T2$%L8T1G4W5"
M=TMN4&Q'03-(;5A4;WAU4DUS;B])=CDU+WAR;59O66-784DX+W4S6E(U=&9N
M4'!X9SAZ)B-X03MW,V=(=UAL=7!*+WDT:550+T,X8S-0845+;F9E1VI5:C%7
M=T1-1G@S67$W1EA9<3E3.'8V=%!P9C50,W1Z8G-6;F%A4T=.:#%";%I5)B-X
M03M*2'5!4U)M>7A4361/4TA,:$MS5G9,8S%R:4IX-5 Q8693=DUU;C-K4DE!
M;59*45 R;S5$>&-F8V-T=U1-6F=S.%5Q:T4O.$%Z:'-O)B-X03LW8GIG6E5!
M0G4W94MD-F9Z071&+WI,>2]8>')*-W<R86ME<$XY5W5:;V9Y6#!T63-+<E!+
M235A9# Y4U9Q9F5O>3-)4TY-4'@S=&MJ)B-X03LK-D1Z34A.631J,%0X<5=,
M868U;&E*<D<Q;T-Y.6EE36<O:FUW,%!+63AN2S O27-',#8X*W S.71D*VU*
M9G$X<5,K:S,R5S1-1S1N)B-X03LR3DUW25,T4T0S3D544G1L=6\R=FY,>C-F
M2G%53VY-<T-X:4]),3119TM457$P:%AL56YE;5I5-#5C-31Q8FE*6D1D2S!8
M-5$K8E=+)B-X03LX>F)29VYF;$E45"]!2494:$A:,E1Y5"M8:VTS-7=W9E8W
M5'DO8FQU6'!2>G@X=6QE26A&8W0W4T9#03DO=T-H;'%/:6HK4R\O2%<Q)B-X
M03M(+VI!=B]%.&HR6#E2.7DV9FU70U@Q.6,S,35.95A,;5,T;EEV234X5"]!
M9',Q:S5'4DI0371*3FTR42]L;V8K9#(P-R]N="]Y66MZ)B-X03M*,$@Y.4@T
M+V-794PV9S<X=S=Y4S4X,S,U63%71FQH465!4E%0*TI63T18>79+5354-FM"
M-5=9:GI.<$Y$5"]43&-B93AQ:DMD3B]E)B-X03M2+W)$-S!1-6AK9C5R,VMS
M=FU:8F1J*S9T-$5#3#)Q.5=9+U1T.3):6&%K:6-L9'=B37@S66AB16DT:4E.
M0TA7:"MN3F1(;4=S33$O)B-X03M.=R\X-TIB9CAW868X;EIC,E!A,SDV4#9V
M-E,R-65A6#)E=&$S<5AL*U!Y>' Q:UI%53AP2&DU1FU(378X9C=)2$DY.'!H
M;7E4>"M&)B-X03M%245I4E%214@U6F5A-49"94M+12M$>7%4+W=N3$1(<W9-
M96=(>%--6EI:<%!L;3DP3'E:<F-6-4EJ>E1W5'9W:DI+<4)#44YY0G5C)B-X
M03LR1TA3>7<T2FE836<O8S)#3E),>6](3V1A1G=/0E9W3T)+-$A!;&UF-5@R
M6FTQ,E<U22M#,FA.1"]L4T5+4'<U6G1E>#AD-51,=410)B-X03M(>E10.#4Y
M2DYZ-61G=C!7<C)%,WAN=VIM;W)F.$]%>F(Y;U%U05!C>#%-8FIF8SA5>E1U
M0S=&6%EQ-T98<4]H85A0<5@U4%@Q=D%P)B-X03MA9$IN;5)2,5!P3W)K53DQ
M0G!M>7AW371/44A,:D<X5'DW3F$T:6(K571,;C%4>DIP.6Y%0V55>4Y)4BMZ
M1V@U3S,P2TUT=U%-<&=-)B-X03LX8V)K1U%F;D)F4EA0;D)O,$E0,5,S:F=C
M:BMA<E-(+T%*3UIF<C58:SEW8DY19E5M5W5F*U-:,&(O;4E(+T5P<W-Y9C1V
M2#,O<EIZ)B-X03LO=6<X,D)Z6$]+.44O2V8O04AK.'EF.$%-1U K27E:;C9(
M;% S3U9P*W%195%D1W0Y63@P,F1P8W)Y=&=7;&U4<WEX<5<T;C)9,$)Z)B-X
M03M(,'5-5'E!2&LQ-%DS2FQN;G(X>4Y:<SE7;3!J4GET;&(R6CE*<%%I<S=%
M1&5N2496561"45IL87)74T5U1T]W1&)L>D5'9W<R-3@S)B-X03ME84PR37=4
M-FYC>5)V<UEW-T%.6'-1=$LU9WDQ1U-7>$IA5&MK97)/+W=!-W8K;$PO=T)(
M4"]-;DTO=%0K2#0O;V(Y5#!1;C5,9CA!)B-X03M(5S%(+VU(6"]I958Y;695
M9F-U;C5L-31$;7)C9&Q0-5IN+VYD=$XO-3=F.5$X;5IE9R]V;R](-VDR-&9Q
M0T<X-VXO;F)D5B\T>G0O)B-X03M$2SE8+V5Y.38U4'%+:#574"]/>392+WI'
M,B\O04-D6$LY4"]!2&MF-G<K.45/650S.#!Z+W=!-V1,+WAH:2\T:FU2,FPO
M96XS0G-Z)B-X03MF57AA,E X07!%6"MU=C8X=UDX,G-C,F)F;3<O04UP2F)F
M.$%-1VXO04-D;'I9.7)F,V<O<2]P3&)M-7 U9F%M;FMV>6IP,&5N=V\Q)B-X
M03LW9DM'95IH56-U25HS4&I4;%)2;5102BM7=WA%4C9P3FA00T=&>F5E9DYC
M>D9M,4M695A:3TM$-D%O1V%U5W5Z2"M)=%AI1FU8;$]E)B-X03LV=5!Y.3$V
M935K95=75#8R,W%Y17-Z9C9-;W)5.61X;7DP:VED3DUN*VPO=5=Y2#!L-7!M
M:&%M=V-#<F=C0W)G8T-8<3,U6&%C64Y%)B-X03ML=D=&1W9*9FA0:6M8=VHO
M04EB;&Y39&M9=4A'6F9Z:CDS-$QD:D=Z2G1:,#),53E*=3E0;'!W=6]N:G%D
M-D9H.$QF-T4W-7,X:T]+)B-X03M*2&5Z:TQ&4&U3-70U<F$U;'1P,314474P
M8VE(<WEM:$@S:D]B26\P6%9K57 T;V1I<G-696]E5R]-=#,U9"],83(Q1S)J
M5U4O<$9O)B-X03LU66XV36I+4U)59$1T,7I:67-X>#114B]/8W5%*TA(86<V
M+VQ*-6AL83EN;FXP5S9K*TME,U=I2U=056EQ4W Y,5!L:V8S1U1C,T5O)B-X
M03LO9'DS-4EV+T%"6#5$.&]713!F;&A49C9P379%,TPX:4(T1C-92TM$<GA1
M8C50>#A7265J95-F16A!96YM.'=U<G%E-G5:8FTT8WE4)B-X03MZ3UI*6D<V
M<WI'<$]A,&MK,EA&2G9D;#)Q*UHY2VXO3&I43D-H:UIT470U*V,X6E9G071:
M5%5-4E$O8EA-<65A2G=I4%<O,70P<V<T)B-X03M!3W)$37A':&U(:T1Z2'!7
M:E<K=$IF>4Y',3=B96QB.%9:<712>'918F9A1UI7;7EX9TI8,41F:&U),V%3
M95=T9&XP4%=R8E4T5D5H)B-X03MG63@T>G1Y4F=66F$Y<7%C;W<U1$-1:T=U
M12M%,CE',4=8.')F3FMV,2LT=E@P,B]C1#%I5#9416=52%!M<GAT4VY65&UW
M;6-'6&-M)B-X03MI-5(X3V4V1FIU+WEU.')0.5IS5$IR5W!2-W=C>GI65TA1
M.'5+4FHU9TU2:T),0FDS2'%K:3AC3U<U8CAX*UI02U!M,U%B96$Y=E=S)B-X
M03M.5W-O-4=7,D5B34=K6D)643%#3TQ-9V]A+U!(4&UX-6]!:S%)3$MC6FIF
M;6LO-5HK6F1*,$Q53'EB57!':FIM:59)>7%S.5-'<BMY)B-X03M$;$=I>E)X
M>4IK=W=Z16)T:#1/6413>41Y3'%L:G!N;6UY=G(V6#!B5T@Q9E5K-',Q3U5,
M<4YL1$XY<&@R>DDP:WA$24I(;"MX<WAY)B-X03M!;%I54$Y..6$S,VU,54QY
M,&8Q3&5E679%.4-T5E!E:D%(2SE425-Y16IL87I.;%,P0S9G=&1C,#8V;F)H
M0D)D47EY=E%M:4I)1UDP)B-X03M&4V%!9'-J:&M"3TI0245,13!1;2]N-U8Y
M4#%8>DA*96%F3#8Q<S!C86E4:7EB<4M(6G=P>3-86DEZ>5A(:WIY4T)/>5%1
M3T9M4FU.)B-X03M&1$%K*W=/66<U<T%Y<CAX=&,P=E=.8V=U9$]M.65"3%I)
M,F9I-E5C4U--4E)W<#9-37IE,$TP8VMW66UX6#8R>DQ)13=*-W!F;7IY)B-X
M03MV<E=H=V%0-6Q5=WDR-FA9-VEJ8U1X2$981$Q5<3%/=&1V,5IK-#E6:7DT
M>$1,,&)"34555G P3#AR<DDK=DYQ<VPP9S-705-"-BMX)B-X03LY2D$S-&I)
M*T)P23=M5B]J>5AH9T]Q4'-V>D$X<UA55C-O.#!,861P3'A'0S)D5DI01C%:
M6#5"03-%-S=B2#-Y,D=V>%-"9U)W=W%G)B-X03MY1U%C;FYU<E%A9F(V:DQ$
M<#EY8G4P6&HV5G=62VQQ<4,R>' P66M:<&,P66E215198516-TE82VQB0G=+
M<E<P371X4$A"179+5U9G)B-X03MK86IU>D=G1TU9;5)O8WEL-S=P;&I(66%D
M8E=59C)B94Y9-CE+:T1C+U-D.#=41FI%24-)-D)Y44M23U=*94DO;2\U94YH
M<C8V;$5T)B-X03M,8E5L-4Y18D-:2T)X+W-H4G9V>E,V+T9W>C1U:&-(55%O
M,S-S0WI#8V0R2W5X5FUL,R\U2T]Y+S=A>"\U37E:;'DO>&-F,6TX+S-9)B-X
M03LY-T,X>$=H,DMU>%8R2W5X5C)+=4)W2W5"=TMU0GA3,D1G4W5"=TMU0G=*
M8D)W2W5"=TI8031%<F=C0W)G8T-7=V-#5G=/0E9W3T)+)B-X03LT2$%L<TA&
M5G=/0DLW06QM9C5984MB>E=7=C5&<D)90W$Q-D=6-FAF=494.3)B4'-R0GA:
M3TDX;R]E,EEX=3EA>G!'.3)+<$@U,#AU)B-X03M*-6<X=C-&9T%0<D$O93)J
M;G1+;C)F.$%G=#%0>GEJ55EV16=2,5E:26-1<#@U4U)Y4E-.2$EP4U)#5F1'
M1D-'0F]14FY0:T]S2S-&)B-X03M867$W1EA9<3=&6%EQ-T9867$W1EA9<31(
M07$T2$%Q-$A&3%E/0DLT2$%Q-$A!;'-(07$T2$%L8T1G4W5"=TMU0G=*8D)W
M2EA!-$98)B-X03M!-$5R9V-#5W=C5E9),&52,6IJ571)-4-Q;S-*2C)!07=!
M6'-%:#=T-54P2F1&,%=#>DY06% W>3599#5'-B]D.6XV338S4UE00WAI)B-X
M03M06'$U55DP13-Z2EI/>%8R2W9(9GIF.$%+4#%3.$=V,FEF-DYD349V1D@W
M33-:+VLO9CA!>79N;6\Q*T-J>&IK6$0Q1T]V54AM,F$Y)B-X03MX6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA!-$98031&6$$T<&)"=TI8031&6$$T171G
M-$98031%<F=C0U9W3T)6=T]"3%E/0DLT)B-X03M(07$T2$%L8T1G4WHO=T1+
M-WEZ.5IU:G)6>78W:3)*5S!5+W13.3,K4V9R*U=B9G-V4SA2.%$X:'EB<U5E
M<C%03C@S=7A6,DMU>%91)B-X03MV-T,Q=C=+87EU-'A*8EA#1DI54&-(*U!H
M:UI216A2-4E)<U4K9&9.,VQE.#AU87A*67HQ944O2&%Z,#)K:DHR4'I(4F@T
M-6]-*T4T)B-X03LU55A7-4UF0V%36$M71'-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)G8T-R9V-#<F=C571G-$5R9V-#<F=C0U=W8T-R9V-#5G=/0DLT)B-X
M03M(07$T2$%L<TA!;&-$9U9/9DLO;#(V,3=617,T87)%4&IU6G5Y4FIQ9FUE
M9T=8-F)4;DQ/:#A78TDR6'4Y;%HR,6QA4E=L<V=J9V=5)B-X03M*1V<W05HQ
M54E#24%(24]70E-T:VMU>%8R2W5X5C)+<$HU=3AR5UAM4%-M<S=I:51,.&1R
M8U5Q,&-N:B]!2W V35 W37!Z-%)K:E)9)B-X03M:24-1<#@Y-G9P3CEP3V]4
M5T8Y2#9D>D-A34]O24\T6E0S0D<T>E%49UEM:GID9$M*:6%+1'E,1C)+=7A6
M,DMU>%8R2W5X5C)+=7A6)B-X03LR2W5X5G=/0E9W3T)6=T]+5W=C0U9W3T)6
M=T]"3%E/0E9W3T)+-$A!;&-$9U9C1&=3:DY+,'DY,5,K:7-B3U Q3&E9,%5D
M04%.>5-E)B-X03MW07EE4$9+8W5%8S)54EHR93=E5B],9&YO1VU,85%F2$TS
M>%A-.4M'4B\V1'---F)486-9;S!0:35K63!%,WI)6D]X5C)+=7A6,DMU)B-X
M03MX5C)+<V(X-BM3<DAZ3EDX5W!$<4U)4#%7-G P-SA(<#%1+V@Q2'9J-FI4
M:DE03G)Y67A)4$).5S!J54Y*=C5,1R]H34YX1C%5-V=G)B-X03LY1U5J66<K
M3V%+8T1%,%A8>6E9;6EG.&EX9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F-$
M9U9C1&=68T1I;'-(06QC1&=68T1G4S)$)B-X03MG5F-$9U-U0G=*4G5L85AF
M-G!E>#)6:D5:8FE4;V\V041Q>DAS0C0U4$AJ;$TP3V)+35-4464T950O2CEL
M-61S=4LP;'8U45!R3GI4)B-X03MR,S1*-$M0>'IO=$QP4FE(.4IZ25$T47E$
M37!M-T9867$W1EA9<3=&6%EQ-T9867%K=FUN>6QP6&U3>"MR,VDX6FM"3G1D
M2CEU3FHT)B-X03ME25!D5"]B;$]B0DA)2TQ#94U31S=W;GI2-5$Q:GDU9"MJ
M97@X;TA*.4,W4W!J:TAS97IE2VY.2FUW4WAM:31'5$=9.#!K>6QR9&ER)B-X
M03MS5F1I<G-69&ER<U9D:7)S5F1I<G-68T1G5F-$9U9C1&EL<TA!;&-$9U9C
M1&=3,D1G5D\O3%!L5%9V348Q-E9M;D=&0U!8=6YQ23!()B-X03MU93=E04=8
M64Y.3$MA1%I#0FLY=3AS*U9D3#AV,F9O5VDX<&Y!*W-83&9B:TDO55!!6C!'
M;C X8U%O3V)#06E%-'DY:S=&6%EQ-T98)B-X03M9<3=&6%EQ-T9867$W1EA9
M<6]8,6A:6#ER2F%8<TMZ,CAO;SA4:6]/4FQ%4T9&0D8X,VMV;3,X;C=Y,DPS
M96=%,TYV=7AS;5 W,5(Q)B-X03LK06XW63EU=GIZ5EHY05)V1&1X36UN-GAE
M8GEX4WA33D9+:E)Y26%/:D%Q=TDW14A.95)4:6M,8U9D:7)S5F1I<G-69&ER
M<U9D:7)S)B-X03M69&ER9V-#<F=C0W)G8U5T9S1%<6M58W-S:7AX23!K:FUI
M;V]*66LY9T)I0F%H-DXU5"]+5S=U4VPS<GA.=&(W34Q.5"LY8G8X6D@R)B-X
M03M"-V1F;&UX,"]:-4\X.6@S3U9J=V0W,5=Y<V)/>'1K=&)/1EE,94U54TY"
M441.=D=!:4M(2GE12U8X:VPR2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU
M>%8R2W5X5C)+<$HU:#AM*U@Y9E$O<$,R2'(P;W0Q2#A%>2\W261F:S%2;$]8
M5'=N>D1#94U3-79,=DU0-5!A-UEL<&1,)B-X03MD9%)T:'5%1D5M02\Q4V5,
M9E%F;WI76F1"2U P-VAX2C99:FQU=U<V=$QQ,&UA0S9H94-:4'124W%5669-
M3E$U:$=*0F]T0D)(3E-W)B-X03M)9&ER<U9D:7)S5F1I<G-69&ER<U9C1&=6
M6'1B5S9U<&QG=%E8;FUF-TU586PR4'E#,4]%4DI.0DE"4$IN9FPW.&]D9'93
M<W5Q3TY/)B-X03MT>G553DAM22]W0E5(:78P;C9->F-86C@U9E9S2$EH<'EE
M8C O=T%V*U0Y03!&4#E!=&=*-E5A-FLK3UIV.6ME;GE79WI:-&101$AY)B-X
M03M$;%%X:5!*3W-V6G5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%9#86IP3VPV;$0V3V]7<U8Q1T]G;%%.)B-X03M3=CA!2U1U
M4&]Y13AC6F-X841%2&UW>E9V>6$X=%A23#)-<S)N=65I9RMR1U Y:2]X9CA!
M1%II5#=09V57>E),5'A03%II96\O:W0U)B-X03MK9W$Q;F-7.31O-DQ5>$]F
M;UE&9BM'>D5N,F9-8VE#,4A42&]X*S@O3#=Z;F%%:5136C-P,VA!;4@O2DUV
M;$5T3&M(4G%/1U$V2E10)B-X03MP1W)7-4EU3$ME17(Q16M4<E1E;F-$2VI#
M435H:5E(=5%R;S9':G%64&=25$ES86-I3S5O:6QJ-$%6>%=K5D)P1W)80D%T
M-TME670P)B-X03M%8U1T6&5N64A*0T5J>41)45!C;3%N*U@S;D\W245E:WIP
M6'9-0D-0*U-H5$Q9-EA)96I)65I(;WE$5'9Y5SAY5#!A.'5,97I5.59Q)B-X
M03M:6$@P2T%V+T%!,EAW-U!M95I!8E)P:C%:6G!8-4YE5W)5<3DY3$YF=4]Q
M:RML1V8Y:6YX9CA0;59$<RM!-3=T<V1016,Y,EHV9'!/)B-X03ML-F)$-D]N
M,G-6<D=E;VE13%=N.'A'-2MN37E'3TUE47!V15%/4TQY85A9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ+W=$+S)1/3T\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @
M(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.D4T-4(R,3,U-3(X-D4Y,3$Y-3 S.#0S1C$U03 T1CA&/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX
M;7 N9&ED.D4T-4(R,3,U-3(X-D4Y,3$Y-3 S.#0S1C$U03 T1CA&/"]X;7!-
M33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N
M=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM
M<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I
M=&EO;D-L87-S/F1E9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @
M(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D4S
M-4(R,3,U-3(X-D4Y,3$Y-3 S.#0S1C$U03 T1CA&/"]S=%)E9CII;G-T86YC
M94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D4S
M-4(R,3,U-3(X-D4Y,3$Y-3 S.#0S1C$U03 T1CA&/"]S=%)E9CID;V-U;65N
M=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U
M:60Z-40R,#@Y,C0Y,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO
M;D-L87-S/F1E9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @
M(" \+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R
M>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z0S-#1C!$1D(U
M,#@V13DQ,3DU,#,X-#-&,35!,#1&.$8\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,3DM,#8M,#-4,34Z-#,Z
M,3<M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W
M<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D4T-4(R,3,U-3(X-D4Y,3$Y-3 S.#0S
M1C$U03 T1CA&/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#$Y+3 V+3 S5#$U.C4R.C(Q+3 W.C P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU<W1R871O
M<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @
M(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU
M<W1R871O<CI3=&%R='5P4')O9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @
M(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP
M5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6
M:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ
M/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM
M.G<^-C$R+C P,# P,#PO<W1$:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^
M-SDR+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^
M4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%109SI-87A086=E
M4VEZ93X*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @
M(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z
M;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @
M(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U
M;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @
M(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@
M(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E
M<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB
M(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO
M<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L
M:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !5 %4#
M 1$  A$! Q$!_\0 '0   00# 0$             !@ %" D$!PH# O_$ #T0
M  $$ @ #!@(&" 4%      0! @,%!@<($?  "1(3(3$4(A4609&AL2-14F%Q
M@<'1%Q@DX?$E,D)BU/_$ !T!  $% 0$! 0            4  P0&!P@" 0G_
MQ !/$0 " 0," P0&!@0*! \    ! @,$!1$2(0 &,1-!4? '%")AH;$C,G&!
MD>$(%231%C,T0D1B<G/!\66RL[87)4-24U5C='6"@X2TM=/_V@ , P$  A$#
M$0 _ ._CLN%PNRX7$2.(WC2TKPV0R5V3W#\BSI\#9@M?XR^ R^5LK$<//<RO
MD:%CH,J.9(V:TF880.YTU97V7EN9VSOG7TF\L\D(8J^=JVZE-45HH2DE7AAE
M'J6+"*CA;8ZYV$CIEX(9M)' ^KN5-1^R[:Y>Z)""_N+;X0=^^Y&X!XIJVEWG
MO$+L$@D;#2*G4^/2JYD(F.C0VN0.'=SY--R:X&FD^(;S3D31UU"Y$1J(Q?F6
M3E7FKT^<]7=I([1)3<MT9)"QT,:5%<4).!+<*I'(D&V)*2"CZ#;O(.6\U,K8
M33"G<%PS$>]V'4?U0G?WYQ$*[VOLC,IGSY;L#-,FEE<KGNOLHNK;GS7GR1IQ
ML[6,3GR9&QJ,8WDUC4;R1<.NM_YAN[,]TOMXN+,3DUMRK*G[L33.%QW* % V
M  V#0G>3Z\CL>XLQ.?Q/7SUX91R.?)>?K^?^_P"?\>2K4I8L;'S^?SZ'?ZSB
M.5/N\_#_ #'#Z*5RY*B]==?LCIH=7V_/\_/VS%;.X\_O!^/!0$;[>OKU^'Y?
M>G8-/!UV\^(\_#H^K?CY\_ [X)*!B45$5%_NB_V_X7TY*@::$@D@?:/F0/F.
M)"MG[>" 4KV]?7\^OM3[/R&2Q @D#(/4>?)^;RMC8].X^?(^SH00E<V^_P"/
M^Z=?OY\QDD/M?N_/S\.'U<J,?XXXZ=NW[Z\.\5&=X)WA3=+R':6TP>*3M289
M&97E3$A+%UX.5$CXZ\&-_F#DYD1 ]DZH0R06A&EADFBGL2(XP,*]*GI2;EX2
M\O\ +TB->GCQ6UPTR+:4<;1Q*<J]>RD-[0*4J%696E8"*M7J]BE)I*4@U&/I
M9-B( 1L .AE(WWV0>+'V>> N\LKJQ-M[BP-MK6S*G.LK.R*G.L#S29'2DF&&
M$OE(**(E<^2>:>1\LKW.>]RN5>W'M6TM5++/4RR3U$SM++/,[2RRRNQ9Y7D<
MEY'=B6=F)9F);.K.::)69B[,69CEF8DEB=\DG<MWYZ]?> X#$^WKUUU^L1+%
MC((W^!'[O\QMD";'(&'GSGQ'WCN((!B?;UZZZ7G\PF>#J0-^\>/GN/Y$RD?'
MV>?C\_<00" 8GV]>NNEY_,)EBSG;SX'W_/Y3$?.Q^X^/Y^>O#\.1SY*B^OY]
M=>O)5&RQ8V/G\_GT._UGT<J?=Y^'^8X?A2N7)47KKK]D=-#J^WY_GY^V8K9W
M'G]X/QX* C?;U]>OP_+[T[!IX.NWGQ'GX='U;\?/GX'?!)0,2BHBHO\ =%_M
M_P +Z<E0--"020/M'S('S'$A6S]O#Y$5\OJO+K[/1?N^S[NPYX<G*]_GQ'GX
MNAR!CKQ>7QV\4,'"QHFWRNME&?L'*)G8GK<&=L<K?K :-+)/>D#/1Z2U^,5[
M)K69LL3Q23VU=42Z-+1CT_:GG_FH<I\OSUD)4W&J)I+9&V#^TNI+5#(<ZHZ6
M,&9@05>010MCM0>(E\N8M=$THP9Y3V5.NQ^D(),A'>L2@L>XMH0D:QQR68G2
MY]N//@Z#'@;G.=A9S<E20C,E<;<WUR:XBQL3"BBY6HZ1R-+L;*P-(9#!"PDX
MTB.&.:7MQ7'07&^W%*>ECGN-SN,[E5!,D]1/(6EED=W(RQP\LTLC!0H>61E"
MLPS" 5%54*L0>>>=R<9R\C'+,22>NQ9BQ  !)(QD/F=X!G.I\ML\&V+C5EB6
M64[HVGT]HR-)F,F8DHY(\X\DX9P1,3FRBG@$DA%QJCQR)&\G=AMXLMQLM;-;
MKK1S4-; 1VD$P&H!AE9$92T<L3C=)(G>-QNC$;B;+%-32-#/&T4B8U(W49W!
M!!PRD;AE)![CD9#,.1[>OI^7[T_JGV_>B )8M6QZ^=Q_B/O&_7TCD'SO^?GQ
M WOB^DMO91KK(=MT&!7UGKG%72MO,K@AA: *@Z-<9+#%+/&;8C5S'(^U*K13
M!JJ/G)92C,1SNTZ'D_F.NLU;S#26BKGLUOU"JN"*G8H$&965699)HX0<U$D$
M<D=./:E:,9 +00U$L#U"Q.T*?7D &!CJ0,@G3_.T@A>I(V(S]7:GV?M\RQ U
MGA-]F9-./ 5:I3">=#70DODC%<:5*^(4=Q3XIT%BEF;*3Y!"P,D;!,K0]IY0
MY@YGEJ(N7[16722F19*E:6+4L*R$K'VLC%8T:0JW9!G#2!'*@A&(D4\<TQ(B
MC:3 !;2,X!Z$G8 G!\,X/>"%WS!P9\5+>7BTGF2?QBK_ /[UZY^_KS*2>AWT
MDMD#D^['_P L'_[]??\ <?<16DJ^A@D^W ^._7C,*X2N):G -M;/3^6!U]8&
M38'E2Q I$,&'"\@HB16FN7P0P1OD?R15\+%Y(JHBJ*J_1!Z2*6GJ*JHY0NL=
M/30RU$\K+!ICAA1I)9&^F)PB*S' )(!ZGZSJTU4FYB8*,DDXV W.=^FV_P -
M^K+A&E]L9WA=]L/#\,LK_$,6(-%O;:OGKGN!GK:\2T.C^C7FLMBOAJ\T4J5P
M8)#$BD54<JQRI%5[=Z/>;>8;)<>8K-8ZFXV>U23Q5]93/3,89*:GBJYP*4SB
MLE,5//%,Y@IY0%8D$E7'#T:/(AD1257J1C;;)'OV/<#L> \(WV]?7K\/R^].
MV<3P==O/B//PZ.*WX^?/P.^"2:$E%9S1?Y*J>GW\^OY=A$D'M;;?=M^7O'$@
M,"-]CQB=[AO$C9/%0=@@9;I<7TK3B8B%"Q_B&DR>U@%O,PL&M5>;"D)GK<=+
M3Y4\6,QJB>\COTA]+MW:Z<S/0HY:FLL*TJ*#[)J90L]7(!W/EHJ=O'U8??G'
M-MQ]8N[4RM]%0HL0&?9[5P))F^W=(V\#$/MX".ZSF\?'/I!OZV;+_#4.?+_3
MK[ OHL3'/]A/_BGV'_B:XC/[_?\ 'YRNV;U1?^YV]_JD_GSCCH8XJ^''2_&&
M%D&NBKJJJ-UZZK0;"GOA6,=D6+CW\,Q=1%=!+Y1%QA=Y+#.R6)KWPP%PER5Q
M(MF.0R3H+G7E*P\]PU-KDGA@O]KBCDIZI #54:U*EX5GC]EI[?4%6#+DJKJ[
M1.DR,#H5QH:2Z"2#6JUE.JLKC^,C$@)0.NQ>%R#D= 02I#@\5&<,_=>;5RO:
MUW7[XJ3,*UU@%R@=L2-/^GV+/&V,F 3"SFHGF8^8-)!,?DR,C<-',M6+$V]B
M/;38-RGZ%;Q7WNHCYF@>WVBV5&B=D8:[JRZ76.WR#^B2(5:6KP- )AC45(E%
M/6[=8*F2H<5B&*"%L-O_ !Y&"!"PZQD8+2;8V4#M =%T.U2M<IPA;^I-5OH4
MQ#"M0;@PL8/&FQMIJH['<+NQ;&H&?"WX>:6O*5\!TL,D_.P:4PB9YC">6_W\
MVC_@]YLI+)ZJ+?;^7>8K:D5&!ZO!)2VVJCE@32-+-%)E92I;Z4.'8R!\6R<P
M"W5:T^CLX::IC C'LJ8XG#*.XE3L<9]K()SGB _<UO\ 'CN^W?;],Z\3G^M/
M@LO5/7^:_P .:_;S[9%^C:A2DYNR.M59]_'Z*X_#?[-]L= *Y<;5'5'^M#\I
M.OGX8X+;'B^[P,>TL10^$=Q (QYD 9*ZXVC)\0+"1)&//YD=\V-_G1-9)XXV
MHQWB56(C>795?I,]-44\\=/Z-1-%'-*D;_J/F ]I&CE4?4M8%.I0&!79LY&!
MQ(]?N>HCU';) /8S;CN/UOO^SPWQHK<?>!<5%=37>N-@:GQC6%GE^,%CJMEB
M^8560145TAU1-958E_?RP<IO(L!!C9@2H&$03*QCY8.3<ZYS]./I,IJ*MY>O
M7+%MY=J+M;9HM4]ONM/7+15@FI7J*:.MKFCRVB>**5X9461&(!9-O$EQJL-%
M+$L1=2-TD5M+97(#M[B <$9!XDOW;LGCX4MQ._5G&;)]VN,07^O7OVN_Z.JZ
M?17SB#_UW?/]W+1U\_CU,RW?R67^\?\ V:<4K"E<N2HO777[/!<T.K[?G^?G
M[82MG<>?W@_'@D'-^3W_ !5/NY=)V$20>UX>?L/GW8X>#;;_ #'^)&?GX^)@
M7MS+I\_VKLO.29'2SYEGV891*]SE<JNOL@L+3DBK_P"+4*1K&HB(UB-:U$:B
M(G9EWJVK[K<JUCJ-77UE23G/\?422#&>X!L#P&!QBE;.U16U=03EIJF>7/\
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M*K/$I7$D-N>,AQVI)!J9!%*D>5CC61A*C]=S6]13+%2Q/3R2+B>0L"5&/:6
MC?VCD:V"N!LH#'4)3<(\BO[J/<4BJJK]0^)!55?555,?OEY\_=?X^_[U]^UD
MY)&/0ES"/]%\W?&DJOW\%[4P;ERH/=V-?_J2<,7<O2>9C6_OW76N_P 0<O\
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M22@  BAQ':FOFJ.;%LSQTAME3%34M32FBI6[<2VF(M/),\35#50<AXJCM1)
MR1B$QI&J<%S6/)>10,L/JTBPQ21=C$=>ND3,C.5,AEU'4DFK5&0H32H X'M2
M6L>L]0ZSGM]F8#I,G/OK!EP8HVHF;HV7M>E9D]ABU>9D4%O2)18YAHQ^.6N/
M8]B\N3CP798UW=V59Y)HY2!K81:K/;&ENEOL;7 U-8JI91>[I=X14R4D;U*S
MP=A3T2/3S4]/1M5!9W$\\L1$BN/=%(*:DIBU1!1&?M)@/5/7*FJ3M&B5G#)V
M<<(:)XXXC*-9#R,FX/!SEUK7Z&LN.4W7N*X:'98IQ0X%A."G6N*T>0?4&IL5
MXB'EKB85Z'95]?*\&D'JH4E%)B%%="0/%'95]6:'YN!CY<?T@RVNCMZ34G-M
MMH;=)-14]4;;#+_"?M#11U4<L43&.!(5!1U1,,@$L<,D<R1UH&O34\40:*YT
M\4),:/V*MZ_J$0<,%VC"C8X&",,JLN'0[.N<%"X,\6QBIPP*NSC"P3<^>7@V
M(7)N=06_$/M/&IJK)CKBE.,/J8:6J8% %\1&QC"9G>+S(PW#"XKK46Q?1_04
M5/;HX;C;X7NIDME!427-:CFF\TC05DM132R2TZT\0C6/4,!V8[B,HY%5-$MK
MCB6(+-"K39BB8S!ZZI33(S*6*A4 QMU.-P-/WD><&YK#Q;8,=48N)ANM*&>U
MUKCE/B>.UD>$E4?$'K#!*Y:.P K(+CS9,5R6YJK:<NP*(OW&R'7,AUBC"6"[
ME6R72/GZUS4U#';K/2&HLM'!04<"VR2FYMLELA:EFB@6I#-0UM3!4,\SM5F4
MRU)DF </F=I#<H2J"*G0M3QI&B]D4K((5TD#5G0[*Y+,7R2Q+ XDGCX-$F56
M>C\GS?7XCZK7.=TMOP_8AJJ.\KJ&]Q/5&16Q,]UMJTJ*8J;.ZF]IOIZZRBJ*
MN2(\DCEJ0;&6N:L<5B@I*3U^HY5K[G9XQ!9+M35')]NY>6J@I:JW\O5M0SU/
M,-134TC7:FJZ85=17P25,HK5:GBF: $*20KK:E>6$%895:EB@#!'C@=B6J"J
M9F5EU,X+MKRJG3L*OQB?;UZZZ7G\W,L\'4@;]X\?/<?R)&H^/L\_'Y^X@@7%
M=VAHJGV9C&U<JRH5TM5'=XQ04DR,1WBL*T"WL;R/F_T^0>[HG?*JK^D7Q>[5
M7I+]'OD:CO\ 0<SW.YQ%J85EMH:-@O6:FAJYZP$G;V4K*/IOOOW<6&V0K.DK
MN 0&55. =P"6_#*\:O[ZSAW)$OL(XE\?!<^NMQ1M>;">/$JH+;@(25A]V5X&
MN<K;.M4Z@(*E6. =U+1"(KISXT=J'IEY?99J+F2!/HY56WW J/JRIJ>DF;^\
MCUP,QPH[&!?K/O4^>[81)3W6-?99135.!T=<F&1O[2EHR>@T1CJ>*8]-9_\
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M"F.+9DI3M))W@S=\:_U-I#T;1C?H;!!"JP@ZVM#%KZZO%'!  !'B$"""$B9
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E2TRB0#';R$RS'8@X=\Z,@X*QA%/>O$I^UHX*\+LN%PNRX7'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g841008g84s08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g841008g84s08.jpg
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M 0$! 0$! ?_  !$( #0 - ,!$0 "$0$#$0'_Q  ;   " P$! 0
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M6Q''%*ZI'8F20A$FCU?;L);:&)5@A.K5LV8R\4>Y VW4LB^H $CU$$Z CO\
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E(6GFVJPEM,)64D ^E0J1*0?#"/>/.[7OQ85U/^)%Q[KN.X__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g841008g97g16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g841008g97g16.jpg
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ML&Y;=4/ETWVY*^$._K\MAP'4$3RZ;[<E?"'?U^+#@.H(GETWVY*^$._K\6'
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M"DG()0# MJ"/64GL#C1$S#'2H3RQ:G77F(^%P+]YH-+@#;UZ=%T\O]/?H5X
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M^5WV)'[=;:0+AP1EL,!2DN]FJQK*RRYA^/K\C3VA!KS-6YL))^Q19R8X>$6
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MB,/$,F(KH.3.F!8SU@;'I/$10B42(/# A(E,#P%RW_)8+6',XYCE:;Z;=O\
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M$3_GI?VW+RNJ_":C\_+^\<L[<T5H)PB<(G")PB<(G")PB<(G")PBA*]^]O\
MM$W^>B'"@V>4^LK"74D=V:&J]*C:HES8-DLNSZM694F V!\I;!D8QAXCXLVR
MU:YAA2<JB1O&)S*X13'^XC#>%/8SS)MM;\%'7TMQ6NVR.H[<M-;MFOAM5E2K
M76:YF"W9'D9-6Y9"%K$/>7MFRQ8VBB*&0HLZRS9>L8[XR/!S(N4?.61$-M3P
MJ!0&G7^@WV&V]]_O=8EQ&F_K.P$G9:V[TJ@@]3VVZY*+-V$.B='<G>0-V.V0
M9P2DU=A6S>KJ##G%,5"DDK&MTB!U!KJGQ%(R39F$[169K$%DC/?3:UAI]F_1
MO:3XE<Q';N&I&X7W6]];EL?5)?9]A&4RO5)X*69V($'V.8R-,D7QU8C=1?3G
M1.Y=@FJ[#4VB]:XVG;C+<IZ)#)"X07SE$8C.-K?AS+OVBWV'IW65S>0[^L#>
M-X*KM/\ 51LC;-RK]9CZS$AQA0J2D3[%,(',18]6@UZJ'L9B1L"E.^R%3YPD
M <'&U@ID0F+D-&A(,M )U^/2T 7OY.F_9K]IWP.)-M/Z>_N%*8ZGGZG7=P$;
M.\T:,ZOVO;W#=?\ -TH<5%:,"7> *(6J U$&X9+JJ]1G/6-OQEN/FXXYUGRC
M,A]#N)EV;@;:])':KFV[R+Z= /8K*1U7[V::<E$='!83<2*6FD1BS=H46B8K
M]:TW:"8Y/<U=^%((R$;6EU^#E#^(WG6I%967'V<*A-7*./JZ>GB#Z L<YX>3
M?N^P_;L45&ZL-PWDS7Q=&J%<8SF_NC24QA\\3#QAD%W= .16[E*D5?"Q!2>[
M0@%N'N@'7'7(4]D:Y*CQ)<8D3N4"]]W]-1KTV\?'8F8FUOMZ=-A\>F[3I4BK
MK/V,_$Q-A:4[9$BGA3[%7E$+,BQC\EM<4N]-V$SENI*'LTB2:M,W7<*?$>DE
M,V8,O+D++V28H,R#CT;.FUAKT=FRZ9SPZ=OIV=*YS?5SM>MC;$HQJ@)@C#)G
M@M?<@D;*Z/)$*ILW86NB&9CD\(+B06["FBM':PF48B-/1CHR"F:1+3A0\G T
M$C4Z^+@#]O3Y$S$7N-=UMFVQOJMXZ187;=2ZC:WQS@A^SU<!87A+KBG71CIH
M5$).#G'5LQUNN0ER<QEN+CL*6IK*E,M9SE"<#H2."U!J >*KI?[^!O\ 12_^
MX?PH=H\?V%5)@P)KXDF>/$QX0&%@2RI@P6F1QPL4,@,.2IQ$C/EN,Q84&'&:
M=D2I<EUMB.PVMUUQ"$J5@JN*.?!2RCH2*9%23+ H>>?$QR$1XDR#+2)T068=
M@MO*E-BR4H82C0""VL1)CX^:U'=<<BOI;(I;A%&-F@[I+(=HL-<+I;ENJ%MS
MHRR*6H&!>9SBH27<R4HAX-ALRE9;QB/@N,R[E&)T7O27W;U)\(G")PB<(G")
MPB<(G"+H._X0_P#YQLY_8[JW^Z%N=VP'\ 'YZ3_^5Z#R;_%H_/R__P KX8\Y
MI<^O[C&59PE.,J4K.,)3C&<YSG.>S&,8Q]W.<Y^YC&/NYSPATU.P+)EOTMMV
M@8EKN^LKU4VX#,Y^:\?JY@6Q$:%EPH GF1(EQ&F6E##=CKPDBVMS#D$B=#Q)
M2&GR<)#VDR:&2P9*QY-K97 WN"X6L=;AKB#O#3P*T(ZFGEL(YHWEV@#7 DW:
MYPTZ6M<1Q#21L*QES56NN:/'?EOLQ8K+TF3)>;CQX\=M;S\A]Y:6V6666TJ<
M=>=<4EMMMM*EK6I*4IRK.,<(2 "2; :DG0 #:25>)36FQ EJ$T8Q1K8+N9Z0
M.B ZK/KY2+8#$HO.4+&1Q8EZ,B;/?GE$.#(K45EU;Q%IZ A.9;+K*,!)&YA>
M'M+&W+G!P+0 +FYV"PU-]VNQ:39H71F5LC#&VY<\.&5H:+FYW6&NNZQV$*TI
MT&:+FS!I*))@$1TJ1!GP)C#D:9"FQ'EQY427&>2AZ/)C/MN,OL.H0XTZA3:T
MI4G.,9 @@$&X(N"-X.PK4!#@' @@@$$:@@Z@@\"%S"1)0\4'A @^86,%ID8<
M+%CHSLR>0GS'4,1(4*(PA;\F5)?6AIAAI"G''%)0A.59QC@D-!<X@  DDFP
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M'765Y1XS3BT92K-!#@'#4. (/$$7&U5K@YK7--VN <T\01<'774*-Y55]+/
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MQ)NXE@[\]Z&7>YUX51U3$56OK:J&RQ&3Y:Y?#SY/SX@/L0#F]HFR##MGQ:X
MFSUP,)ER;I,+QJP,)5M%G996*G0<!0/%_OC?%D %LS'%EK9<A+7$@,REQ!+;
M9@</BR34\['MV",?-S1GF]&AN4ECBX<W8N+79=H.&MH]3];V-KXY1HE0L=5'
MG[]$M3P$<?"*J N+$O&U[6Y/'!H=9%-)MI49LN#7B!%EJ"/PU3H;K<%8R8(
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MH$KFL ?SA(?*T@$Y&:LN!FL+ZDAJ[-O/T07;$X16;?\ ^"A/^E!_.$7A8O\
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M=3ECL^6CIHWG6XD9'9X-P+D.VG4$ZW*XZOF9.^F<Q^<LHJ6.0]]<2LCM("7
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MJ\_PVN'^M-@_.TOGIL?]W'_V-_9"]=@_N(?S4?[ 7J(]+?\ )EZ=/["=1?\
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M6W'4(7)?0P])6S'0I6%/.IC1Y$A3;>%+2PP\[G&&VEJ21<W")PBA9?[^!O\
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M->:FZF3(H%<)UVL59(0BRI 2HVW9^S9J(X9K?.[#LR):84B.EZQL$]/6;6P
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MQU;J:*L[A=AEC"S$VT4T56["'UC<6$+V@T/.N;$[-A'?.DA(M@V3VWKF (E
MHEGBDI5R ,PI-=GDEAX)N/(7/PV^,F%FW1L68TI;$B<T[%:6MYM:$]GFY5\F
M:>!E3/R@P:*GDI8ZV.:3$J1L<E)+,::*I8\R@/ADJ 8&2-):Z5KHP2YI Z/3
M<@>7%95OH:7DAREJ*R*OFPN6EBP7$7SQ8E3TPK9Z&2,4Y='50T;FU4L+PV2.
MG<V9[1&YKCS,;RTQ)0*<C;6UV^@[FO)"K9N !Q)55ME$(-70/RB?G$M=@FB2
MD,.ACQU$)0V='C8<>B/H1DWE1R;>("S'L'>*HT8IBW$:0B<X@^6.A$1$MI#5
MR4\\=.&W,KX96,NZ-P&$G(7EK":MLO)+E)&[#QB)K@_!<1::08/%33XJZI!I
MP86X=!64DU:9,HIX:FGEE+631N=_0>\--V8\*JU=VIKXY9#@[!8*!%6X%.+%
MQBF%RDSQL"/.<DSHN8K3DK#T9MU&8S:W\9[I"EX4O*CDW75<%#1X]A%56U4/
M=%-208A2RU%1 6EXEAA9*7RQY&N?F8UPR-+OF@E*[D-RSPS#ZO%<1Y*<HJ'#
M*"I-%75]7@]?3TE'5B1L1IZJHE@;%!*)7-B+)7-/.N;'\\AI.[OTVRUA]W:F
MOFV<Q9D[O%VX%A&(0ZQ>Q"=,4K,[L3%B6O\ ^6I$A78TT=[12UXG8RQP[E1R
M;8W._'L(:WFY9LQQ"E $4-9\7RR&\NC(Z\&C>X]ZVJ!@)YSO5&<AN6;W9&<E
M.43G\]!3Y1@]>29ZG#?CFG@ YC66;"/_ +I%&+O?A_\ ;&@T_P!\5#&Z@]$S
M)1^#%W'K*1,JKF&K)$:N]=7)!.9+, ?%*,X(=Y"S@W*BB%=^E&$DI+$)79)>
M;;5I,Y7\E9'U<3.4>"/DH79:V-N)T9?2GNAM+]_:)KQ_VE[*<EP $SV1DYW-
M!W$GP=\O88L/GEY%\J8X,6;GPR9^!8FV*O;W))B%Z1YILL]Z&*6L'-EUZ6.2
M<7B8YPFP.WM56DDV&K6QZ0?+/%RP!H8'LX8C/<. (7G$V(1$B3'7U$A _/EI
M*'A&9$*+_CY#;;?[+FYI.46 UT[::BQG"ZNH=45%(V"GKJ::5U521<]54XCC
MD<XS4\/WV:,#/''W[P&ZK8XAR/Y6853.K,3Y-8[A](RCH\0?4UN%5M-3MH<0
MG[FH:QTTT+(Q2UE1]XIIR[FYY?O<;G.T4G?_ ."A/^E!_.$7G,KK3_FGR>L+
MRJKS_#:X?ZTV#\[2^>FQ_P!W'_V-_9"]=@_N(?S4?[ 7J(]+?\F7IT_L)U%_
MP_KW/.*C\(G_ #TO[;EY75?A-1^?E_>.6=N:*T$X1.$3A$X1.$3A$X1.$3A$
MX10E>_>W_:)O\]$.%!L\I]94WPJM/;K2-SJV)8[G69#SXMK8U1<#"<%K#$).
M (M#JS#DB"XW>(U2S37[NU*@7BNDZ6Z8?KK]L.@B3AU &.O($6'B/#CXMMMA
MOM\JP(-R1MTX[+#I M?;Y5;$6;U2K;%E2 >TJF8B&0TA4>91H$V @@[JV=F:
MY%0'*@2#D4G"NHH7,52),ED>N2PF0Z-<9NLYWO1Z==OE&[?9.^TV[QK;?;T7
M%[VV=:_(6X=3QD>;0J*?B6,/%J@^Q0T5ZA9#ARC]+TV=/-5Q_+TF:1.9-'=@
M19K[OLF$BQ4=V4*KYPB.KXFTN]]?'74](W6Z3T:E 2;[^K;8>G;XN"F(1[JN
MD2G<DJ^0$Q%#:AY0S#S0S3\(6ZQKW-O(BY*X(UJ5?HRY&Q<P(TAF=7I,D;#9
M]AD.,L5(,N]]?'B;>2UNGTJ]][VX"]NF]]IMIL5.&$=244"1("7[%&L4=F[Q
MQT"TO528Y87!#%SMU#<-*?>(B@S%IL-N%U<\@"Y!<AC:PQ$AD!<1J)*BWO?5
ML!TW'QVM<=)WJ#-T[]N_AINO?7H&EES"0G40:MU8L!0O<1,*.W(!.^.FB94R
M#EFFYY M-&9#L"Y%BDL0FA40FNMB\1 RHZ$@\3O*RQ&7;;8#U]%NGCH@S7UO
MPW;-;GAM \G%<M5.]3TUQOV6![8%&O9S*:6*C:Q,V!LX\.K6(E?F9EP 0E-*
M:(^S%!6<F!'.1Y$83Y%:YP>2P3G#EMIMV;^OQ^CH0%V^^ZUN/5LUUTTMMXQX
M%SJEC5VI!>\MB3++%%"'21R)KT@U&KN*?6V;A:EDEI>FD]AQ=AYL,)AB2J6"
MFTR.V5=$RBCC)>>[W7RD;=MS8>*WKZG?:;=U]FRPOY;^KKSMJD[=C1K84*Q$
MF"P*F6%ZFA#;3(E"K-/C32)H@5<6)88B]X%"FZM1RS,>./;9N]6NZ5#V$>3-
MLPVTZ1?W])\5E1?7HT\?_ L.M9JY%DH67^_@;_12_P#N'\*':/']A7-..!1<
ML3 )EQ8Z>>ENP 4*<0B1)9J>Q$?GO0A,:0ZV\1ELP8TF:[&AH>>;B1WY"T89
M:<6DJL6[>+U:N1H1>SZ\-7J,3&&* O 9-7EK4/O<^NPIM5<#V&T@9)E5NFCQ
M#*( B 8?<2,<[_$1G.?**!??:VN_=OTX*&V\7OINW[MHVJQRC?2[&1+<(V*K
M0%#IB1LR6F]%ATQ$WOKV;RIZ=&.QYDEY:7-G.2267GE.C%7^!)E*%^R2+R]\
M=Q\@\71_V^+13O=>WQ[^O7?J%3V(+TQ5WS$HA'!0\F3D@)&(B#Q.++7/!P+;
M674EB8TS&(RXHF*S9Z$RW)>FIA,$9-.C,-CIS\'(9MU]->.WWOZ4.4;?%IU;
MN&Q7W5C.B!<E/L2/TQ#]5"6%W#@XZS,2+!&954)V-]3_ ):^TJ'*DHITR;(6
MXYW6) AW"VVI[69$.;>#KT=2H+=Q&E]]^D]*LH-;>GLT[+.2; &Q'M<N>3$I
ML)*$,3W1Q^FO6%D3 \K8(0X$H_5*X>+J+165MEGW)J9&($O*4VSAI;J'C^P^
MY4NWCOTU\1\@N-^SQ*TU2>FR1!L*(, ,DE7F&HRZU8+88P,GQ"55%R'50QPP
MO81I=ARF6=-=0F+!DYEA(2ZAEQBL"48@.^OK?7@.GR6U%]W'>I=HV6)'3_S?
M3^NQ9TJ^L=?X$B"3%+$B7YD>$95!AD724,=,EJI17,0?,CR/(GAX^50Z:R-P
M/;9%M0ZT+9&QHX]/DZI<^_E[2LK#W\G8%^9&B]52G9CKU4;_ ,ODS)TMAHN?
MCPG2,\8X%FE<0(Y5J$T7DB',#72S,=LDJ$S$C^5=U"AI87/N!QOZTRCU[SOT
M5Q@M?UVN%(Q,4S(;S!#D0XZ/(E/S?(\'S[MFM9)4V:Y(*3RUM,I'3K 0*3IL
MF=*$Q)65IDNSG92_OZNI+=GOX]ZO?D53A%TH?#J">E*;U\''MQW[J$K=N^I3
MK5/F_6>HM;W6N>;\12ODCWGFT[NH!/RQQ/C>41O,7<,YQC#<I_&<YQV_!35"
MB',QP.9SLFLDLC'7TOHV&06V6[Z^W1=XP U@P\<S'3.9STFLLTK'W[V_>L@>
M -EN^).N@7QT]CW@^_?=ZQ__ +<])_\ 5+SELU=^2I/K$W\JN;S8C^2HOK$_
M\JGL>\'W[[O6/_\ ;GI/_JEXS5WY*D^L3?RJ9L1_)47UB?\ E5DE73UTJH%B
MC:R7A D!SD:'-$%%=)6K4P"$0BF"X.E1I2NIG#+D<BR4&R![N%^).BD(,N*I
MZ-*8=<TNZ*FY%J&[=".ZI;BQ(.G<VX@@\"#P*T>ZJJ[F_P#VZ["0X=U37!%[
MZ=S;K&]MA!!U6/TU+H%7$?GHVKUFJ@QI$6'(EIZ;]+9CL2IS4QZ''==QU2>(
MAZ4T/G.,-JSA3J(DA2,9PRO.-3/77 YJDN;D#NB;8+7/X+NN.L<5JY\0!#>:
MHKD$@=T3Z@6N?P7=<=87-#I70<0CE9<#9W6G,B@X#94U(B]-6F7V!(QXH-"-
M$"+K?5$I$.&X8,"1:),C+;*B!*#$2O+\IAM8OK18&*C!<;#^TS:FQ=8?V74V
M!/B!*%^( M!BH07'*T=TSZFQ=8?V7;E:X^(%7'8]-='%/& S5LM77?6A%F9[
M^ODSG2OJ47!,M>1P2.%#I,WJ=9:E94-*"R:$M*4M8PH,(I3F$1AOOXMFJWES
M6-HG%OS@VJE)&I&MJ;B"/&"-H*P9/62.<UC</>YGS@VJF)&I&ZFX@CQ@C:%0
M%M7]$P%X''-WGKD$/V<6.-UQDETO:@A.G0Y?/8**"&Y'4^VHB/)9Q_D,N+AU
MB5__  5KY1+6.S%K*,AI(=:IF-B-H-J7:-XW(V>M>'%K*!P82'D5,_>D;0?[
M+H1OX*%FU'H'&S)8XAM3K/@SX$I^%.A2^F[2\>5#F175L28LEAWJC2ZQ(CO-
MK:>9<2EQMQ"D+3A2<XY0^N(!$5(01<$5$VH.P_@JS#\0< X141! ((J)]0=0
M?P7>%5"J'T)G'G(X79/6P6?93%4\T.Z9]-S%L(FDH :&X_B/U0N=PW*+E!@N
M.X[XB'2)&#"0I4F6PVX,E:W5T=&!KMJ9AL!<?_\ 6W $^($[E'25[!=T="T:
M[:F<; 7&W]FULT$V&X$[E&>Q[P??ON]8_P#]N>D_^J7ES5WY*D^L3?RJRS8C
M^2HOK$_\JGL>\'W[[O6/_P#;GI/_ *I>,U=^2I/K$W\JF;$?R5%]8G_E4]CW
M@^_?=ZQ__MSTG_U2\9J[\E2?6)OY5,V(_DJ+ZQ/_ "J^L/@7272+0^N&OV#5
M5WZC[;:&]=;#BY$[!U!K*E@,C9(R,F7)P9KF\[T1\N96ECR>)YD\G?2M[+LQ
MC+:,.<3C)JC1.YV.G:SG(]8Y9'NO?31T,8MQ[[R+A<?-8</=ST=,V/G8KF*:
M5[[W-K-? QMN)S"VX%=P_P"N!JWN.?\ R8[UASJ"Z,NJ86ZE-VOUXW;5]2_4
M2S.=KCXMD1%WULV&MJ]/BVR:[$R)B6R/#BBD#''B; Z(ML='.8:BLUU%:1Y&
MGYYDQ/%3!)5?'F*@NBYL1#%:YKA5/C$O/")LX8V,1$O#00P36:(>8&5?MW1<
M@?@[9C.'8 WX(?@Y? ,2CK7XC-\&_)">%W)V.O?0-PN2NFPJ2IFK75S&4<E3
M,QU3)AQ?,_%78N[G37C^J_<<>4T%C=0NXU6$!'M!=9)_?%L*32:*_4T' C,N
MMS>KTOX\W!4006?:F:MF0R< GB,NEAVX+T=W4;B^)AW,MQBNY^%E1*7_ !O-
M(Z3F*;GXPZG?RBD<79XG\Z'4!#VOL:6,-+3HU7P8<@'TIQ2;X+N2#<+Q2?!,
M/;2,^#"@HZ:C=B^/?%5=)#C</P&4, I^Y<0I6X=)!RT@DI*BC,T?*"O?41R,
M[-&.M'2OLY3K9R>6CW-9&*&:$2AKL9$@S-JY.ZPPT0J]X@:68E5((;L<<5&(
MND'A 4Q.;CJ8%SUQ_H N V_9V]"_$NQM?=Y%<EAZI=9U-EQ^Q^>Q3*' <=IQ
MT8Z^@@0LQ58.OA@RHF7_ #Y82Y9&($&N!O+SK\A^&E(_.)\+,BWW[N/BOV;>
ME2U_?@IZL=0%*N IHR"C'7X#TPL/QF8+>$3&IP(M,!%XDD87\A)1) \N/F09
M#,J(RM+K"LXPIM2%KJ*ZV]FAG,X3B$2QG/[6%)BXSG&,]F<XQY5GM[.W';_X
M=N/_ !X12#=\&._]F)/Q_P"J8_\ X=O\TC/"*0;M<%W_ +,>7C_U2S_X=O\
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ME[43DC4D*$P2CQB)33C$U\7*-3H;$^SE) _R*+&C0%91XI01R"0RS.L[-;F
MV]FS-%[2$7 EL#;8T ZDE9PXMAL4W/<].[O@ZPILM[-G8+VEL2!-;-E!(: ;
MDDKD ^",Z^0%XL>QXFG]7-7*_37#U^+PNJ&7 5(L3]MJ%TG>PF(SK)4*GU<X
M5K9,78 1&/;BLVHV<G58%H%#<*Q(AQ.A+&Q\[+EC!;&#3 V;E>P9SSMWN:'
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MJXH^56+LCCJ9V,8VHL&L9*]K6@9= UH '0%[Q34-*:> F-US#$3]]FVEC?\
M_HN_;H$ .QHC2F$*)L(QJ37&$,Q3IR+&91[#@WBM1XL8BU'C,-X[$-1X[3;+
M+>$MM-H0E*<?4V%32U&%X;43O=+//04<TTCS=TDLM/&^1[CO<][BXG>25XG7
M -K:QHT#:JH &IT$KP-3J=..JRWY@@_?S7QDL7K3F_6U3S!!^_FOC)8O6G")
MY@@_?S7QDL7K3A$\P0?OYKXR6+UIPB>8(/W\U\9+%ZTX1/,$'[^:^,EB]:<(
MGF"#]_-?&2Q>M.$3S!!^_FOC)8O6G")Y@@_?S7QDL7K3A$\P0?OYKXR6+UIP
MB>8(/W\U\9+%ZTX10H %"4-[<OF?WP,X_8V*P)Q]PS/QC[B2>,=O9C[N>SM5
MGM4K.59SG)0;/*?65(3AP49"F$B)$G"'CXLB=.F2K0?9C1(<1I;\F5(>65PA
MIB.RVMUUQ><)0VA2E9QC&<\*JTJ5;=7['A32-!OL*X0ACC+)&37;\3*MCW)$
M?$N.F;Y(;=S%\IBJQ)CY?PWA]C_&M96WC*L+$;19+@[#=?RE6W5VQVR;U OT
M&YM!I#,4JY6K^2,I@/24+=B>4Y@G'L-M36FW'8,C/^3SFFG7(CKR&UJ32"-H
M(\:@(.PJIBV'7,V29AP[HS)E5V,3F'H[%Y+./!XH8C.$%I!%M)G*HC(TH,(C
MYKCV$)CS(,J.YE+C#B4RQX)<<525RX:LN$^"+JM_@6(D3JD.]#H(:_DB,N;3
M",UT;!M$9B*;<<=!RR##T*.20G,5V4TXPAS+B%)PL>"7&R_2IADA29)V36(]
MG<?L,*0[#F!6KD;<)193 H2<>CR(B2^7F7FPQT*44VXE*\02D&3V=U):4I;W
M]_$>I7W]^M7%Y@@_?S7QDL7K3A$\P0?OYKXR6+UIPBH)D6OP)(J'-*D8LLY-
M=&AX[]I/MNDI[ V>8>APT**XR_(:%"R1!;2,94F)"DO9QXC2\X(J_P P0?OY
MKXR6+UIPB>8(/W\U\9+%ZTX10TL%"P;#I[\SV9BELY[;%8,Y^YB!V=BLD_&3
M^W]W"<XPK[G;V]F.PH=H\?V%3/F"#]_-?&2Q>M.%4\P0?OYKXR6+UIPB>8(/
MW\U\9+%ZTX1/,$'[^:^,EB]:<(GF"#]_-?&2Q>M.$3S!!^_FOC)8O6G")Y@@
M_?S7QDL7K3A$\P0?OYKXR6+UIPB>8(/W\U\9+%ZTX1/,$'[^:^,EB]:<(GF"
M#]_-?&2Q>M.$3S!!^_FOC)8O6G"+&A&TZPJ]F,B[-L(+72&(H=_$ [LIT/.R
MRZW+RA[,:?88TE32^S_%K4C*,X[?$S^WS:38A0T[^:J*VD@D !YN:HAB?8["
M6O>UUCN)%N"U8Z:HE!?'!-(TV&9D4CVW%[B[6D7&EPOY]4O1WOPTWY8&/I3S
M2^-L*_S/#_KM-_$6IW'6>"5/F)?93ZI>CO?AIORP,?2GCXVPK_,\/^NTW\1.
MXZSP2I\Q+[*?5+T=[\--^6!CZ4\?&V%?YGA_UVF_B)W'6>"5/F)?93ZI>CO?
MAIORP,?2GCXVPK_,\/\ KM-_$3N.L\$J?,2^RGU2]'>_#3?E@8^E/'QMA7^9
MX?\ 7:;^(G<=9X)4^8E]E/JEZ.]^&F_+ Q]*>/C;"O\ ,\/^NTW\1.XZSP2I
M\Q+[*?5+T=[\--^6!CZ4\?&V%?YGA_UVF_B)W'6>"5/F)?93ZI>CO?AIORP,
M?2GCXVPK_,\/^NTW\1.XZSP2I\Q+[*?5+T=[\--^6!CZ4\?&V%?YGA_UVF_B
M)W'6>"5/F)?93ZI>CO?AIORP,?2GCXVPK_,\/^NTW\1.XZSP2I\Q+[*?5+T=
M[\--^6!CZ4\?&V%?YGA_UVF_B)W'6>"5/F)?93ZI>CO?AIORP,?2GCXVPK_,
M\/\ KM-_$3N.L\$J?,2^RD6TZPM!VNBZQL(+8R62$V0H>"V4Z8GXC,@B_>R,
M18%ADR4--J4VEQY*,)3X^$+7C#G8K5AKZ&H?S=/6TD\A!/-PU$,K[#4D-8]S
MK#>;:;U@^FJ(VYY()HV@@9GQ2,;<[!=S0-=P63/,$'[^:^,EB]:<W:T5A*5T
MD],<V3(FS=#:LES);[LF7+E4T-(DR9+[BG7Y$A]V*MUY]YU2G'77%*<<<4I:
MU95G.><8[!<'<XN=A.&.<XESG.H*4N<XFY))BN23J2=2=2N_1?"M\*,$44$'
MPD\OH8(8V10PQ<L>44<444;0R.**-F(AD<<; &L8T!K6@-:   OU#Z2^F4=+
MBSQ^B-709T&0S+A38=/#QI<27&<2]'E19+,9#T>0PZA#K+S2T.-.)2M"DJ3C
M.*W!<'8YKV83AK7M<'-<V@I6N:YINUS7"($.! ((-P=0I/\ "K\*%3#-35/P
MD<O:BGJ(I()X)^6'*&6&>&5ACEAFBDQ%S)(I&.<R2-[7,>QQ:X$$A9K\P0?O
MYKXR6+UISDET)/,$'[^:^,EB]:<(GF"#]_-?&2Q>M.$3S!!^_FOC)8O6G")Y
M@@_?S7QDL7K3A$\P0?OYKXR6+UIPB>8(/W\U\9+%ZTX1/,$'[^:^,EB]:<(G
MF"#]_-?&2Q>M.$4(?!0DP6,X?,_OW6L?=L5@5CL58Q2<_<43SCM[,Y\579XR
M5=BDYPK&,X(IOS!!^_FOC)8O6G")Y@@_?S7QDL7K3A$\P0?OYKXR6+UIPBA+
M"]3ZB)E'K79<UH'"QA4PP?NY40,BX5GL3W\Z>;CQFLK5^Q1A;N,K5V)3C.<X
MQS:5U?0X9325N)5E+04<(O+55M1%2T\0.@,DTSV1LN=!F<+G0:K%SV,:7/<U
MC1M<YP:T>,D@+7Q?5ATH(?7'QNN"^XA64Y5$L%ZFL9SC.4_XN3#R_&=QG./N
M*;=6E6.Q2<Y3G&<^<5/PV?!92/<R?EGA@+="8XZZ=FG"2"DDC<.EKB+:WLM
M5E,[YLS#XK[^FUE-B^HSIN-3(8\7M3,R80E1X4-ALQ?4J?E2G4,,,HRYXB<*
M<=<0C&5*2G&58\96,=N>;.#X>O@BJ:NFH8.6V'255740TE/"*7%0Z6HJ)6PP
MQ!QH P.DE>U@+G-:"=2!<K6;(QULK@;[%L'Y@@_?S7QDL7K3GKRS3S!!^_FO
MC)8O6G"*U+N(BQ:T0?:=)J6A4/L3(-F9C.?&FQT9\>/+GOQW.S"LY3WC2O$5
MXJT>*M*58+%_S3Y/6O/WLO\ ".P?UV5_O[_/A/$?QA7?IE3^^>OH.E_!J?\
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M61HD)=&W9LP&'_[?%-6N958A42T[(F4PDCBYBL?22O=*9F9AWF>,!@+C=IR
M!YNK977,YK\Y>*XSK-)XP#IG3L6J,9%M2.9LUPZB;04J@2NE)CP%]FN!P4R
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MFSLL);S/GSYF7YK^)U]_?WV+("P74>\-+_+;*_V9Z_\ [L1Y\K?"[_UA)_\
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M(: \S4NG;R=V $V?'IFDD%(4#8 6766[S;!/?P;3!U4P-+&+JQJHL]:##3U
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MH5>:]=AZXS2&&&FH0-+;]?%T>OR6U07.W=IXR#M]7I69N19*%E_OX&_T4O\
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M YVKE83%)*T"..)TD41D;(Z0^E8'@K\/'/U3FOJG-RAK#=D+3M&8VSR$:%P
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M@/TA/]6<(G>67VH#](3_ %9PB=Y9?:@/TA/]6<(G>67VH#](3_5G")WEE]J
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M1+0MDN(0-G-/BB1=+JI,2Y>OR<1T]/0IGWVT_P">CHUV^57 6ZH25?:>0<H
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M2%MNG,!9=6/IWZ@[SK[I_%Z_U\ K=E)2-S;*NEB#;$$U@W0IHV-KK6*JT55
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M;8Y3GCIJ81Q2QR$-,\L5+S>>&)R]*Y/4=7,8ZRJ$C(F#-"R6^:1Q&CPUVHC
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MT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/
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MT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/
M^CM4++*S?/@;'L<-=ODAA79WU?[<IQYNQG/;@[E.,8RI.,^-G&<^-CL[?N]B
MW2/3V*:Z:'37=P(X]*FO.D[\&S7Y>N^O^+#B/3V*W/ ^CM3SI._!LU^7KOK_
M (L.(]/8ESP/H[4\Z3OP;-?EZ[Z_XL.(]/8ESP/H[4\Z3OP;-?EZ[Z_XL.(]
M/8ESP/H[4\Z3OP;-?EZ[Z_XL.(]/8ESP/H[4\Z3OP;-?EZ[Z_P"+#B/3V)<\
M#Z.U/.D[\&S7Y>N^O^+#B/3V)<\#Z.U/.D[\&S7Y>N^O^+#B/3V)<\#Z.U/.
MD[\&S7Y>N^O^+#B/3V)<\#Z.U/.D[\&S7Y>N^O\ BPXCT]B7/ ^CM3SI._!L
MU^7KOK_BPXCT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/ ^CM6/9E;K%@LIF<>
MU; .3_)0[?E9<-224O#*&YF&V_*9I)YS+:>Q7B(2YE*>S/W$]OW=5D\\8RQU
M$D;;WRLDD:VYVFS;#[5H24U/*_/+30RNR@9I(HGNL";"[@3;AK9<OU/]>^\G
M7/BMKSY]S/NJJ\+G\]-VK#N*B\"IOJ\'LI]3_7OO)USXK:\^?<=U57A<_GIN
MU.XJ+P*F^KP>RGU/]>^\G7/BMKSY]QW55>%S^>F[4[BHO J;ZO![*?4_U[[R
M=<^*VO/GW'=55X7/YZ;M3N*B\"IOJ\'LI]3_ %[[R=<^*VO/GW'=55X7/YZ;
MM3N*B\"IOJ\'LI]3_7OO)USXK:\^?<=U57A<_GINU.XJ+P*F^KP>RGU/]>^\
MG7/BMKSY]QW55>%S^>F[4[BHO J;ZO![*?4_U[[R=<^*VO/GW'=55X7/YZ;M
M3N*B\"IOJ\'LI]3_ %[[R=<^*VO/GW'=55X7/YZ;M3N*B\"IOJ\'LI]3_7OO
M)USXK:\^?<=U57A<_GINU.XJ+P*F^KP>RGU/]>^\G7/BMKSY]QW55>%S^>F[
M4[BHO J;ZO![*?4_U[[R=<^*VO/GW'=55X7/YZ;M3N*B\"IOJ\'LK@;KE8KY
MVN30&K((,AY;/3F:'"TD;*S&R%)H>9S*@DFG4M+6XSE2%N):7E*<9[5X0G.#
MYYY&Y9*B1[=N5\DCFW&PV=<:+..FIHG9XJ:&-^H#HXHF.L=HNT Z[Q=9$\Z3
MOP;-?EZ[Z_YI6'$>GL6O<\#Z.U/.D[\&S7Y>N^O^+#B/3V)<\#Z.U/.D[\&S
M7Y>N^O\ BPXCT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/ ^CM3SI._!LU^7KO
MK_BPXCT]B7/ ^CM3SI._!LU^7KOK_BPXCT]B7/ ^CM3SI._!LU^7KOK_ (L.
M(]/8ESP/H[4\Z3OP;-?EZ[Z_XL.(]/8ESP/H[4\Z3OP;-?EZ[Z_XL.(]/8ES
MP/H[4\Z3OP;-?EZ[Z_XL.(]/8ESP/H[4\Z3OP;-?EZ[Z_P"+#B/3V)<\#Z.U
M/.D[\&S7Y>N^O^+#B/3V)<\#Z.U0E@*3LP&/_EPUC_XW6L]N7J_G]JQBL]G[
M$ZK/W>SLQGL\7&<]JLI3C*L+=(]/8E^@^CM4WYTG?@V:_+UWU_Q8<1Z>Q+G@
M?1VIYTG?@V:_+UWU_P 6'$>GL2YX'T=J>=)WX-FOR]=]?\6'$>GL2YX'T=JX
M9$U^6P]%E50I)C2&ELR(\A=:>8?9=3E#C3S3AU3;K3B,Y2MM:5(6G.4JQG&<
MXY',:YI:[*YK@0YK@2UP.A!!;8@C0@Z%0Z@@MN"+$'*00=H(OJ"L8C-/Z?"F
M$6(-T\4438&WO*$'1E$UA ,(D=OC=^@G%?:FI>\;&%=[A_"^W';XW;SC8\$P
M:&85$.%87%.#F$T=!3,F#KWS"1L(>#?6^:]UM64-#&_G&4-*R2]^<93P-??C
MF#0Z_3=94\Z3OP;-?EZ[Z_YR=AQ'I[%N[G@?1VIYTG?@V:_+UWU_Q8<1Z>Q+
MG@?1VIYTG?@V:_+UWU_Q8<1Z>Q+G@?1VK'^TK,L11C1&=7S;46.H;WJTN '<
MX[TK!81V(;.J6KM<=1C[F/N8SG.?N8SP!<V!'I[%BX]Z=#NX<?&O(ZV)_&!>
MO]<;-^>YW/J>D_!:;]'A_=M7C\_]_-^=D_;*]9WI+_DJ],W_ +?=,_\ #FM\
M^9<3_&6(?IU7_P"1(O6Z3\%IOT>']VU;!<V*W"<(G")PB<(G")PB<(G")PB<
M(H(*ZVR-EO/.(999+V=UUUU:6VVFV[ 56MQQ:\X2A"$XRI:U9PE*<9SG.,8S
MGE.WR#U!0;/*?65B*H=3.EKA1P>P47476:]8CDZNB<W:1&JD^24AKRM#.()6
M0TZE,X6N'8(#F<^*]7B8TJYW+$M/92T@D6U&VWOY/'HIF%K]-O*I\WO;48"3
M78<^]U]4NU60=4PD:'.:G/2C10Q8*_%86F*IWR9GSU5+(*>ER<M1FB(0A!4Y
MY8QEC,L3?39J5;CTV]-E'V;J#U57=76K<,.RQ+I2J<IADQ+H4B#:9.)4F0+8
MCPHK,*9AIZ8^@T+F,,YD-YD#YT2>QEV+*C..K&]K6/3HEQ:^WQ:J)JW5!I:V
M$;Q AW""-:H3COG4L>>B!PT^+#K?LK+DP<Z5*PDB, B$273DSQ&4#EP9W>X[
MJ,X]BEI%M-OOJH' [U./]0.H&I0R/&O=<)L3K =K<XF,,BI8FM$*W3K1>B[E
MJ(8G(9!P8H"G'7%S)6>Y3(BJ:7E"42'6)8\.D=.MM..U6XX_TVG7J7Z^K_I[
M*(\Q.P:FH'*$R2S=F38P/F'LBV,=4G!ZI.26)."BK 5ABTQ,0U=DYQ,%QQN<
MXS&=6/!3,./EW:;O&J@!NND649J,L*=(NPMV/3F:.ZJ(WV/9@58[<7G"*FY+
MC<1E8:ND%L.-KDI=?S':3^Q>[Q*VWH[;*WV=/9=3J-J:U=.$*RW?:DY8114:
M#)!$'QJR<(R8?\D&"Y$),C+[<Z;+_P D8C*1WJI?^393A_\ Q?%CP*7''WV*
MU!O4-ITG-L$-J^5V,U71L4Z^2FEQD841KLFL@+8JRAYRIF6YU>AB;.#\N+XP
MW#CRR$6*IS*Y,?OEB/?6][6(\B7'OLV7V[-ZY)_43H86F(LCN+6\%,X<V7AY
ME7 &SY2.=224W*9PN9C+C:\!3.$X3C*U+$%$83XX^6EEE.RQOLV%,PXC52$7
M=NKI!=H"]=:V.+S;(_50L"<?!HDV$JPR%=PD*U')25RFY"K"(C14N)8E2)<^
M)'1&\>9#Q(6/ ]6S;MZDS#COM[^_0KZE?O\ A_ZN-_\ Y0W(JIOA$X1.$3A$
MX1.$3A$X1.$3A$X1.$74'\,QX9/K1Z&>M\[I31!/6L2CIUCKFRX:M5"9L93S
MF9CEG)JO.#A**KN,J;3W3/==C>.W'C9[>>I<DN26$8SA#:VM;4&<U$\9,<YC
M;EC+0WO0TZZFYOJNG8UC5=05SH*<Q"/FHW=_'F-W7OK<+Y5?;+OA.?=S2'R2
M1?7G.S?<]Y._0K/K1]A<3\I\4^E!YD>TGVR[X3GW<TA\DD7UYQ]SWD[]"L^M
M'V$^4^*?2@\R/:3[9=\)S[N:0^22+Z\X^Y[R=^A6?6C["?*?%/I0>9'M)]LN
M^$Y]W-(?))%]><?<]Y._0K/K1]A/E/BGTH/,CVD^V7?"<^[FD/DDB^O./N>\
MG?H5GUH^PGRGQ3Z4'F1[2?;+OA.?=S2'R21?7G'W/>3OT*SZT?83Y3XI]*#S
M(]I/MEWPG/NYI#Y)(OKSC[GO)WZ%9]:/L)\I\4^E!YD>TGVR[X3GW<TA\DD7
MUYQ]SWD[]"L^M'V$^4^*?2@\R/:3[9=\)S[N:0^22+Z\X^Y[R=^A6?6C["?*
M?%/I0>9'M)]LN^$Y]W-(?))%]><?<]Y._0K/K1]A/E/BGTH/,CVD^V7?"<^[
MFD/DDB^O./N>\G?H5GUH^PGRGQ3Z4'F1[2?;+OA.?=S2'R21?7G'W/>3OT*S
MZT?83Y3XI]*#S(]I4[O^$I^$T>?BR%F])=Y$4ZIGLU-&QC&7FE,K\;'GO]E^
MP5GL_P##/W>/N>\G?H5GUH^PGRFQ3Z4'F1[2J/MEWPG/NYI#Y)(OKSC[GO)W
MZ%9]:/L)\I\4^E!YD>TGVR[X3GW<TA\DD7UYQ]SWD[]"L^M'V$^4^*?2@\R/
M:3[9=\)S[N:0^22+Z\X^Y[R=^A6?6C["?*?%/I0>9'M)]LN^$Y]W-(?))%]>
M<?<]Y._0K/K1]A/E/BGTH/,CVD^V7?"<^[FD/DDB^O./N>\G?H5GUH^PGRGQ
M3Z4'F1[2?;+OA.?=S2'R21?7G'W/>3OT*SZT?83Y3XI]*#S(]I;Q^#7\/!U\
M]4?7)T[:"VH6U._K[9=P(!+.R!UO'#EUP8U5L!=O$$F@L^J([Y8-C94YAE?:
MWA:.S]GVXX?E!R+P3#<&KZZF95">GA#XR^H+V9C(QNK<HOHX[UOL,Q_$*JOI
MJ>5T)CE>6ORQ!IME<=#?34!=VKGCZ[RG")PB<(G"*%/_ +A8_KJM_I$+Y1M\
MA]14.SRCUA37(JG")PB<(G")PB<(G"+#/4%_%):OZ0'])!',F?.'E]16+_FG
MR>L+R1MB?Q@7K_7&S?GN=SZFI/P6F_1X?W;5X]/_ '\WYV3]LKUG>DO^2KTS
M?^WW3/\ PYK?/F7$_P 98A^G5?\ Y$B];I/P6F_1X?W;5L%S8K<)PB<(G")P
MB<(G")PB<(G")PBQ^6JL&\T*W4LG+)P!EL1>*Z2EA928)9D<9+&A\[(^<IF1
MY'*7%?=;:E(:4]'4O#S"FWD-N)IT(/0WU!8@7!'2[UE8;A=(FK !;!>CD+QK
MUW$W,O$:I67NXS;<P&*KA^'&R;@&Y<)FSA:]6():5"EQBT5%8"N5\D#>9DN2
M[F)VV/DZNK_FZ91N)']="J9_I1UH.E$+%)/WY;<0QBSQHV)PB8P%AP[?=[_-
M BH<:K.SIHD@5V!<69+<[)BPK'E40AI6,^/$.PV8[-/>P!V[K(6C;K[WN-.-
M_&J+4VE=&2-4V'7E'('B]/(60(X6GSA40$47/H$D!"&!ER$4^ML%$ E4F$&)
M2)L D:>=BD6#I:246^\@2;W.WKVWZ3Q0 6(!OXK>^Y662Z+-35&IUD*!+YKE
M#J5R!;%MTNSSW2$E\#3(UJD%1S)1N0(8A#;,.ME@#W667\Y19%:)SFDQVWL,
MO-W.3>^I(L+=)'8+6\2F0#?X[\/Z[U>$;HFTA'%3P7<GG!L^87>PRB6$'RHT
M$K3;Y2F0J"8@".+3X(83L6T2@LHW.*GHY)]F3),S&6%1W)F/OY.P='0KE'OY
M>WQJ:7TGZ_=F-'7+1?G+HDL[8/9VHK7?9$]:562OV3%A7$35\53,]ERKBA"(
M"*T@#YE:>BNAG)#JYF&8\!PMKLX;;_;TIE'3QW;>.S^BF(NB:02H6FA-/N]P
M"B]6MMF-<7&L&*Y-*R8I>K%JYB4_/,UTZ&+Q2E?L<["7DBT][Y0U)CN(4E"L
MR^ITV[1KQNK;0:[-ATX>*VQ6A,Z6M1 S1&Q.6>S!;-:;F'.C; AVF-FAUU7:
MHUSDR!,UZFO.S7;59HB2)858O/H9.5JC!!P:&W&8CW,=FEM=.BW7H/ZJ91MU
MN3M\M[<-O8J:/T/Z1B0YL./FV-.DZ0$UZ1F^>H*YI*KU@'51-=A$.]$.1IZ@
MDRF@++ 5+BOH:/M3E+;6',EP\YG/IOY3>_7?W*91Q.X'9NMT= 5P0^D/4\**
MQ%:78<8:[MQU<=X ,1+F>8-P5^5/=@AJZ-%1Y1%K>%Y(S4CA\&(LLZ-DL18[
M45Z/+9C[WX@\>@)E&S7T=/1TKB3TA:S08K)=LQ>$8JUK!72"+66#RQ+U@KD^
MF$!<UR-.K\IV$^ARC"8LJ6#D"",\;))#9LU^%(88BLYZ-XZ[]/2F0"VITU]]
M%L=*_?\ #_U<;_\ RAN8K)6%MFR6JE#@]NKH\C880R=,A6"IC(29LXVT9%3(
M-;5!PU%>GM2X]US6HC[[3K4"&"*'211MQJ T]%H /1T^+;Z+J$D:[M_V:^/U
MK I;9FX*Q*559JY1"97K/JZ%)L6:<0GS]D1))>DQK^Q5(X,4D6%9'CU&2)A;
MXTL_Y'8VVPKPR0*P\S;#;X]+[-MO'[W6-SLX$#QZCJ].W1?D!U$WPND0B4%'
MB9;UOEP),<E2+$ADS4X-5I%DF$ Q /;[!"C&5$K1,I0,?#=MLBP'(:YBX 5D
M/98 IEV[_+L.NW3HO?2P\EV;B;>3=QV^3?Z[3E!L&WMP/QK+Y8FGBJM9\AY0
MY<2=7T6"')K-3L;9J/#BE+=!,L0II^8$<CKL#T"3)J\F,XH1,+%X (<HN/Z[
M_)P])VZ(,QMN&G1N\O'RVW:KFO.ZKK42MA;%@9)]<:[DQ3 IH$Z13$#5^MZ[
M(9&^512H944G8DVTA9(DY*+*2CB6E+CU,F,$&)XP #T:;;])U\FRVSIU%Z21
M??;=PT'KO>]S8;MMK=G]1-\APU3AP6!9V'[$;:%,C*18QY&17@#X2*I!F 1M
M^5@2I]PB4(!,QW#QA%=#Y-RZ3E/L@B5:Y1XMFTZ:[[VW>DZ7XS,=VOB![=_E
M\2JI^X=ISU %CHT82M^4 E6-AJE6:6Q38TS9^L 9^J6=9!MN*4/5^JFK2^1,
M C(UEJ*B44<!08K HJ_+"WJUVZ'7KMH?$F8WX?\ +>/"YU'CT40.W)M\B4H;
M+PR;!:=%T;%@ >Q<CDX^L]/T4J=8C!ET4H0S <;N5Z@('C!XA<?%>-J7)5-'
MD&*HL/7XO\6ST;SM'EF8Z>D;]@M<Z[;Z:#LE&]];@B-55HKKEEZ6;?AR)DH:
M"-LCD>7U?59^)4D-D334Z,;=E7VS#$&HS9YU>:"2D8I..](L@EAKK[ZZZ Z:
M7\NWCD7'33WTT]-O(=.&R.N#1([7IL@H[F3('W'8-<9F*;;:7,@5:]V*N#9#
MJ6D-MYDY@"X[4QY#33<F8U(DM-(9>;3B';Y!Z0%1L\I'I5^<BJ<(O.P_PEO_
M #G1_P#L2U)_<S//>/@]_P"G6?IE5ZV+SCE/^-'?F(?4Y=?[G>%UY.$3A$X1
M.$7T<U1TT=-]LJG32Q>;S::W?=^MU93#(^Y0I+KTXWU9V/1\L8(H+.F2BAXU
MG7=8+67%M.;/RS'L4*2ANO%$J'5XCUZJQ+$8I<1YB"*2"A,@)="X -9A4=:'
MOG-8S,XU$C(^:937,;A]\;WSV\G#2TKV4HDD>V6IR6M(#JZL= 0(^8-AS3'.
MSNET>/FG1IMJN="A>Y"7S]9V'#D R=6<MM)(E:VH8X>&B:>-N5L8(!&CY"S8
M)@8)2+#P.U\$V=)S.F!U'D5F >$39>I+CC87!DM,0]LG-3-9*'9'.F=#$6O,
M;8\LCFEV:=],,H=DYQS'M;BW#W/;F;*+%G.1YFV+@&-D>"T.<^[0X"T39M2W
M-D#VD\ELZ#+%6*Y=+6G8M8F!08FREZH_F355NV^/2:5+O%J4EL'>K"VEI,(?
M/# W:B]?,OV.%/&VQNE-AK%+"R+'&220Q=SR![WQLEMSMH3-,(8@<\$9O=S7
MO$H@M&YKHC,7QAY^'/8U[^<86M#RPW9W_-QF1_S9';@6M+.<NX$/YL->6X:.
M:BK$7IM@;9B0[N(N,*[TBLFXEA>P@$="WT+M$T(M5<'/4P,F*%<7KY801*'7
M:]R#$\7;I9L=2(\:N,6#>1U<KL1=2ET#X3#-(PQCOV/@?3,=%([GGDO^_P"=
MX=!"UC71!CYB9,F@Z%@I1,!()!(QK@[1KFR-F<U[06-LT\T6M(DDS%KRX1V8
M'[3[.Z0.G]K8FQ=6:KV02BV[7MTMM4*(M5YC6\8+'QM[:;TK2+):2@[3&N!@
M606+; L35AK Z>?4":$8L$BPLQ8$8-:^,IL6K^YZ>JJ:9IAGABE;S4)A<]QH
MJNLFCB:ZLJ'/#&01F.5S8^<+N;$=W%\6\EHJ?G98892'QO>PYY ]H'=,%/&]
MY$$0;=TKLS 790W/GL U]KTSH'D3+I2:I>K_ "A$PJ:UXW=1 &HS)L^J#;'M
M_6^BKK6I!8A-B#8NU*'L_8/L>)TZ;&S&0/ $K Z52J4 !G=67';132P4X<UK
M)^9?)*&ME='23UL,@8UKG&EGIH.<;,TWS/;'ET>]FG'AQ,D;'R6+G19PUA)8
M'S14\C+D@<]'-+D=':UFN>7"[&OM6S]&:Z5HVS;D-6B5-3%UP.M <*S'"C)@
MVQD+CTR-L#K#!8,V4FF&JA=06)3T(K&IAR/8Q\25$CEZF[!*G]2+&.?K8Z1D
M0;>H=&]Y+W!T;8L1NZ-V2-N;GZ&P+3,PQN(=DES,CQ=0Y*=\[GDVB#FM[UI#
MR^DL'C,\VYJIN0[FW!X! <RSG13FE-,V/6VN;!7U["HQHMJJ\[5NY^SVT%?P
M285 N)VBRPE7IP+6E%*L3[$4ABR Z45NDR((9>E#IWEV,I,Q\A6UD=34QR"G
MG8RI@I88XHGT[RZHACG:^6:2IG9EC:7M<&P@O-G-R_,,[G@=%$]O.QN=#)-(
MYSVRMM$]T9:QC8HS=Q ()D(:+@W^<,H6/H$54H^PK$9M4CS#32V\0GF*+("K
M.QIE,U;U2WW6DQ^<M>"LT::E=-<[)^45U]289<,9B.TJ=.==)/UO;Q8[SQ@C
M9$.<E91OSD/R$2U.&P5(#?FM+!B#>;#:B8M>TB9K;-$NJ[#LG.N<\Y8W5#<E
MVY@8X:R2(WVEKC2',711AS7 QDW);\V>=B7%IPB<(G")PB^IO@3?\Z?T;?VC
ME_T!M_.M\K_^F\6_1V_OHERN"?C6B_.G]AZ]0/GSFO4TX1.$3A$X10I_]PL?
MUU6_TB%\HV^0^HJ'9Y1ZPL>[^V QJG1VW]E/F8U>Q1M:W6T,&Y;/E,<;.#UX
MA,'25Q,0B2IBDD&HV&H2!I!R8ZI$9N#,6ZF.YRN 4!Q7',(PT0NJ.[L2HJ5T
M#'9721S5$;)&A^>/)>,NN\R1A@NXR, S#@^5&*-P3DWCV,.J&4GQ;@^(UK:F
M1N=D,E/22R0O+.;FYPB4,RQB&4R.(8(I"X,/72Z+>N/K?W]U%],^J3?5O3;&
M)N\NR7N^P@>H@ PF;HM6D6!V36H<F=HH)#$LR8]")1UE<D@IA7LH=S!?6[%"
MNK^B.6G(CD3@')WE+BL').LIYJ)M-04#Y\6J)8H:ZJ;3AM4]K,<F?*6.KXW"
M+FYH?[*,[0'S ?)7P=_"3\)'*GE;R.P.IY=X?608C)68GBD=-@-)#-4X91.J
MB^CC?)R8IXX&O;A<S#/SU-4'NT\VXF.G<?J7U,=2NUJ#NF_5VCGBR:E0](N6
M,Q %!M?S6Q%U-*D"Z\7+3K3$\XY#Q9QZK2Y(X;(G3I+R&F614B&_.QSYF8P%
MH)M<NL+WV;]F_P!'$\/LYSC<VW#79[[PK&'=0&_)UNUY5R&W2@T>KIZ$[6V=
M8H54U*VW6B-@=(FHQ,JDU7DHC@PH,O5HY2&%B$#DB,RIT>&ESWI+ZZ6ML3;_
M !$-U.H%O<7MMUW)=UP+[KDV&FEUEK5O4';X6Q]V0=H;C"R*IK4'5Z@"63 @
MA8@ULC-(F';:;4\"KT.P9@095,M)%R!AQ#$,=/6RN,F0Q!::Q+19MFF[B3TA
MM[  $[[[?%TIF-S<[ !LWV\5]QNM?)W5)U$0->VQ)/9;PC<-8MM=H<BI/TBA
MN09I2[G%EZW9@1-(-4>77W*<%)CXT-<>8Z^[+185%946>*9AYAC<W%I!(U((
MMM!VZ\?4IF=;;KXAL(]]V]7G'ZF]X,;^)Z:F728Y7#-S'#*I>7*S2$/1J_KV
MP$!&TYWB,@$#I#!5BOVO*GY$9]T3,%PLP&XT.0ZI<RM+,P&HVC7?L\?#3>2F
M9U[7WVO8;MI_Y4[TH]1^]=N[2$Z[NIF='4#B']CGGUUVIPEG]?FP53<H8F7B
M&&;Q!6U+/1S&)PO$&9-ADT1Y+R\,)PW'M:!F&PZ#H.M]_E5:XDVOT[![^_5O
M5U!?Q26K^D!_201S!GSAY?45D_YI\GK"\D;8G\8%Z_UQLWY[G<^IJ3\%IOT>
M']VU>/3_ -_-^=D_;*]9WI+_ )*O3-_[?=,_\.:WSYEQ/\98A^G5?_D2+UND
M_!:;]'A_=M7S-\)YU,;DT_U-='.JZ+OS<FBM?;6HG4B>OD_1/3I6^I._F3>O
M6M7.4MJ+2BFKMHFFQL=VQ&&B4L0.@Q&F)O?%9*4,QG6.P\G<.I*K#L5J9J*D
MK9Z:;#V0-K:]^'P-9/W3SI,S:FF87'FV%H<XDD6:-2#Q>*U,T-3111U$]/',
MRJ=(:>F;4R$Q"'F[,,,KK7>;D "QU.Q4731U]]848!TB:/W7TT6K9/4QONJ[
MAOA$N?G5;IWGA]4ZSVX,J@S8.R]>DQDQNHV(SKNQ![3,J )C,M1SR0-&"C6S
M+KX2XA@F%9\3K*/$(X,.HI:2 -C$E>'5-12NE?#3SM<WG8V5$;HFRO-LEWE[
ML@SJ7$*T-HX)Z9TM54,GD+G%M,1%%,&"26(@Y'.C<UY8VYS6&4!QRS$#PT&N
MA6Q]NT[9>J6JT UGJ'?FXHI_7^[=7[Q,S!73\5AP+#4[>%UU*F5BCWP_&(0I
MH.OL[ M28CLID=9)P.7B2F/@[DG4.IZ66GJ3(^HJJ&D+)Z.IHV!U<USHY8GS
M@230QEI$CS!%>Q=&UXM>C&XA),R6+(V*&HFS1SQ3NM3$!S7MB);'(X$%K><?
M8G*\M(-KFV;UP]0D?3-1O%ZZ?]B]+#]AWWT>5ZK'0=\T]MD;?Z5OO8X,*0!K
MG$*Z02")#A\Q(S88I56C$!<8K'>HUXE$/&(0-.GP>A-7+##6P8CDHL5DE8^"
MJIG034,#WM?E;(W.UQ&:!W.%KBTB:$#0Y2UU0(6/DIY:7-4436.;)#,)&5$K
M6EMRUP:0-)!E! <.;>=HDZ?X4V38=LU6IF>FRR5?4ELZO=U=%,'<[^RJJ2[=
MNZAS>)#<YO7T88T;53+&,H\]U9N42A2@A+RD?D85CQ8Y,A)>389322LQ".2J
MBPJDQ=U(*>5O]EJN9%N?+BSG8W3-&0-(<VSLS;EK:S%2Z9K#2N;"ZMGH>?,K
M#]^ASF_-@9LCA&=206D$6(L3#4/PMT>U-:^N)KI9VH"TYU!4_?%MZ5KN&LM4
MNEOW6O0M1LE\(UN=JP3Y.:H%DOU4J9B=KD?-+'?/<Q,,5.<$S9C:,93<F#&9
MXF8E3/JZ&6BBQ*%\<L45)W;+' V1M2Z[)XX)96-J'!L>07<W.T%2/& _FWNI
M)FP5#*A])(US)'S]SL=(6F%O?1ND8QQC%W7-FG*2M;+OX9G8>P^BG?V]>GW5
M>N!6PM6F=##41\;THFRE5L7N+80FF$G;?0W!M.V)4KM6IDUNMK#6ZBQJMD\8
M9,!K%=!E6L8K/(1<DX*?%Z&BKJFH?!4LK77[CFIN<=2P.E:(I\TT$L4@&?/%
M*9 QF5\<+I8W+:R8V^2AJ*BFBC$D3J8 <^R0M$\HC.>,ADC)&$Y+/C#,S@YK
MI Q[5M3M3PILC3O4;K/IYN>A@[1B_7K1VJ9_FGJ/U38KU7-C;S$#70V']5UQ
MLO8XVO05I*1ZF2N]TET.>4<:DGZQ4#@',&9.XVFY-]U4%17Q5CRR&&LJ6YJ"
MICAD@HW.SVJ9,L9G?$TRMAB$S6@ADDK'W:W=RXL8:F*FDIVWDDIX3EJ872-E
MJ ,OWIMW<VUYR&1YC)L7-8YMB<Q^#%ZEMW]6'3.]MO>],!5"SR-O;MJPGV.%
M8$X23KM*VK;:I!:CP(:,OBLU9P._275D9<^;8G:VNV9D)8.LQV-IRAP^CPS$
M!2T4SY8Q2T<KN<:6N;)-2Q2N[XZ.YS.)A8-$?.<U:["3KX74SU=+SU0QK'F:
M=@RD$%L<KV#0?-RV,>I)=DSW[ZP^B'."7(IPBA0'[A?_ *ZLGZ1%.4[?(/4%
M!L\I]94UR*IPBUEL_36*M(J/ GG6') ].YG!<R0 3(S#F;>V8'V$^O"4EF)*
M(D&$,ETLRQ!FP)=EKIPNP@B#1+=87EFMZ/0+?UZ"L<OV[N)O_3RK'A?HW;,,
MCH;]V$,P1U9M]=9CMT62^['1<1&UADUJ'/GW:7/R#BKV=Y7!KQ:08BC\@6HP
MEX7'(+3$9MNFVV_A8\-NFT6VJ9>G<1LXW\N_8KO7TJUUS,R<@F+%V.<2D$W+
M/7JC##FH4B7M$KL!U8B=YSE31[K 4L]18#RI<E<0.C"\]]$6L1EF]R;[K:^M
M,O7T#9K?^FU1M9Z2 @)L)F09"RY( O!,#5Q:G-:BP942P:C,NO"HYJWV-X-(
M(1=5Y'37!LQAAS-CES,Q<N,RFRPNO?IZ?'T=/H3)I;[/%Q)X>G8IB;TNAR6N
MJKKTA842X=4KL@# 1(KS#X",\G75EU\,."JR\2<8$&(_L@;LA*4S/>42.0G'
MV,C,RT+ALVM[=NT';Y/2KETM?LV$;/+Z%2Q^ER.];[)9#]J'EQ]I+SIAD,Q4
M,"<EA<HO9YK HQ+BV)<.>]$&6>2%\[I$1I\U"'9\]4F7,>REFL--W3?=;JWV
MXVX)EN;GU6WWZ]U^'6N4)TQY&V^G70I>I%F.@,0)!LJ5$$&2YDO /V0WDJ,F
M#+5!BA'2D4]#K)MB</L3!&K5P*%4EN.ROQF;0BVW=N]7ETMJF78;Z\>.OCW[
M-;Z+:WF*R3A%"2OW_#_U<;__ "AN$4WPB<(G")PBIVXL5EZ3)9C1VI$Q32I;
M[;+:'I2F&\,LJDNI3A;ZF64X::RZI66V\80CL3C&.$51PB<(G")PBIXL2+!C
MM1(4:/#BL)\1B-%9;CQV4=N<^(TRTE#;:>W.<^*A.,=N<Y[/N\(JCA$X1>=A
M_A+?^<Z/_P!B6I/[F9Y[Q\'O_3K/TRJ];%YQRG_&COS$/J<NO]SO"Z\G")PB
M<(G"*N04)M.C7VB,YMX-A& [R)<A#HG#<U\FW@:XES"X.&R4J201B+EKQ)LA
M^6GL?=<<5CE;9PRML_YXL+.[T-[[Z7>@-UOWH V!6YT-S=OS=3WNM].&I)TW
MF^U2\6YW""-E!H-LLL,/.;9:FBHITI'&S&H\>3#CMRH+,I$60VQ$FS(K*'6E
MI:CRY+",):?=2O PPN<'NBB<\7(<8V%PN0XV<1<7< 38ZD [0%0]X!:'N#3M
M:'&QT(U%['0D>(D;%4SM@7PHH\HE=K<15:F1\>SJG60S+59(XGQ?-3![,B:Y
MDPR,\1'F]HAY0B'XB?)DM^+CLC:>!O-Y886\T7&++&P<V7?.,=F]X7?XBVQ.
M]4R2'-=[SGMGNXG/EV9M>^MNO>VY1$BP'I@<=7I9LO* !WYDH0#D$ICX<7)(
M*2N?)'#'7E0H+\Y:$*F/1F&G)*DI4\I>4XSC,1QA[I Q@D> '/#0'N#?FAS@
M,Q W D@;E"YQ:&ESBUMR&DG*"=I V"^^VU4[A4HZ^1E.DI[LHPI:BTER9(6^
M44[-9)N*(O*<RY-4X1CQR"\R5.Y7-89E*[7VD.)N5H#0&M 9\P6%FV:6]Z/\
M/>DMTMWI(V%2YU-S=WSM3WVM]>.H!UWB^U2[=UN33#D5JVV9N,]8&[:]';/%
M4,.VIE7C,V9QI,O#:[ TK.5-FE)R20K/:F3C/,##"2"8HB1&8@3&RXB.V(&V
MD9WL^:>"RYQ^S.^V;/\ ./S_ *>WYW_Y;>E?HK>+J=B-P#=PM!B"S#;'-0BM
M@+$(C0]F2U-:@-QY<MYE$-J8PS+;BI1AA$EEI]*,.MH7@R&%ANR*)A)S$LC8
MTEQ&4NN #<@VOMMIL1TDCA9SWN%K6<XD6O>VIV7 -MEQ=0J2A-+*(R2,Y,=N
M*_!;83+D89;A2G\RI,-#6'/$3%D2E*DOQTIPTZ_G+SB%.9RKF>1M[Y6W)#KV
M%[@6!O;:!H#M T"QN>)V6V[KWMXKZVXZJ=E7N\3H#(N=<K7,&1W"CL<=*L)>
M1 8=.8G8-.LPWIBX[3A?!,E@HM#:5$,$)WE>7O*W^\P$$+7%S88FN.4%PC8'
M')ER7(%SDRMR_1RMM:P61DD(L7O(U-BYUN^OFTO;OKF_&YOM*M3FJL$X1.$3
MA$X1?4WP)O\ G3^C;^T<O^@-OYUOE?\ ]-XM^CM_?1+E<$_&M%^=/[#UZ@?/
MG->IIPB<(G")PBA3_P"X6/ZZK?Z1"^4;?(?45#L\H]85#=*13-CUDI2]@U.N
M7BGFTQD&:M;0HZQ5TLB%-C$H:"08M'ECYJ8I"'$G1TR8[F&9<6/(;PEUEM:=
MS1UM9AU3%6X?5U-#60%QAJJ2:2GJ(B]CHWF.:%S)&%T;WL=E<+L<YIT)"V>(
MX;A^+T<V'8K0T>)8?4A@J**OIH:NDG$<C)HQ-3SLDBD#)8XY6![#ED8QXLYH
M(QK3NF+IOUY9AEUH.@M-4FX!8+@P/:JIK.FU^Q"AKT)T:] '&10:(0A0W1SS
MT%R-'D-LKB.NQU(RTXM&>2K.4W*/$*:2BK\>QFMHYGB2:EJ\3K*BGED#Q())
M(99GQO>)&AX<YI<'@.!N 5P^'\C.2.$UD.(X7R7Y/8=B%/&88*VAP;#Z2K@A
M=&87115$%.R6.-T3G1%C'AIC<6$920KH*Z:U$=(&2QO5^OBY2Q(:;L!(G3Z_
M.G&VV7H<EELM+DCW7R*&I ^ ^VB6XZE#T*(XG&%QV<HX7,X;'.TV:G1=DL.
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M$G/(Q#L4@PB!.:S)Q*E)?BX;0ZRM.(6%NW@#UH' VVZZ;MWE5Y]07\4EJ_I
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M9:%$)XA1N8ZI1DC!BR)4C+STE^/.=[6G)Y?&KY/$M44V/3[,"O'=DZ^ Z^;
M7B_6L&/HLNP%*^^;U#<':43MMO0$J%/$R'XER*0<T]@_&*O2BYT9/A,QS.7V
MHF=CL!)TMK;81>PN>'J6%QM(MK?3?8VUT&]<%QO_ $EN#Q%ADTX'8'FFK_L^
MO"!U00Q#LUEKE<O\*TKEL8B1P-AL#4&HW*&Y,*X)Q($Z##FJFQY4^N29RSAO
MX-V[KCT;/>Z=[ML-E_?COX@;;K(TK9_3ZX<<G&*U&BD:^3)*?M!K64UF*#GQ
MK,5!DYZK+)!99B9]F-1F#7YK,S"GRXZ-(PMQE#,Q,L[KZ1LZ^!5NW;]A[%%
M]E],1*'7X5>K%?E07#I"(.B"M9X<@@C1M^F@9S\K$0&J"$D'5[%ID"9(6ME^
M4P?0V2RED<:P-$.WWZ_&>/04NWHZO$#ZQ=3H?=.E@M2A7Z.-BU^5?QPVWV8,
M!KC)"W1EE*61OF2-Y'5B++GMO-U(46*I)ETY\XQ(F4CG9;\N)'D+'9MMH.&V
MVE^E+MZ!?7IV7ULK*/V7IVCEH8(95F&W]6;!@VJ;6*X*+58=&L?B'V&+<]6
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M@T./)&E#ADF+R=BDE"R12?/'JC2Y;SRUSU^_D\B6'5[^7RK(_(JG"*$E?O\
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L<(J*?_W#?^FC?SC%X15O")PB<(G")PB<(G")PBM2[_P9)?\ K#_O\7A%_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
